Fanconi_Anemia

Genetic MONDO:0019391 Pathograph 60 Bone Marrow Failure Congenital Disorder

Fanconi anemia is a rare inherited bone marrow failure syndrome characterized by genomic instability, congenital abnormalities, progressive bone marrow failure, and increased susceptibility to malignancies. Most cases result from biallelic pathogenic variants in genes encoding components of the Fanconi anemia/BRCA DNA interstrand crosslink repair pathway, with recognized exceptions including X-linked FANCB and autosomal dominant RAD51-associated disease (FA-R). Between 21 and 22 complementation groups are cited depending on nomenclature and curation conventions, with FANCA accounting for 60-70% of cases. The phenotypic spectrum is highly variable even within the same complementation group, reflecting genetic modifiers and environmental factors.

Ask OpenScientist

Ask a research question about Fanconi_Anemia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Definitions
2
Inheritance
22
Pathophysiology
0
Histopathology
92
Phenotypes
60
Pathograph
25
Genes
8
Treatments
24
Subtypes
0
Differentials
2
Datasets
3
Trials
6
Models
10
References
3
Deep Research
🏷

Classifications

Harrison's Chapter
hematologic disorder hereditary disease
🔗

Mappings

MONDO
MONDO:0019391 Fanconi anemia
skos:exactMatch Orphanet ORPHA:84
Orphanet ORPHA:84 lists MONDO:0019391 as an exact cross-reference for Fanconi anemia.
📘

Definitions

1
2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)
Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.
CASE_DEFINITION Suspected Fanconi anemia in pediatric and adult clinical settings
Table 1 FA screening indicators
Major congenital, hematologic, and reproductive indicators associated with FA.
Core clinical characteristics
  • Short stature
  • Microcephaly
  • Anterior pituitary hypoplasia
  • Interrupted pituitary stalk
  • Hearing impairment
  • Microphthalmia
  • Epicanthus
  • Ptosis
  • Strabismus
  • Cataract
  • Triangular face
  • Micrognathia
  • Cleft palate
  • Abnormal heart morphology
  • Tracheoesophageal fistula
  • Esophageal atresia
  • Duodenal atresia
  • Jejunal atresia
  • Anal atresia
  • Annular pancreas
  • Intestinal malrotation
  • Abnormal renal morphology
  • Abnormality of the genital system
  • Absent thumb
  • Hypoplasia of the radius
  • Clinodactyly
  • Aplasia/Hypoplasia of the ulna
  • Toe syndactyly
  • Talipes equinovarus
  • Hemivertebrae
  • Fused cervical vertebrae
  • Scoliosis
  • Kyphosis
  • Absent/hypoplastic coccyx
  • Cafe-au-lait spot
  • Hyperpigmentation of the skin
  • Pancytopenia
  • Myelodysplasia
  • Leukemia
  • Cryptorchidism
  • Hypospadias
  • Micropenis
  • Aplasia/hypoplasia of the uterus
  • Gonadal dysgenesis
  • Vaginal atresia
Notes: This criteria set is intended to guide screening suspicion and referral; it is not a strict diagnostic-count rule.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews describes the broad congenital anomaly spectrum present in ~75% of FA patients.
Notes: This is a screening definition/case-identification aid. Definitive FA diagnosis still requires confirmatory genetic and/or chromosome breakage testing.
👪

Inheritance

2
Autosomal recessive inheritance HP:0000007
Orphanet records autosomal recessive inheritance for Fanconi anemia, consistent with most FA complementation groups being caused by biallelic pathogenic variants.
Autosomal recessive inheritance
Show evidence (1 reference)
ORPHA:84 SUPPORT Other
"- Autosomal recessive"
Orphanet explicitly lists autosomal recessive inheritance for Fanconi anemia.
X-linked recessive inheritance HP:0001419
Orphanet records X-linked recessive inheritance, matching the FANCB-associated FA-B complementation group.
X-linked recessive inheritance
Show evidence (1 reference)
ORPHA:84 SUPPORT Other
"- X-linked recessive"
Orphanet explicitly lists X-linked recessive inheritance for Fanconi anemia.
◆

Subtypes

24
pathway tier
Core Complex Subtypes
FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCT/UBE2T) encode the E3 ubiquitin ligase complex that monoubiquitinates the FANCD2-FANCI heterodimer. Patients with core complex mutations generally have a later age of cancer onset compared to downstream pathway defects.
  • FA-A
  • FA-B
  • FA-C
  • FA-E
  • FA-F
  • FA-G
  • FA-L
  • FA-T
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Patients with FANCA mutations developed cancer at a significantly older age compared to patients with mutations in other Fanconi genes (mean 18.5 and 5.2 years, respectively, P=0.001)"
Israeli cohort demonstrates later cancer onset in core complex (FANCA) vs downstream gene mutations.
ID Complex Subtypes
The FANCD2-FANCI heterodimer is monoubiquitinated by the core complex and recruited to DNA damage sites. Mutations in these genes cause intermediate-severity FA phenotypes.
  • FA-D2
  • FA-I
Downstream Effector Subtypes
Downstream effector genes (BRCA2/FANCD1, BRIP1/FANCJ, PALB2/FANCN, RAD51C/FANCO, RAD51/FANCR, BRCA1/FANCS, SLX4/FANCP, ERCC4/FANCQ, XRCC2/FANCU, MAD2L2/FANCV, RFWD3/FANCW) mediate homologous recombination repair downstream of FANCD2-FANCI. Patients with FANCD1/BRCA2 and FANCN/PALB2 mutations have notably earlier cancer onset and increased risk of childhood solid tumors including medulloblastoma and Wilms tumor.
  • FA-D1
  • FA-J
  • FA-N
  • FA-O
  • FA-P
  • FA-Q
  • FA-R
  • FA-S
  • FA-U
  • FA-V
  • FA-W
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."
Israeli cohort demonstrates more severe congenital anomaly profile in downstream pathway gene mutations.
complementation group
FA-A MONDO:0009215
60-70% FANCA link
Most common complementation group, accounting for 60-70% of all FA cases. FANCA is a component of the FA core complex. Patients tend to develop cancer at a later age compared to other FA subtypes.
Show evidence (2 references)
PMID:31558676 SUPPORT Human Clinical
"two-thirds of genetically diagnosed patients had biallelic FANCA mutations. These numbers are similar to the International Fanconi Anemia Registry, in which 60% of the diagnosed patients had FANCA mutations"
Israeli cohort confirms FANCA accounts for approximately 60-70% of FA cases.
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCA causes autosomal recessive FA.
FA-B MONDO:0010351
<1% FANCB link {'name': 'X-linked recessive'}
X-linked FA subtype caused by hemizygous FANCB mutations. FANCB is part of the FA core complex. Affected males may have more severe congenital anomalies including VACTERL association.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"a hemizygous pathogenic variant in FANCB known to cause X-linked FA"
GeneReviews confirms FANCB causes X-linked Fanconi anemia.
FA-C MONDO:0009213
~10-15% FANCC link
Second or third most common FA complementation group depending on population. FANCC is a component of the FA core complex. Common Ashkenazi Jewish founder mutation (IVS4+4A>T).
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)"
Israeli cohort shows FANCC accounts for 13% of genetically diagnosed FA cases.
FA-D1 MONDO:0011584
~2% BRCA2 link
Caused by biallelic BRCA2 mutations. Associated with very early-onset malignancies including medulloblastoma, Wilms tumor, and AML, typically before age 5. Distinct from heterozygous BRCA2 carriers who develop breast/ovarian cancer.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"one patient with a FANCD1 mutation developed medulloblastoma at the age of 3 years. Patients with FANCD1 mutations have been previously described as uniquely developing solid tumors early in life"
Confirms early-onset solid tumors in FANCD1/BRCA2 patients.
FA-D2 MONDO:0009214
~3% FANCD2 link
FANCD2 is one of two components of the ID complex that is monoubiquitinated by the core complex. FANCD2 mutations cause a moderate FA phenotype.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCD2 causes autosomal recessive FA.
FA-E MONDO:0010953
<1% FANCE link
FANCE is a component of the FA core complex that directly interacts with FANCD2.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCE causes autosomal recessive FA.
FA-F MONDO:0011325
<1% FANCF link
FANCF is a core complex adaptor protein required for complex assembly and stability.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCF causes autosomal recessive FA.
FA-G MONDO:0013565
~10% FANCG link
Third most common complementation group in some populations, accounting for up to 14% of cases. FANCG/XRCC9 is a component of the FA core complex.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)"
Israeli cohort shows FANCG accounts for 14% of genetically diagnosed FA cases.
FA-I MONDO:0012186
<1% FANCI link
FANCI forms the ID heterodimer with FANCD2. The complex is monoubiquitinated by the core complex and recruited to sites of DNA interstrand crosslinks.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCI causes autosomal recessive FA.
FA-J MONDO:0012187
~3% BRIP1 link
Caused by biallelic mutations in BRIP1 (BACH1), a BRCA1-interacting helicase involved in homologous recombination repair. Heterozygous BRIP1 mutations confer increased breast cancer risk.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)"
Israeli cohort shows FANCJ accounts for 3% of genetically diagnosed FA cases.
FA-L MONDO:0013566
<1% FANCL link
FANCL is the E3 ubiquitin ligase of the FA core complex responsible for monoubiquitinating FANCD2 and FANCI.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCL causes autosomal recessive FA.
FA-N MONDO:0012565
<1% PALB2 link
Caused by biallelic PALB2 mutations. Like FA-D1 (BRCA2), associated with very early-onset childhood malignancies. Heterozygous PALB2 mutations are a moderate-penetrance breast cancer susceptibility allele.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms PALB2/FANCN causes autosomal recessive FA.
FA-O MONDO:0013248
<1% RAD51C link
Caused by biallelic RAD51C mutations. RAD51C functions in homologous recombination downstream of FANCD2. Heterozygous RAD51C mutations confer ovarian cancer susceptibility.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms RAD51C/FANCO causes autosomal recessive FA.
FA-P MONDO:0013499
<1% SLX4 link
Caused by biallelic SLX4 mutations. SLX4 is a scaffold protein that coordinates multiple structure-specific endonucleases for interstrand crosslink repair.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms SLX4/FANCP causes autosomal recessive FA.
FA-Q MONDO:0014108
<1% ERCC4 link
Caused by biallelic ERCC4/XPF mutations. ERCC4 is a structure-specific endonuclease also implicated in nucleotide excision repair, creating a phenotypic overlap with xeroderma pigmentosum and Cockayne syndrome.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms ERCC4/FANCQ causes autosomal recessive FA.
FA-R MONDO:0014986
<1% RAD51 link {'name': 'Autosomal dominant'}
Caused by heterozygous dominant-negative RAD51 mutations. The only autosomal dominant form of FA. All reported cases arise de novo.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"a heterozygous pathogenic variant in RAD51 known to cause autosomal dominant FA"
GeneReviews confirms RAD51/FANCR causes autosomal dominant FA via de novo mutations.
FA-S MONDO:0054748
<1% BRCA1 link
Caused by biallelic BRCA1 mutations. Extremely rare, with phenotypic overlap with both FA and hereditary breast/ovarian cancer syndrome. Heterozygous BRCA1 carriers have high breast and ovarian cancer risk.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms BRCA1/FANCS causes autosomal recessive FA.
FA-T MONDO:0014638
<1% UBE2T link
Caused by biallelic UBE2T mutations. UBE2T is the E2 ubiquitin-conjugating enzyme that works with the FANCL E3 ligase to monoubiquitinate the ID complex.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms UBE2T/FANCT causes autosomal recessive FA.
FA-U MONDO:0014987
<1% XRCC2 link
Caused by biallelic XRCC2 mutations. XRCC2 is a RAD51 paralog involved in homologous recombination repair.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms XRCC2/FANCU causes autosomal recessive FA.
FA-V MONDO:0014985
<1% MAD2L2 link
Caused by biallelic MAD2L2/REV7 mutations. MAD2L2 functions in translesion synthesis and also plays roles in mitotic checkpoint signaling.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms MAD2L2/FANCV causes autosomal recessive FA.
FA-W MONDO:0044325
<1% RFWD3 link
Caused by biallelic RFWD3 mutations. RFWD3 is an E3 ubiquitin ligase that ubiquitinates RPA at stalled replication forks to promote homologous recombination.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms RFWD3/FANCW causes autosomal recessive FA.
⚙

Pathophysiology

22
DNA Repair Deficiency
Mutations in FA genes impair the body's ability to repair DNA damage, leading to increased sensitivity to crosslinking agents and propensity for chromosomal instability.
Downstream
Genomic Instability
Show evidence (1 reference)
PMID:35596788 SUPPORT Human Clinical
"At least 22 genes are associated with Fanconi anemia, constituting the Fanconi anemia DNA repair pathway. This pathway coordinates multiple processes and proteins to facilitate the repair of DNA adducts including interstrand crosslinks (ICLs)"
Bone Marrow Failure
Inability of the bone marrow to produce sufficient blood cells due to hematopoietic stem cell defects.
Downstream
Pancytopenia
Aplastic Anemia
Show evidence (1 reference)
PMID:38424108 SUPPORT Model Organism
"we identify increased protein synthesis rates in the fetal hematopoietic stem cell pool at the onset of hematopoietic failure in Fanconi Anemia, a prototypical DNA repair disorder that manifests with bone marrow failure."
Demonstrates that bone marrow failure is a defining manifestation of Fanconi anemia, with origins in fetal HSC dysfunction.
Genomic Instability
Increased tendency for genomic alterations including chromosomal breaks, deletions, and rearrangements.
Downstream
Hematopoietic Stem Cell Attrition Unrepaired genomic damage in HSCs triggers checkpoint-mediated apoptosis and senescence
Developmental Progenitor Apoptosis Genomic instability in embryonic progenitors activates p53-mediated cell death
Clonal Evolution Accumulation of somatic mutations drives malignant transformation
Epithelial Cancer Susceptibility Impaired genome maintenance in epithelial tissues promotes carcinogenesis
Show evidence (1 reference)
PMID:35596788 SUPPORT Human Clinical
"ICLs can interfere with DNA transactions, including replication and transcription. If not properly removed and repaired, ICLs cause DNA breaks and lead to genomic instability, a hallmark of cancer."
Hematopoietic Stem Cell Attrition
Progressive depletion of long-term hematopoietic stem cells in bone marrow due to replication stress, aldehyde-induced DNA damage, and chronic inflammatory signaling.
hematopoietic stem cell link
cellular response to aldehyde link cellular response to oxidative stress link
bone marrow link
Downstream
Bone Marrow Failure
Show evidence (2 references)
PMID:38424108 SUPPORT Model Organism
"proteostasis deregulation itself is driven by excess sterile inflammatory activity in hematopoietic and stromal cells within the fetal liver, and dampened Type I interferon signaling similarly restores fetal Fancd2-/- long-term hematopoietic stem cells to wild type-equivalent numbers."
Demonstrates that inflammatory signaling drives HSC pool deficits in FA, and that dampening inflammation rescues HSC numbers.
PMID:24037726 PARTIAL Human Clinical
"the FA proteins might counteract aldehyde-induced genotoxicity in hematopoietic stem cells"
Establishes that aldehydes cause genotoxicity in HSCs and FA proteins normally protect against this damage.
Translesion Synthesis Defect
Impaired ability to bypass DNA lesions during replication through translesion synthesis polymerases, requiring functional FANCD2-FANCI complex and PCNA monoubiquitination.
translesion synthesis link
Downstream
Genomic Instability
Show evidence (1 reference)
PMID:25237197 PARTIAL Other
"Establishing the interaction network involving the FA proteins and their associated partners has revealed an intersection of FA with several DNA repair pathways, including homologous recombination, DNA mismatch repair, nucleotide excision repair, and translesion DNA synthesis."
Demonstrates that the FA pathway intersects with translesion DNA synthesis, establishing the mechanistic link.
Homologous Recombination Impairment
Defective repair of DNA double-strand breaks following interstrand crosslink unhooking, due to mutations in FA genes involved in HR pathway including BRCA2, PALB2, and BRCA1.
homologous recombination link
Downstream
Genomic Instability
Show evidence (1 reference)
PMID:25237197 PARTIAL Other
"the fact that 5 FA genes are in fact familial breast cancer genes and FA gene mutations are found frequently in sporadic cancers suggest wider applicability in hematopoiesis and oncology."
The overlap of FA genes with breast cancer genes (BRCA1, BRCA2, PALB2) establishes the connection between FA and homologous recombination repair.
Aldehyde-Induced Genotoxicity
Endogenous aldehydes (acetaldehyde and formaldehyde) from normal metabolism generate DNA interstrand crosslinks and DNA-protein crosslinks; impaired detoxification by ALDH2 and ADH5 exacerbates DNA damage burden.
cellular response to aldehyde link
Downstream
Hematopoietic Stem Cell Attrition Endogenous aldehyde-induced DNA damage preferentially depletes HSCs when FA pathway is absent
Show evidence (2 references)
PMID:24037726 SUPPORT Human Clinical
"We examined 64 Japanese FA patients, and found that the ALDH2 variant is associated with accelerated progression of BMF"
Human clinical data showing that impaired aldehyde detoxification (ALDH2 variant) accelerates bone marrow failure in FA patients.
PMID:25237197 SUPPORT Other
"recent studies have shown a major involvement of the FA pathway in the tolerance of reactive aldehydes."
Establishes that the FA pathway is required for tolerance of aldehyde-induced DNA damage.
Core Complex Dysfunction
Mutations in FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, UBE2T/FANCT) disrupt the E3 ubiquitin ligase that monoubiquitinates the FANCD2-FANCI complex, abolishing the central signaling step of the FA pathway. FANCA mutations account for 60-70% of all FA cases.
FANCA link FANCB link FANCC link FANCG link
FA nuclear complex link
protein ubiquitination link
Downstream
DNA Repair Deficiency Loss of core complex prevents FANCD2-FANCI monoubiquitination
Show evidence (1 reference)
PMID:35596788 PARTIAL Human Clinical
"At least 22 genes are associated with Fanconi anemia, constituting the Fanconi anemia DNA repair pathway."
Core complex genes form the upstream signaling arm of the FA pathway.
ID Complex Dysfunction
Mutations in FANCD2 or FANCI disrupt the central ID2 complex whose monoubiquitination is the critical signaling event in FA pathway activation. In wild type, the core complex E3 ligase monoubiquitinates both FANCD2 and FANCI, causing the ID2 heterodimer to clamp onto chromatin at stalled replication forks and recruit downstream nucleases and HR effectors. Loss of either subunit abolishes this signaling hub.
FANCD2 link FANCI link
protein monoubiquitination link interstrand cross-link repair link
Downstream
DNA Repair Deficiency Absence of functional ID2 complex prevents recruitment of downstream repair effectors
Show evidence (1 reference)
PMID:32106311 SUPPORT Human Clinical
"This reflects the indispensable role of FANCB protein in the enzymatic activation of FANCD2 monoubiquitination, an essential step in the repair of DNA interstrand crosslinks."
FANCD2 monoubiquitination is the essential central step in ICL repair.
Downstream Effector Dysfunction
Mutations in downstream effector genes (BRCA2/FANCD1, PALB2/FANCN, BRCA1/FANCS, RAD51C/FANCO, XRCC2/FANCU) impair homologous recombination and translesion synthesis. These overlap with familial breast/ovarian cancer genes; biallelic mutations produce the most severe FA phenotypes with early-onset solid tumors and more congenital anomalies.
BRCA2 link BRCA1 link
Downstream
Homologous Recombination Impairment Loss of BRCA2/PALB2/BRCA1/RAD51C directly impairs HR-mediated DNA repair
Show evidence (1 reference)
PMID:25237197 PARTIAL Other
"the fact that 5 FA genes are in fact familial breast cancer genes and FA gene mutations are found frequently in sporadic cancers suggest wider applicability in hematopoiesis and oncology."
Downstream FA genes overlap with breast cancer susceptibility genes.
Inflammatory Bone Marrow Microenvironment
Excess sterile inflammatory signaling (TNF-alpha, interferon-gamma, Type I interferons) in the bone marrow creates a hostile microenvironment for HSCs. Both hematopoietic and stromal cells contribute to chronic inflammation, driving proteostasis deregulation and accelerating stem cell attrition.
hematopoietic stem cell link
inflammatory response link
bone marrow link
Downstream
Hematopoietic Stem Cell Attrition Chronic inflammatory signaling drives proteostasis deregulation and HSC depletion
Show evidence (1 reference)
PMID:38424108 SUPPORT Model Organism
"proteostasis deregulation itself is driven by excess sterile inflammatory activity in hematopoietic and stromal cells within the fetal liver, and dampened Type I interferon signaling similarly restores fetal Fancd2-/- long-term hematopoietic stem cells to wild type-equivalent numbers."
Inflammatory signaling in the BM microenvironment drives HSC loss in FA.
Developmental Progenitor Apoptosis
Unrepaired DNA damage in rapidly dividing embryonic progenitor cells activates p53-dependent apoptosis during critical developmental windows. This mechanism underlies the congenital malformations of FA, explaining the midline predominance of anomalies and correlation between pathway position and congenital abnormality burden.
apoptotic process link embryo development link
Downstream
Congenital Structural Anomalies Loss of mesodermal and endodermal progenitors causes organ malformations
CNS Developmental Anomalies Loss of neural progenitors causes midline brain and pituitary defects
Endocrine Gland Dysfunction Developmental pituitary defects impair hormone production
Skin Pigmentation Changes Melanocyte progenitor defects cause pigmentary anomalies
Intrauterine Growth Retardation
Show evidence (1 reference)
PMID:26369989 PARTIAL Human Clinical
"The incidence of central nervous system (CNS) abnormalities in FA is higher than previously reported, with a midline predominance that points to impact in the early stages of CNS development."
Midline predominance of anomalies supports developmental progenitor loss during embryogenesis.
Clonal Evolution
Progressive accumulation of somatic mutations and chromosomal aberrations in genomically unstable hematopoietic cells drives clonal selection and malignant transformation. Characteristic cytogenetic changes include gain of 1q and 3q and loss of 7q. Clones with selective growth advantage expand, leading to MDS and AML. Single-cell DNA sequencing has revealed polyclonal evolution at the MDS stage, with sequential acquisition of driver mutations and MDM4-mediated p53 dampening via chromosome 1q gain as the canonical initiating event.
hematopoietic stem cell link
bone marrow link
Downstream
Myelodysplastic Syndrome
Increased Risk of Leukemia
Show evidence (4 references)
PMID:31558676 PARTIAL Human Clinical
"30% developed myelodysplastic syndrome (MDS), leukemia and/or solid tumors"
30% malignancy rate reflects ongoing clonal evolution in FA HSCs.
PMID:36736290 SUPPORT Human Clinical
"Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia."
Longitudinal study of 335 FA patients showing chromosome 1q gain (containing MDM4) as the most common early clonal event, dampening p53 and driving clonal hematopoiesis.
PMID:36167633 SUPPORT Human Clinical
"Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution."
Single-cell DNA sequencing of FA patients transforming to MDS/AML revealed polyclonal patterns with sequential acquisition of UBASH3A, SF3B1, RUNX1, and IDH2 mutations.
+ 1 more reference
Epithelial Cancer Susceptibility
Impaired genome maintenance in epithelial tissues renders them vulnerable to accumulation of oncogenic mutations. Squamous epithelia of the head/neck, oral cavity, esophagus, and anogenital regions are particularly susceptible due to high proliferative turnover and exposure to environmental mutagens including HPV.
epithelial cell link
Downstream
Squamous Cell Carcinoma
Early-Onset Solid Tumors in FANCD1/BRCA2
Show evidence (3 references)
PMID:20301575 SUPPORT Human Clinical
"Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA."
Confirms epithelial tissue susceptibility to malignancy in FA.
PMID:36912284 PARTIAL In Vitro
"We developed the Fanconi Anemia Cancer Cell Line Resource (FA-CCLR) to foster new work on the origins, treatment and prevention of FA-associated carcinomas. The FA-CCLR consists of Fanconi-isogenic head and neck squamous cell carcinoma (HNSCC) cell line pairs generated from five individuals with..."
Isogenic FA/sporadic HNSCC cell line pairs provide a platform to identify FA-dependent cancer phenotypes and test therapeutic strategies.
PMID:36450981 PARTIAL Computational
"Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer."
Computational genomic analysis defined the primary structural variant signature of FA pathway deficiency in squamous cancers, enabling computational classification of FA-associated vs sporadic carcinomas.
HPV-Mediated Epithelial Damage
Human papillomavirus infection compounds epithelial cancer risk in FA patients. HPV oncoproteins E6 and E7 degrade p53 and Rb tumor suppressors, further disabling the already compromised DNA damage response. HPV vaccination is recommended to reduce gynecologic and oropharyngeal cancer risk.
Downstream
Epithelial Cancer Susceptibility HPV oncoproteins synergize with FA pathway deficiency to accelerate carcinogenesis
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Human papilloma virus (HPV) vaccination to reduce the risk for gynecologic cancer in females"
HPV vaccination recommendation implies HPV is a significant co-factor for epithelial cancer in FA.
Endocrine Gland Dysfunction
Widespread endocrine abnormalities affect approximately 73-80% of FA patients. Developmental pituitary/hypothalamic defects (68% have small pituitary on MRI), direct effects of genomic instability on endocrine cell function, and chronic illness contribute. Manifests as GH deficiency, hypothyroidism, glucose dysregulation, hypogonadism, dyslipidemia, and metabolic syndrome.
pituitary gland link
Downstream
Growth Hormone Deficiency
Hypothyroidism
Abnormal Glucose Homeostasis
Delayed Puberty and Hypogonadism
Osteopenia and Osteoporosis
Short Stature
Impaired Fertility
Show evidence (2 references)
PMID:17426088 SUPPORT Human Clinical
"Endocrine abnormalities were present in 73%, including short stature and/or GH deficiency (51%), hypothyroidism (37%), midline brain abnormalities (17%)"
Giri et al. documents 73% endocrine abnormality prevalence.
PMID:26369989 SUPPORT Human Clinical
"Abnormalities were identified in 18 (90%) patients with FA, the commonest being a small pituitary (68%, p < 0.01 females and p < 0.001 males)"
Small pituitary in 68% provides anatomical basis for endocrine dysfunction.
Congenital Structural Anomalies
Developmental progenitor loss during embryogenesis causes structural malformations affecting limbs, heart, kidneys, GI tract, ears, and genitourinary system. Approximately 75% of FA patients have at least one congenital anomaly, with burden correlating with complementation group, mutation type, and pathway position.
Downstream
Skeletal Anomalies
Radial Ray Defects
Absent or Hypoplastic Thumbs
Congenital Heart Defects
Genital Malformations
Abnormal Renal Morphology
Hearing Loss
Microphthalmia
Strabismus
Structural Anomalies
Dental and Craniofacial Anomalies
Cryptorchidism
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies."
75% of FA patients have physical abnormalities.
CNS Developmental Anomalies
Midline brain structural defects from neural progenitor loss during early CNS development. Includes small pituitary (68%), posterior fossa abnormalities (30% including Chiari I malformation and Dandy-Walker variant), and corpus callosum structural variation (30%).
brain link pituitary gland link
Downstream
Microcephaly
Developmental Delay
Show evidence (2 references)
PMID:26369989 SUPPORT Human Clinical
"Abnormalities were identified in 18 (90%) patients with FA, the commonest being a small pituitary (68%, p < 0.01 females and p < 0.001 males)"
90% brain MRI abnormality rate with midline predominance.
PMID:26369989 SUPPORT Human Clinical
"Posterior fossa abnormalities were seen in six cases (30%, p = 0.01) including Chiari I malformation (n = 3), Dandy-Walker variant (n = 2) and cerebellar atrophy (n = 2)."
Posterior fossa and corpus callosum anomalies reflect early CNS developmental impact.
Skin Pigmentation Changes
Melanocyte progenitor defects during embryonic development cause characteristic pigmentary anomalies including café-au-lait spots and hypopigmented patches. Skin pigmentation changes are the most common congenital anomaly in FA, affecting over 50% of patients.
Downstream
Café-au-Lait Spots
Hypopigmented Skin Patches
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"More than half had café-au-lait spots (52.3%) followed by renal anomalies (39.6%)."
Café-au-lait spots are the most common congenital anomaly in the Israeli FA cohort.
MYC-Driven HSPC Dysfunction
Single-cell RNA sequencing of primary FA patient bone marrow HSPCs revealed MYC overexpression as a novel pathogenic driver alongside p53 and TGF-beta upregulation. Distinct HSPC subpopulations co-expressing high TP53 or high MYC coexist in FA bone marrow. MYC-high HSPCs show downregulation of cell adhesion genes (including CXCR4), promoting enhanced egress from bone marrow to peripheral blood and contributing to HSC exhaustion and bone marrow failure.
hematopoietic stem cell link
regulation of gene expression link
bone marrow link
Downstream
Hematopoietic Stem Cell Attrition MYC overexpression drives proliferation and DNA damage, accelerating HSC exhaustion
Bone Marrow Failure
Show evidence (2 references)
PMID:32997960 SUPPORT Human Clinical
"In addition to overexpression of p53 and TGF-β pathway genes, we identified high levels of MYC expression. We correspondingly observed coexistence of distinct HSPC subpopulations expressing high levels of TP53 or MYC in FA bone marrow (BM)."
scRNA-seq of primary FA patient HSPCs identifies MYC as a novel driver of BMF alongside known p53/TGF-beta pathways.
PMID:32997960 SUPPORT Model Organism
"Inhibiting MYC expression with the BET bromodomain inhibitor (+)-JQ1 reduced the clonogenic potential of FA patient HSPCs but rescued physiological and genotoxic stress in HSPCs from FA mice, showing that MYC promotes proliferation while increasing DNA damage."
BET inhibitor targeting MYC rescues genotoxic stress in FA mouse HSPCs, validating MYC as a therapeutic target.
Differentiation-Induced Genotoxic Stress
Transcriptional reprogramming during hematopoietic differentiation generates a surge of genotoxic stress from formaldehyde, an obligate by-product of oxidative protein demethylation during transcription regulation. In the absence of functional FA DNA repair, this differentiation-associated DNA damage causes aborted differentiation and depletion of FA progenitor cells, providing a mechanistic explanation for the hematopoietic-specific failure in FA despite it being a germline disorder.
hematopoietic precursor cell link
hematopoietic progenitor cell differentiation link cellular response to aldehyde link
Downstream
Hematopoietic Stem Cell Attrition Differentiation-coupled DNA damage depletes progenitors, contributing to HSC pool exhaustion
Bone Marrow Failure
Show evidence (1 reference)
PMID:33338401 SUPPORT In Vitro
"reprogramming transcription during hematopoietic differentiation results in an overload of genotoxic stress, which causes aborted differentiation and depletion of FA mutant progenitor cells. DNA damage onset most likely arises from formaldehyde, an obligate by-product of oxidative protein..."
Demonstrates that transcriptional reprogramming during differentiation generates formaldehyde-induced DNA damage that specifically depletes FA-deficient progenitors.
iPSC-Revealed p53-Driven Progenitor Exhaustion
Induced pluripotent stem cell modeling of FA hematopoietic differentiation revealed that FANCA-deficient human hematopoietic progenitor cells undergo accelerated terminal differentiation driven by p53/p21 activation. GAS6 (growth arrest specific 6) was identified as a novel p53 target gene; GAS6 signaling modulation rescues hematopoiesis. This iPSC-based new approach methodology overcomes the lack of faithful murine FA models and enables drug screening for FA therapeutics.
hematopoietic precursor cell link
intrinsic apoptotic signaling pathway by p53 class mediator link
Downstream
Hematopoietic Stem Cell Attrition
Bone Marrow Failure
Show evidence (2 references)
PMID:33002135 SUPPORT In Vitro
"FANCA-deficient human HPCs underwent accelerated terminal differentiation driven by activation of p53/p21. We identified growth arrest specific 6 (GAS6) as a novel target of activated p53 in FANCA-deficient HPCs and modulate GAS6 signaling to rescue hematopoiesis in FANCA-deficient cells."
iPSC-derived FA model reveals p53/p21/GAS6 axis driving progenitor exhaustion and validates GAS6 as a therapeutic target.
PMID:33512438 PARTIAL In Vitro
"disease model iPSCs displayed drastically defective cell expansion when stimulated into hematopoietic differentiation in vitro, displaying increased levels of DNA damage. The expansion defect was partially reversed by treatment with a new small molecule termed C1, which is an agonist of ALDH2"
ADH5/ALDH2-deficient iPSCs modeling FA-like aldehyde toxicity confirm hematopoietic differentiation defects and identify ALDH2 agonism as a rescue strategy.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Fanconi_Anemia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

92
Blood 6
Pancytopenia VERY_FREQUENT Pancytopenia (HP:0001876)
Decreased levels of red blood cells, white blood cells, and platelets. Over 80% of FA patients develop bone marrow failure. Typically presents in the first decade, often initially with thrombocytopenia or leukopenia. Notably, patients with FANCD1/BRCA2 mutations may not develop BMF. FA-S (biallelic BRCA1) patients also characteristically lack bone marrow failure.
Show evidence (1 reference)
PMID:35596788 SUPPORT Human Clinical
"Fanconi anemia is a genetic disorder that is characterized by bone marrow failure, as well as a predisposition to malignancies including leukemia and squamous cell carcinoma (SCC)."
Context-specific annotations (4)
VERY_FREQUENT
Over 80% of FA patients develop bone marrow failure.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"82% of the patients developed BMF"
Israeli cohort quantifies BMF prevalence at 82%.
Genetic FA-D1 FANCD1/BRCA2 EXCLUDED
Neither FANCD1/BRCA2 patient in the Israeli cohort developed BMF. One was transplanted for AML before age 6 months; the other had no complications by age 17.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"neither of the patients with FANCD1 mutations developed BMF"
FANCD1/BRCA2 patients characteristically lack bone marrow failure.
Genetic FA-S BRCA1 HOMOZYGOUS EXCLUDED
FA-S (biallelic BRCA1) patients characteristically lack bone marrow failure, distinguishing them from most other FA complementation groups.
Show evidence (1 reference)
PMID:38146508 SUPPORT Human Clinical
"Unlike most other types of FA, FA-S patients lack bone marrow failure."
FA-S defined by absence of BMF despite other FA features.
Japanese
The ALDH2*2 dominant-negative variant (rs671), carried by nearly half of the Japanese population, is associated with accelerated BMF progression in FA patients. Birth weight and physical abnormalities were not affected.
Show evidence (1 reference)
PMID:24037726 SUPPORT Human Clinical
"the ALDH2 variant is associated with accelerated progression of BMF, while birth weight or the number of physical abnormalities was not affected"
ALDH2*2 acts as a genetic modifier accelerating BMF in Japanese FA patients.
Increased Risk of Leukemia FREQUENT Leukemia (HP:0001909)
The incidence of AML is 13% by age 50 years. Patients with FANCA mutations develop cancer at a significantly older age (mean 18.5 years) compared to non-FANCA groups (mean 5.2 years, P=0.001). Patients with FANCC mutations show a trend toward more MDS. FANCG patients may have less MDS and cancer overall. All FANCA patients in the Israeli cohort developed their first cancer after age 10, while all non-FANCA patients developed cancer by age 10.
Show evidence (1 reference)
PMID:24037726 SUPPORT Human Clinical
"It is characterized by phenotypes including progressive bone marrow failure (BMF), developmental abnormalities, and increased occurrence of leukemia and cancer."
Clinical description confirming that increased leukemia occurrence is a defining phenotype of FA.
Context-specific annotations (5)
Genetic FA-A FANCA Onset: mean 18.5y
All FANCA patients in the Israeli cohort developed their first cancer after age 10.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Patients with FANCA mutations developed cancer at a significantly older age compared to patients with mutations in other Fanconi genes (mean 18.5 and 5.2 years, respectively, P=0.001)"
FANCA patients have later onset of hematologic malignancy.
Genetic FANCC FANCD1/BRCA2 FANCG FANCJ/BRIP1 Onset: mean 5.2y
Non-FANCA complementation groups tested in the Israeli cohort (FANCC, FANCD1, FANCG, FANCJ). Not exhaustive of all non-FANCA groups but represents the specific genes analyzed.
All non-FANCA patients in the Israeli cohort developed cancer by age 10. FANCC mutations show a trend toward more MDS. FANCG patients may have less MDS and cancer overall.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Patients with FANCA mutations developed cancer at a significantly older age compared to patients with mutations in other Fanconi genes (mean 18.5 and 5.2 years, respectively, P=0.001)"
Same abstract sentence viewed from non-FANCA perspective; non-FANCA groups developed cancer significantly earlier (mean 5.2 years vs 18.5 years, P=0.001).
Genetic nonsense
Patients with nonsense mutations developed first cancer at a significantly younger age than patients with deletions (P=0.011).
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"patients with nonsense and splice site mutations developed the first cancer at a significantly lower age than patients with deletions (P=0.011 and P=0.012, respectively)"
Mutation type affects cancer onset age independent of gene identity.
Genetic splice_site
Patients with splice site mutations developed first cancer at a significantly younger age than patients with deletions (P=0.012).
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"patients with nonsense and splice site mutations developed the first cancer at a significantly lower age than patients with deletions (P=0.011 and P=0.012, respectively)"
Splice site mutations associated with earlier cancer onset.
Genetic FA-G FANCG
Trend toward less MDS and cancer in patients with FANCG mutations compared to other FA genes (not statistically significant).
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"There was a trend towards more MDS in patients with FANCC mutations and less MDS and cancer in patients with FANCG mutations, compared with patients with mutations in other genes (NS)."
FANCG mutations may be associated with a milder malignancy phenotype.
Aplastic Anemia VERY_FREQUENT Anemia (HP:0001903)
Show evidence (2 references)
PMID:24037726 SUPPORT Human Clinical
"It is characterized by phenotypes including progressive bone marrow failure (BMF), developmental abnormalities, and increased occurrence of leukemia and cancer."
Progressive bone marrow failure is a cardinal feature of FA leading to aplastic anemia.
ORPHA:84 SUPPORT Other
"HP:0001903 | Anemia | Very frequent (99-80%)"
Orphanet's curated HPO annotation classifies anemia as very frequent in Fanconi anemia.
Thrombocytopenia VERY_FREQUENT Thrombocytopenia (HP:0001873)
Listed in FA clinical screening manifestations and commonly contributes to bleeding risk.
Show evidence (2 references)
PMID:20301575 SUPPORT Human Clinical
"Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia"
GeneReviews documents progressive bone marrow failure with thrombocytopenia and leukopenia as typical hematologic manifestations.
ORPHA:84 SUPPORT Other
"HP:0001873 | Thrombocytopenia | Very frequent (99-80%)"
Orphanet's curated HPO annotation classifies thrombocytopenia as very frequent in Fanconi anemia.
Leukopenia VERY_FREQUENT Decreased total leukocyte count (HP:0001882)
Included in the FA screening phenotype table for bone marrow failure manifestations.
Show evidence (2 references)
PMID:20301575 SUPPORT Human Clinical
"Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia"
GeneReviews documents progressive bone marrow failure with thrombocytopenia and leukopenia as typical hematologic manifestations.
ORPHA:84 SUPPORT Other
"HP:0001882 | Leukopenia | Very frequent (99-80%)"
Orphanet's curated HPO annotation classifies leukopenia as very frequent in Fanconi anemia.
Myelodysplastic Syndrome FREQUENT Myelodysplasia (HP:0002863)
In the Israeli cohort, 30% of patients developed MDS, leukemia, and/or solid tumors. Patients with non-FANCA mutations (FANCC, FANCD1, FANCG, FANCJ) developed first cancer (including MDS) significantly earlier than FANCA patients (mean 5.2 vs 18.5 years, P=0.001). There was a trend toward more MDS in FANCC patients.
Show evidence (2 references)
PMID:31558676 SUPPORT Human Clinical
"30% developed myelodysplastic syndrome (MDS), leukemia and/or solid tumors"
Israeli cohort documents that 30% of FA patients developed MDS, leukemia, and/or solid tumors.
PMID:31558676 SUPPORT Human Clinical
"The mean age of the first cancer was 18.5 years (SD 6.3 years) for patients with FANCA, relative to 5.2 years (SD 3.7 years) for patients with FANCC, FANCD1, FANCG and FANCJ mutations, with a statistically significant difference (P=0.001)."
Demonstrates significantly earlier cancer onset in non-FANCA complementation groups.
Context-specific annotations (1)
Onset: mean 13.3y
Mean age of first MDS event was 13.3 years in the Israeli cohort. There was a trend toward more MDS in FANCC patients.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"30% developed myelodysplastic syndrome (MDS), leukemia and/or solid tumors"
Israeli cohort documents MDS as part of the 30% cancer rate in FA patients.
Cardiovascular 7
Congenital Heart Defects OCCASIONAL Abnormal heart morphology (HP:0001627)
Part of the VACTERL association overlap with FA. Heart abnormalities contribute to the congenital abnormality burden score (CABS). Patients with missense mutations had significantly less congenital heart disease (P=0.022) in the Israeli cohort. Downstream FA genes (FANCD1, FANCJ) may be associated with more severe congenital anomalies.
Show evidence (3 references)
PMID:20301575 SUPPORT Human Clinical
"Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
GeneReviews lists cardiac anomalies as part of the FA clinical spectrum requiring subspecialty management.
PMID:31558676 SUPPORT Human Clinical
"Patients with missense mutations had significantly less congenital heart disease (P=0.022)."
Israeli cohort study found genotype-phenotype correlation for cardiac defects and mutation type.
PMID:20301575 SUPPORT Human Clinical
"Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
Context-specific annotations (1)
Genetic missense OCCASIONAL
Missense mutations associated with significantly less congenital heart disease (P=0.022) in the Israeli cohort.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Patients with missense mutations had significantly less congenital heart disease (P=0.022)."
Missense mutations are protective relative to other mutation types for cardiac defects.
Patent Ductus Arteriosus OCCASIONAL Patent ductus arteriosus (HP:0001643)
Listed in FA guideline cardiac manifestations used for FA screening.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
Atrial Septal Defect OCCASIONAL Atrial septal defect (HP:0001631)
Listed in FA guideline cardiac manifestations used for FA screening.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
Ventricular Septal Defect OCCASIONAL Ventricular septal defect (HP:0001629)
Listed in FA guideline cardiac manifestations used for FA screening.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
Coarctation of Aorta OCCASIONAL Coarctation of aorta (HP:0001680)
Listed in FA guideline cardiac manifestations used for FA screening.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
Truncus Arteriosus OCCASIONAL Truncus arteriosus (HP:0001660)
Listed in FA guideline cardiac manifestations used for FA screening.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
Situs Inversus OCCASIONAL Situs inversus totalis (HP:0001696)
Listed in FA guideline cardiac manifestations used for FA screening.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
Digestive 8
Esophageal Atresia OCCASIONAL Esophageal atresia (HP:0002032)
Included in the FA guideline atresia spectrum used for diagnostic screening.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
Duodenal Atresia OCCASIONAL Duodenal atresia (HP:0002247)
Included in the FA guideline atresia spectrum used for diagnostic screening.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
Jejunal Atresia OCCASIONAL Jejunal atresia (HP:0005235)
Included in the FA guideline atresia spectrum used for diagnostic screening.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
Anal Atresia OCCASIONAL Anal atresia (HP:0002023)
Included in FA guideline diagnostic manifestations as imperforate or bifurcated anus.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
Intestinal Malrotation OCCASIONAL Intestinal malrotation (HP:0002566)
Included in FA guideline gastrointestinal screening manifestations.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
Annular Pancreas OCCASIONAL Annular pancreas (HP:0001734)
Listed in the FA guideline gastrointestinal anomaly table.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
Tracheoesophageal Fistula OCCASIONAL Tracheoesophageal fistula (HP:0002575)
Included as a diagnostic screening manifestation in FA clinical care guidelines.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
Rectovaginal Fistula OCCASIONAL Rectovaginal fistula (HP:0000143)
Included in the FA guideline female-genital manifestations used for FA screening. GeneReviews lists genital anomalies broadly as an FA manifestation; rectovaginal fistula as a specific subtype is documented in the FA clinical care guidelines but not individually named in available PubMed abstracts.
Ear 5
Hearing Loss OCCASIONAL Hearing impairment (HP:0000365)
In the Israeli FA cohort, 18% of patients had hearing loss, all with a conductive component. Hearing loss contributes to the congenital abnormality burden score (CABS). Hearing aids may be helpful per otolaryngology evaluation.
Show evidence (2 references)
PMID:31558676 SUPPORT Human Clinical
"Of the 18% of the patients with hearing loss, all had a conductive component"
Israeli cohort documents 18% hearing loss prevalence with conductive component in FA patients.
PMID:20301575 SUPPORT Human Clinical
"Hearing aids may be helpful for hearing loss as per otolaryngologist"
GeneReviews recommends hearing evaluation and hearing aids as part of FA management.
Abnormal Pinna Morphology OCCASIONAL Abnormal pinna morphology (HP:0000377)
Included in FA guideline otologic manifestations and supported by dedicated ear-phenotype sections.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Hearing aids may be helpful for hearing loss as per otolaryngologist"
GeneReviews documents hearing loss among FA manifestations and recommends otolaryngology evaluation.
External Auditory Canal Atresia OCCASIONAL Atresia of the external auditory canal (HP:0000413)
Described in FA guideline otologic sections as part of structural ear anomalies.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Hearing aids may be helpful for hearing loss as per otolaryngologist"
GeneReviews documents hearing loss among FA manifestations and recommends otolaryngology evaluation.
External Auditory Canal Stenosis OCCASIONAL Stenosis of the external auditory canal (HP:0000402)
Included in FA guideline otologic manifestations as a narrow/atretic canal.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Hearing aids may be helpful for hearing loss as per otolaryngologist"
GeneReviews documents hearing loss among FA manifestations and recommends otolaryngology evaluation.
Middle Ear Ossicle Abnormalities OCCASIONAL Abnormality of the middle ear ossicles (HP:0004452)
Included in FA guideline otologic manifestations as abnormal middle ear bones.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Hearing aids may be helpful for hearing loss as per otolaryngologist"
GeneReviews documents hearing loss among FA manifestations and recommends otolaryngology evaluation.
Endocrine 6
Anterior Pituitary Hypoplasia OCCASIONAL Anterior pituitary hypoplasia (HP:0010627)
Included in FA guideline CNS screening manifestations as small pituitary/stalk anomalies.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including central nervous system anomalies.
Interrupted Pituitary Stalk OCCASIONAL Interrupted pituitary stalk (HP:0034978)
Included in FA guideline CNS screening manifestations as stalk interruption.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including central nervous system anomalies.
Hypothyroidism FREQUENT Hypothyroidism (HP:0000821)
About 80% of FA patients have at least one endocrine abnormality. Hypothyroidism is one of the most common endocrine manifestations. Annual TSH and free T4 screening is recommended.
Show evidence (1 reference)
PMID:25575015 SUPPORT Human Clinical
"About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
Consensus review documents hypothyroidism as a common endocrine abnormality in FA.
Context-specific annotations (1)
FREQUENT
37% prevalence in the NCI cohort (n=45, Giri et al. 2007). Annual TSH and free T4 screening is recommended.
Show evidence (1 reference)
PMID:17426088 SUPPORT Human Clinical
"short stature and/or GH deficiency (51%), hypothyroidism (37%)"
Giri et al. NCI cohort quantifies hypothyroidism at 37% in FA patients.
Growth Hormone Deficiency FREQUENT Secondary growth hormone deficiency (HP:0008240)
GH deficiency affects approximately 51% of FA patients (Giri et al. 2007, NCI cohort). Patients with GH deficiency were significantly shorter than those without (P=0.01). Growth hormone therapy may be used but requires careful monitoring given cancer predisposition. Ninety-two percent of FA patients aged 18 or older had osteopenia or osteoporosis.
Show evidence (2 references)
PMID:17426088 SUPPORT Human Clinical
"short stature and/or GH deficiency (51%)"
NCI cohort study of 45 FA patients found GH deficiency in 51%, establishing it as a frequent phenotype.
PMID:25575015 SUPPORT Human Clinical
"About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
Consensus review identifies GH deficiency as a recognized endocrine abnormality in FA.
Context-specific annotations (1)
FREQUENT
51% of FA patients had short stature and/or GH deficiency in the NCI cohort (n=45). Only GH deficiency correlated significantly with short stature (P=0.01). Midline brain abnormalities were found in 17% of patients, and 60% of those were GH-deficient.
Show evidence (1 reference)
PMID:17426088 SUPPORT Human Clinical
"short stature and/or GH deficiency (51%), hypothyroidism (37%), midline brain abnormalities (17%) (these patients had very short stature and 60% were GH-deficient)"
Giri et al. NCI cohort quantifies GH deficiency at 51% with pituitary abnormality association.
Delayed Puberty and Hypogonadism FREQUENT Delayed puberty (HP:0000823)
Pubertal delay and hypogonadism are among the most common endocrine abnormalities in FA (present in up to 80% of patients with at least one endocrine abnormality). Pubertal staging and hormone levels should be assessed at puberty and every two years until complete.
Show evidence (1 reference)
PMID:25575015 SUPPORT Human Clinical
"About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
Consensus review identifies pubertal delay and hypogonadism as prominent endocrine features of FA.
Context-specific annotations (1)
VERY_FREQUENT
65% of peripubertal or postpubertal FA patients had gonadal dysfunction in the NCI cohort (Giri et al. 2007).
Show evidence (1 reference)
PMID:17426088 SUPPORT Human Clinical
"65% of peripubertal or postpubertal patients had gonadal dysfunction"
Giri et al. NCI cohort quantifies gonadal dysfunction at 65% in peripubertal/postpubertal FA patients.
Delayed Menarche OCCASIONAL Delayed menarche (HP:0012569)
Included in the FA guideline female-genital and endocrine-reproductive manifestation spectrum. GeneReviews lists genital anomalies broadly as an FA manifestation; delayed menarche as a specific feature is documented in the FA clinical care guidelines but not individually named in available PubMed abstracts.
Eye 6
Hypertelorism OCCASIONAL Hypertelorism (HP:0000316)
Included in FA guideline facial manifestations used for diagnostic screening.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
Hypotelorism OCCASIONAL Hypotelorism (HP:0000601)
Included in FA guideline facial manifestations used for diagnostic screening.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
Microphthalmia OCCASIONAL Microphthalmia (HP:0000568)
Ophthalmic anomalies are listed among the congenital features present in approximately 75% of FA patients. Microphthalmia may be more common in patients with higher congenital abnormality burden scores.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"ophthalmic and genitourinary tract anomalies"
GeneReviews lists ophthalmic anomalies including microphthalmia among FA congenital features.
Strabismus OCCASIONAL Strabismus (HP:0000486)
Part of the ophthalmic anomaly spectrum in FA.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"ophthalmic and genitourinary tract anomalies"
GeneReviews lists ophthalmic anomalies as part of the FA congenital phenotype spectrum.
Cataract OCCASIONAL Cataract (HP:0000518)
Included in the FA guideline diagnostic manifestation table under eye abnormalities.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"ophthalmic and genitourinary tract anomalies"
GeneReviews lists ophthalmic anomalies as part of the FA congenital phenotype spectrum.
Ptosis OCCASIONAL Ptosis (HP:0000508)
Included in FA guideline eye-abnormality screening manifestations.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"ophthalmic and genitourinary tract anomalies"
GeneReviews lists ophthalmic anomalies as part of the FA congenital phenotype spectrum.
Genitourinary 11
Impaired Fertility FREQUENT Infertility (HP:0000789)
Male infertility is very common due to primary gonadal failure. Female fertility is reduced but pregnancies have been reported. Fertility preservation counseling should be offered early.
Show evidence (1 reference)
PMID:25575015 SUPPORT Human Clinical
"About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
Impaired fertility is listed as a key endocrine abnormality in FA patients.
Context-specific annotations (2)
MALE VERY_FREQUENT
Near-universal azoospermia due to primary gonadal failure.
Show evidence (1 reference)
PMID:25575015 SUPPORT Human Clinical
"About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
Male infertility in FA is near-universal due to gonadal failure and azoospermia.
FEMALE FREQUENT
Reduced fertility with diminished ovarian reserve and premature menopause, but pregnancies have been reported.
Show evidence (1 reference)
PMID:25575015 SUPPORT Human Clinical
"About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
Female fertility is reduced but not absent; successful pregnancies have been documented.
Cryptorchidism OCCASIONAL Cryptorchidism (HP:0000028)
Part of the genitourinary anomaly spectrum. Genital anomalies were significantly more common in patients with downstream FA gene mutations (FANCD1, FANCJ) compared to core complex mutations in the Israeli cohort.
Show evidence (3 references)
PMID:20301575 SUPPORT Human Clinical
"ophthalmic and genitourinary tract anomalies"
GeneReviews lists genitourinary anomalies including genital anomalies as part of FA.
PMID:31558676 SUPPORT Human Clinical
"Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."
Israeli cohort found genitourinary anomalies enriched in downstream FA gene mutations (FANCD1, FANCJ).
ORPHA:84 SUPPORT Other
"HP:0000028 | Cryptorchidism | Occasional (29-5%)"
Orphanet specifically lists cryptorchidism as an occasional phenotype in Fanconi anemia.
Context-specific annotations (1)
Genetic FANCD1/BRCA2 FANCJ/BRIP1 FREQUENT
Downstream FA pathway genes
Genitourinary anomalies including cryptorchidism were significantly more common in downstream FA gene mutations (P=0.03).
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."
Downstream pathway mutations enriched for genitourinary anomalies including cryptorchidism.
Testicular Aplasia or Hypoplasia OCCASIONAL Aplasia/Hypoplasia of the testes (HP:0010468)
Included in FA guideline male genital manifestations used for diagnostic screening.
Show evidence (1 reference)
ORPHA:84 SUPPORT Other
"HP:0000035 | Abnormal testis morphology | Occasional (29-5%)"
Orphanet lists abnormal testis morphology as an occasional phenotype in Fanconi anemia; aplasia/hypoplasia of the testes is a specific subtype.
Hypospadias OCCASIONAL Hypospadias (HP:0000047)
Listed in FA guideline male genital manifestations used for diagnostic screening.
Show evidence (2 references)
PMID:20301575 SUPPORT Human Clinical
"ophthalmic and genitourinary tract anomalies"
GeneReviews lists genitourinary tract anomalies as part of the FA congenital phenotype spectrum.
ORPHA:84 SUPPORT Other
"HP:0000047 | Hypospadias | Occasional (29-5%)"
Orphanet specifically lists hypospadias as an occasional phenotype in Fanconi anemia.
Micropenis OCCASIONAL Micropenis (HP:0000054)
Included in FA guideline male genital manifestations used for diagnostic screening. GeneReviews lists genitourinary tract anomalies broadly in FA; micropenis is a specific subtype reported in the FA clinical care guidelines but not individually named in available PubMed abstracts.
Bicornuate Uterus OCCASIONAL Bicornuate uterus (HP:0000813)
Included in the FA guideline female-genital manifestations used for FA screening.
Show evidence (2 references)
PMID:20301575 SUPPORT Human Clinical
"Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
GeneReviews lists genital anomalies among the FA manifestations requiring subspecialty management.
ORPHA:84 SUPPORT Other
"HP:0000813 | Bicornuate uterus | Occasional (29-5%)"
Orphanet specifically lists bicornuate uterus as an occasional phenotype in Fanconi anemia.
Uterine Aplasia or Hypoplasia OCCASIONAL Aplasia/hypoplasia of the uterus (HP:0008684)
Included in the FA guideline female-genital manifestations used for FA screening.
Show evidence (1 reference)
ORPHA:84 SUPPORT Other
"HP:0000130 | Abnormality of the uterus | Occasional (29-5%)"
Orphanet lists abnormality of the uterus as an occasional phenotype in FA; aplasia/hypoplasia of the uterus is a specific subtype.
Gonadal Dysgenesis OCCASIONAL Gonadal dysgenesis (HP:0000133)
Included in the FA guideline female-genital manifestations used for FA screening. GeneReviews lists genital anomalies broadly as an FA manifestation; gonadal dysgenesis as a specific subtype is documented in the FA clinical care guidelines but not individually named in available PubMed abstracts.
Ovarian Hypoplasia OCCASIONAL Aplasia/Hypoplasia of the ovary (HP:0010462)
Included in the FA guideline female-genital manifestations as small ovaries. GeneReviews lists genital anomalies broadly as an FA manifestation; ovarian hypoplasia as a specific subtype is documented in the FA clinical care guidelines but not individually named in available PubMed abstracts.
Vaginal Atresia OCCASIONAL Vaginal atresia (HP:0000148)
Included in the FA guideline female-genital manifestations used for FA screening. GeneReviews lists genital anomalies broadly as an FA manifestation; vaginal atresia as a specific subtype is documented in the FA clinical care guidelines but not individually named in available PubMed abstracts.
Premature Ovarian Insufficiency OCCASIONAL Premature ovarian insufficiency (HP:0008209)
Included in the FA guideline female-genital manifestations as early menopause. GeneReviews lists genital anomalies broadly as an FA manifestation; premature ovarian insufficiency as a specific feature is documented in the FA clinical care guidelines but not individually named in available PubMed abstracts.
Head and Neck 10
Microcephaly OCCASIONAL Microcephaly (HP:0000252)
Part of the congenital anomaly spectrum. Skull anomalies were significantly more common in patients with downstream FA gene mutations (FANCD1, FANCJ) compared to core complex mutations (P<0.001). FA-S (biallelic BRCA1) patients also frequently present with microcephaly.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
Context-specific annotations (4)
Orphanet curated aggregate FREQUENT
Orphanet classifies microcephaly as frequent in Fanconi anemia.
Show evidence (1 reference)
ORPHA:84 SUPPORT Other
"HP:0000252 | Microcephaly | Frequent (79-30%)"
Orphanet's curated HPO annotation classifies microcephaly as frequent in Fanconi anemia.
Genetic FANCD1/BRCA2 FANCJ/BRIP1 VERY_FREQUENT
Downstream FA pathway genes
Skull anomalies were significantly more common in patients with downstream FA gene mutations compared to core complex mutations (P<0.001).
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."
Downstream pathway mutations associated with significantly more skull anomalies including microcephaly.
Genetic FA-S BRCA1 HOMOZYGOUS VERY_FREQUENT
FA-S (biallelic BRCA1) patients frequently present with microcephaly.
Show evidence (1 reference)
PMID:38146508 SUPPORT Human Clinical
"this FA-S cohort phenotype includes short stature, microcephaly, facial dysmorphisms"
Microcephaly is a characteristic feature of the FA-S phenotype.
VERY_FREQUENT
90% of FA patients (18/20) had brain MRI abnormalities including small pituitary (68%), posterior fossa abnormalities (30%), and corpus callosum structural variation (30%). The high incidence of midline CNS anomalies points to impact in early stages of CNS development.
Show evidence (1 reference)
PMID:26369989 SUPPORT Human Clinical
"Abnormalities were identified in 18 (90%) patients with FA, the commonest being a small pituitary (68%, p < 0.01 females and p < 0.001 males)"
Stivaros et al. found 90% of FA patients have brain MRI abnormalities, much higher than previously recognized.
Micrognathia OCCASIONAL Micrognathia (HP:0000347)
Included in the FA guideline facial manifestations that should raise suspicion for FA.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
Cleft Palate OCCASIONAL Cleft palate (HP:0000175)
Listed in FA guideline facial manifestations used for diagnostic screening.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
Triangular Face OCCASIONAL Triangular face (HP:0000325)
Included in FA guideline facial manifestations used for diagnostic screening.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
Midface Retrusion OCCASIONAL Midface retrusion (HP:0011800)
Included in FA guideline facial manifestations as mid-face hypoplasia.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
Pointed Chin OCCASIONAL Pointed chin (HP:0000307)
Included in FA guideline facial manifestations used for diagnostic screening.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
Facial Palsy OCCASIONAL Facial palsy (HP:0010628)
Included in FA guideline facial manifestations used for diagnostic screening.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
Epicanthus OCCASIONAL Epicanthus (HP:0000286)
Included in FA guideline eye manifestations used for diagnostic screening.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"ophthalmic and genitourinary tract anomalies"
GeneReviews lists ophthalmic anomalies as part of the FA congenital phenotype spectrum.
Almond-Shaped Palpebral Fissures OCCASIONAL Almond-shaped palpebral fissure (HP:0007874)
Included in FA guideline eye manifestations used for diagnostic screening.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"ophthalmic and genitourinary tract anomalies"
GeneReviews lists ophthalmic anomalies as part of the FA congenital phenotype spectrum.
Dental and Craniofacial Anomalies FREQUENT Abnormality of the dentition (HP:0000164)
In a systematic review with 46 additional Brazilian cases, 93.5% of FA patients exhibited dental/craniofacial anomalies. Root abnormalities (69.6%), tooth rotation (54.3%), and tooth agenesis (26%) were most common. Anomalies in tooth size and shape were more prevalent in patients who underwent HSCT at age 14 or older.
Show evidence (1 reference)
PMID:39568270 SUPPORT Human Clinical
"In our cohort, 93.5% of patients exhibited anomalies, primarily root abnormalities (69.6%), tooth rotation (54.3%), and tooth agenesis (26%)."
Systematic review demonstrates very high prevalence of dental anomalies in FA patients.
Integument 3
Café-au-Lait Spots FREQUENT Cafe-au-lait spot (HP:0000957)
One of the abnormal skin pigmentation findings in FA
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
Abnormal skin pigmentation, including café-au-lait spots, is among the physical abnormalities present in ~75% of FA patients.
Context-specific annotations (1)
FREQUENT
52.3% of patients in the Israeli cohort had café-au-lait spots, the most common congenital anomaly.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"More than half had café-au-lait spots (52.3%) followed by renal anomalies (39.6%)."
Quantitative frequency from Israeli FA cohort (n=111).
Squamous Cell Carcinoma FREQUENT Squamous cell carcinoma (HP:0002860)
Cancer surveillance is critical due to genomic instability and persistent epithelial cancer risk. Solid tumors in the Israeli cohort appeared at a mean age of 26.6 years, significantly later than MDS/leukemia. All solid tumors in that cohort were in patients with FANCA mutations or undiagnosed patients. HPV vaccination is recommended to reduce risk. Oral examination every 6 months from age 9-10 years and annual nasolaryngoscopy from age 10 years are recommended.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA."
GeneReviews confirms elevated risk of solid tumors including head/neck and skin squamous cell carcinomas.
Context-specific annotations (3)
Onset: mean 26.6y
All solid tumors in the Israeli cohort were in patients with FANCA mutations or undiagnosed patients. Mean age of solid tumor onset was 26.6 years, significantly later than MDS/leukemia.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"for solid tumors 26.6 years (SD 4.9)"
Mean solid tumor onset at 26.6 years, significantly later than MDS (13.3y) and leukemia (10.8y).
FEMALE
Female FA patients have elevated risk of gynecologic squamous cell carcinomas (vulvar, cervical) at young ages. HPV vaccination is recommended. Gynecologic assessment annually from age 13; Pap smear annually from age 18.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Human papilloma virus (HPV) vaccination to reduce the risk for gynecologic cancer in females"
GeneReviews specifically highlights gynecologic cancer risk in female FA patients and recommends HPV vaccination.
Genetic FA-S BRCA1 HOMOZYGOUS
FA-S (biallelic BRCA1) patients have predisposition to breast/ovarian cancer and/or childhood cancers, distinct from the typical FA SCC spectrum.
Show evidence (1 reference)
PMID:38146508 SUPPORT Human Clinical
"predisposition to breast/ovarian cancer and/or childhood cancers"
FA-S cancer spectrum includes breast/ovarian cancer rather than the typical SCC pattern.
Hyperpigmentation VERY_FREQUENT Hyperpigmentation of the skin (HP:0000953)
Included in FA guideline skin findings and commonly co-occurs with hypopigmented lesions.
Show evidence (2 references)
PMID:20301575 SUPPORT Human Clinical
"abnormal skin pigmentation"
GeneReviews lists abnormal skin pigmentation among the physical abnormalities present in ~75% of FA patients.
ORPHA:84 SUPPORT Other
"HP:0007400 | Irregular hyperpigmentation | Very frequent (99-80%)"
Orphanet's curated HPO annotation classifies irregular hyperpigmentation as very frequent in Fanconi anemia.
Limbs 9
Radial Ray Defects VERY_FREQUENT Hypoplasia of the radius (HP:0002984)
Common skeletal manifestation in FA; can include absent or hypoplastic thumbs
Show evidence (3 references)
PMID:20301575 SUPPORT Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews confirms upper limb skeletal malformations as a common feature of FA.
ORPHA:84 SUPPORT Other
"HP:0006501 | Aplasia/Hypoplasia of the radius | Very frequent (99-80%)"
Orphanet's curated HPO annotation classifies radius aplasia/hypoplasia as very frequent, supporting the radial ray defect phenotype.
PMID:20301575 SUPPORT Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
Absent or Hypoplastic Thumbs VERY_FREQUENT Absent thumb (HP:0009777)
Part of the radial ray anomaly spectrum. More prevalent in core complex complementation groups (FANCA, FANCC, FANCG). The VACTERL phenotype is overrepresented in FA complementation groups D1, E, and F.
Show evidence (4 references)
PMID:20301575 SUPPORT Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews confirms upper limb skeletal malformations as common in FA.
PMID:16015582 SUPPORT Human Clinical
"all have radial ray anomalies and 12 of these 13 subjects show at least 1 other feature of FA"
In FA patients with VACTERL phenotype, all had radial ray anomalies including thumb abnormalities.
PMID:20301575 SUPPORT Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
+ 1 more reference
Small Thenar Eminence OCCASIONAL Small thenar eminence (HP:0001245)
Included in the FA guideline upper-limb diagnostic manifestations.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
First Metacarpal Aplasia or Hypoplasia OCCASIONAL Aplasia/Hypoplasia of the 1st metacarpal (HP:0010026)
Included in the FA guideline upper-limb diagnostic manifestations.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
Clinodactyly OCCASIONAL Clinodactyly (HP:0030084)
Included in the FA guideline upper-limb diagnostic manifestations.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
Ulnar Aplasia or Hypoplasia OCCASIONAL Aplasia/Hypoplasia of the ulna (HP:0006495)
Included in the FA guideline upper-limb diagnostic manifestations.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
Toe Syndactyly OCCASIONAL Toe syndactyly (HP:0001770)
Included in FA guideline lower-limb manifestations.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
Clubfoot OCCASIONAL Talipes equinovarus (HP:0001762)
Included in FA guideline lower-limb manifestations as club feet.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
Abnormal Toe Morphology OCCASIONAL Abnormal toe morphology (HP:0001780)
Included in FA guideline lower-limb manifestations as abnormal toes.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
Metabolism 1
Abnormal Glucose Homeostasis OCCASIONAL Abnormal glucose homeostasis (HP:0011014)
Part of the metabolic/endocrine abnormalities seen in up to 80% of FA patients. Two-hour glucose tolerance testing and insulin levels are recommended as part of annual endocrine surveillance.
Show evidence (1 reference)
PMID:25575015 SUPPORT Human Clinical
"About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
Consensus review identifies abnormal glucose/insulin metabolism as part of the FA endocrine phenotype.
Context-specific annotations (1)
FREQUENT
39% of FA patients had abnormal glucose/insulin metabolism in the NCI cohort (Giri et al. 2007). 21% met criteria for metabolic syndrome.
Show evidence (1 reference)
PMID:17426088 SUPPORT Human Clinical
"abnormal glucose/insulin metabolism (39%)"
Giri et al. NCI cohort quantifies glucose/insulin abnormalities at 39%.
Musculoskeletal 8
Skeletal Anomalies FREQUENT Multiple skeletal anomalies (HP:0005775)
Includes areas such as the radius, thumb, and hips
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
Context-specific annotations (4)
Genetic FA-C FANCC
Rib abnormalities were observed only in patients with FANCC mutations in the Israeli cohort — exclusive to this complementation group.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Rib abnormalities were observed only in patients with FANCC mutations."
FANCC-exclusive rib anomaly pattern.
Genetic FA-D1 FANCD1/BRCA2
Cleft lip was significantly more common in patients with FANCD1 mutations compared with other FA genes (P<0.001).
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Cleft lip was more common in patients with FANCD1 mutations, compared with other FA genes (P<0.001)."
FANCD1/BRCA2 specifically enriched for cleft lip.
Genetic FA-B FANCB truncating Severe
FANCB deletion or truncation variants produce earlier-than-average onset of bone marrow failure and more severe congenital abnormalities. Missense variants with residual FANCD2 monoubiquitination activity are associated with more favorable outcome. FANCB is X-linked, so only males are affected.
Show evidence (1 reference)
PMID:32106311 SUPPORT Human Clinical
"Those with FANCB deletion or truncation demonstrate earlier-than-average onset of bone marrow failure and more severe congenital abnormalities compared with a large series of FA individuals in published reports."
Jung et al. 19-child FANCB cohort shows truncating variants produce severe congenital abnormality phenotype.
Genetic FA-I FANCI
44% of FA patients with FANCI mutations (7/16) met criteria for VACTERL association (at least 3 features), significantly overrepresented compared to ~5% in FA overall.
Show evidence (1 reference)
PMID:26590883 SUPPORT Human Clinical
"There are now 16 reported cases of FA due to FANCI of whom 7 have at least 3 features of the VACTERL association (44%)."
FANCI mutations are disproportionately associated with VACTERL phenotype in FA.
Hip Dysplasia OCCASIONAL Hip dysplasia (HP:0001385)
Included in the FA guideline lower-limb diagnostic manifestations.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
Hemivertebrae OCCASIONAL Hemivertebrae (HP:0002937)
Included within vertebral anomalies listed in FA diagnostic manifestation tables.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
Scoliosis FREQUENT Scoliosis (HP:0002650)
Included in the FA guideline vertebral anomaly manifestations.
Show evidence (2 references)
PMID:20301575 PARTIAL Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
ORPHA:84 SUPPORT Other
"HP:0002650 | Scoliosis | Frequent (79-30%)"
Orphanet's curated HPO annotation classifies scoliosis as frequent in Fanconi anemia.
Kyphosis OCCASIONAL Kyphosis (HP:0002808)
Included in the FA guideline vertebral anomaly manifestations.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
Fused Cervical Vertebrae OCCASIONAL Fused cervical vertebrae (HP:0002949)
FA guideline vertebral manifestations list Klippel-Feil among spinal findings.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
Absent or Hypoplastic Coccyx OCCASIONAL Absent/hypoplastic coccyx (HP:0008436)
FA guideline vertebral manifestations include coccygeal aplasia.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"skeletal malformations of the upper and/or lower limbs"
GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
Osteopenia and Osteoporosis VERY_FREQUENT Osteopenia (HP:0000938)
92% of FA patients aged 18 or older had osteopenia or osteoporosis in the NCI cohort (Giri et al. 2007). May be compounded by GH deficiency, hypogonadism, and post-HSCT conditioning effects.
Show evidence (1 reference)
PMID:17426088 SUPPORT Human Clinical
"Ninety-two percent of the patients 18 yr or older had osteopenia or osteoporosis."
Near-universal bone density loss in adult FA patients.
Nervous System 5
Agenesis of Corpus Callosum OCCASIONAL Agenesis of corpus callosum (HP:0001274)
Listed in FA guideline CNS screening manifestations.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including central nervous system anomalies.
Cerebellar Hypoplasia OCCASIONAL Cerebellar hypoplasia (HP:0001321)
Included in FA guideline CNS screening manifestations.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including central nervous system anomalies.
Developmental Delay OCCASIONAL Intellectual disability (HP:0001249)
Developmental delay contributes to the congenital abnormality burden score. Patients with splice site mutations had significantly more CNS anomalies and developmental delay (P=0.038) compared with other mutation types. Patients with downstream FA gene mutations (FANCD1, FANCJ) had significantly more CNS abnormalities (P=0.005). FA-S (biallelic BRCA1) patients frequently present with intellectual disability.
Show evidence (2 references)
PMID:31558676 SUPPORT Human Clinical
"Patients with splice site mutations had significantly more CNS anomalies and developmental delay, compared with the other patients (P=0.03 and P=0.038, respectively)."
Israeli cohort found developmental delay associated with splice site mutations in FA.
PMID:38146508 SUPPORT Human Clinical
"this FA-S cohort phenotype includes short stature, microcephaly, facial dysmorphisms, hypo/hyperpigmented lesions, intellectual disability, chromosomal sensitivity to crosslinking agents and predisposition to breast/ovarian cancer and/or childhood cancers"
FA-S (BRCA1 biallelic) patients commonly present with intellectual disability.
Context-specific annotations (4)
Orphanet curated aggregate FREQUENT
Orphanet classifies intellectual disability and global developmental delay as frequent in Fanconi anemia.
Show evidence (2 references)
ORPHA:84 SUPPORT Other
"HP:0001249 | Intellectual disability | Frequent (79-30%)"
Orphanet's curated HPO annotation classifies intellectual disability as frequent in Fanconi anemia.
ORPHA:84 SUPPORT Other
"HP:0001263 | Global developmental delay | Frequent (79-30%)"
Orphanet's curated HPO annotation classifies global developmental delay as frequent in Fanconi anemia.
Genetic splice_site FREQUENT
Patients with splice site mutations had significantly more CNS anomalies and developmental delay (P=0.038) compared with other mutation types.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Patients with splice site mutations had significantly more CNS anomalies and developmental delay, compared with the other patients (P=0.03 and P=0.038, respectively)."
Splice site mutations specifically associated with developmental delay in FA.
Genetic FANCD1/BRCA2 FANCJ/BRIP1 FREQUENT
Downstream FA pathway genes
Downstream FA gene mutations associated with significantly more CNS abnormalities (P=0.005) compared to core complex mutations.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."
Downstream pathway mutations enriched for CNS abnormalities.
Genetic FA-S BRCA1 HOMOZYGOUS VERY_FREQUENT
FA-S (biallelic BRCA1) patients frequently present with intellectual disability as part of the characteristic FA-S phenotypic spectrum.
Show evidence (1 reference)
PMID:38146508 SUPPORT Human Clinical
"this FA-S cohort phenotype includes short stature, microcephaly, facial dysmorphisms, hypo/hyperpigmented lesions, intellectual disability"
Intellectual disability is a defining feature of the FA-S subtype.
Hydrocephalus OCCASIONAL Hydrocephalus (HP:0000238)
Included in the FA guideline central nervous system screening manifestations.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including central nervous system anomalies.
Ventriculomegaly OCCASIONAL Ventriculomegaly (HP:0002119)
Included in the FA guideline CNS screening manifestations as dilated ventricles.
Show evidence (1 reference)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including central nervous system anomalies.
Growth 2
Short Stature FREQUENT Short stature (HP:0004322)
In the Israeli cohort, 57% met criteria for short stature. Patients with downstream FA gene mutations (FANCD1, FANCJ) were significantly shorter than core complex patients (P=0.003). Patients with deletion mutations were shorter than those with nonsense mutations (P=0.018). Contributing factors include GH deficiency, hypothyroidism, and constitutional factors.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies."
GeneReviews confirms short stature as one of the common physical abnormalities in FA.
Context-specific annotations (4)
FREQUENT
57% met criteria for short stature in the Israeli cohort (n=111).
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"57% fit criteria for short stature"
Quantitative frequency data from Israeli FA cohort of 111 patients.
Orphanet curated aggregate VERY_FREQUENT
Orphanet classifies short stature as very frequent in Fanconi anemia.
Show evidence (1 reference)
ORPHA:84 SUPPORT Other
"HP:0004322 | Short stature | Very frequent (99-80%)"
Orphanet's curated HPO annotation classifies short stature as very frequent in Fanconi anemia.
Genetic FANCD1/BRCA2 FANCJ/BRIP1 More severe
Downstream FA pathway genes
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Patients with mutations in the downstream genes FANCD1 and FANCJ were significantly shorter compared with the others (P=0.003)"
Downstream pathway gene mutations associated with more severe growth deficiency.
Genetic deletion More severe
Deletion mutations associated with shorter stature than nonsense mutations.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Patients with deletions were shorter than patients with nonsense mutations (P=0.018)"
Mutation type affects severity of growth phenotype.
Intrauterine Growth Retardation OCCASIONAL Intrauterine growth retardation (HP:0001511)
In the Israeli cohort, 20% of FA patients were born small for gestational age. Growth deficiency often begins prenatally and continues postnatally.
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"20% were born small for the gestational age, and 57% fit criteria for short stature."
Israeli cohort documents 20% small for gestational age prevalence in FA.
Context-specific annotations (1)
OCCASIONAL
20% born SGA in the Israeli cohort. ALDH2*2 variant did not affect birth weight in Japanese FA patients, suggesting prenatal growth restriction is independent of aldehyde-mediated damage.
Show evidence (2 references)
PMID:31558676 SUPPORT Human Clinical
"20% were born small for the gestational age, and 57% fit criteria for short stature."
20% SGA prevalence in Israeli FA cohort.
PMID:24037726 SUPPORT Human Clinical
"the ALDH2 variant is associated with accelerated progression of BMF, while birth weight or the number of physical abnormalities was not affected"
Birth weight unaffected by ALDH2 status, suggesting different mechanism for prenatal growth restriction.
Other 5
Structural Anomalies OCCASIONAL
Includes esophageal atresia, duodenal atresia, and other malformations
Show evidence (2 references)
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals"
GeneReviews confirms congenital abnormalities are present in ~75% of FA patients.
PMID:20301575 PARTIAL Human Clinical
"Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
Genital Malformations OCCASIONAL Abnormality of the genital system (HP:0000078)
The cited cohort reports a broader genitourinary anomaly enrichment in downstream FA gene mutations; this phenotype captures the genital/reproductive component, with renal malformations curated separately.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
GeneReviews lists genital anomalies among FA manifestations requiring subspecialty care, supporting a genital-system phenotype distinct from renal malformations.
Context-specific annotations (1)
Genetic FANCD1/BRCA2 FANCJ/BRIP1 FREQUENT
Downstream FA pathway genes
Genitourinary anomalies, a broader grouping that includes genital abnormalities, were significantly more common in patients with downstream FA gene mutations compared to core complex mutations (P=0.03).
Show evidence (1 reference)
PMID:31558676 SUPPORT Human Clinical
"Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."
Downstream FA pathway mutations enriched for genitourinary anomalies, supporting a genotype-specific genital/reproductive anomaly context while renal morphology is curated separately.
Abnormal Renal Morphology FREQUENT Abnormal renal morphology (HP:0012210)
In the Israeli FA cohort, 39.6% of patients had renal anomalies, making it the second most common congenital anomaly after skin pigmentation changes. Renal anomalies contribute to the congenital abnormality burden score.
Show evidence (4 references)
PMID:31558676 SUPPORT Human Clinical
"More than half had café-au-lait spots (52.3%) followed by renal anomalies (39.6%)."
Israeli cohort found renal anomalies in nearly 40% of FA patients.
PMID:20301575 SUPPORT Human Clinical
"ophthalmic and genitourinary tract anomalies"
GeneReviews lists genitourinary tract anomalies as part of the FA congenital spectrum.
PMID:20301575 SUPPORT Human Clinical
"Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
GeneReviews lists renal malformations among the FA manifestations requiring subspecialty management.
+ 1 more reference
Hypopigmented Skin Patches VERY_FREQUENT Hypopigmented skin patches (HP:0001053)
The combination of hypo- and hyperpigmented skin lesions is characteristic of FA. In the Israeli cohort, skin pigmentation changes (café-au-lait spots) were the most common congenital anomaly (52.3%).
Show evidence (2 references)
PMID:20301575 SUPPORT Human Clinical
"abnormal skin pigmentation"
GeneReviews lists abnormal skin pigmentation among the physical abnormalities present in ~75% of FA patients.
ORPHA:84 SUPPORT Other
"HP:0001053 | Hypopigmented skin patches | Very frequent (99-80%)"
Orphanet's curated HPO annotation classifies hypopigmented skin patches as very frequent in Fanconi anemia.
Early-Onset Solid Tumors in FANCD1/BRCA2 VERY_FREQUENT
FANCD1/BRCA2 and FANCN/PALB2 patients have the most severe cancer phenotype with near-invariable early-onset malignancy. In the Israeli cohort, one FANCD1 patient developed medulloblastoma at age 3. These patients require cancer screening from a very young age. Neither FANCD1 patient in the Israeli cohort developed BMF, distinguishing this subtype. FA-S (biallelic BRCA1) patients also lack bone marrow failure but have cancer predisposition.
Show evidence (2 references)
PMID:31558676 SUPPORT Human Clinical
"Patients with FANCD1 mutations have been previously described as uniquely developing solid tumors early in life"
Confirms early-onset solid tumor predisposition unique to FANCD1/BRCA2 subtype.
PMID:38146508 SUPPORT Human Clinical
"Unlike most other types of FA, FA-S patients lack bone marrow failure."
FA-S (biallelic BRCA1) patients have cancer predisposition but lack BMF, similar to FANCD1.
🧬

Genetic Associations

25
FANCA (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCA is one of the 21 genes causing autosomal recessive Fanconi anemia.
FANCB (Pathogenic Variants)
X-linked
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"a hemizygous pathogenic variant in FANCB known to cause X-linked FA"
GeneReviews confirms FANCB causes X-linked Fanconi anemia.
FANCC (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCC is one of the 21 genes causing autosomal recessive Fanconi anemia.
FANCE (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCE is one of the 21 genes causing autosomal recessive Fanconi anemia.
FANCF (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCF is one of the 21 genes causing autosomal recessive Fanconi anemia.
FANCG (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCG is one of the 21 genes causing autosomal recessive Fanconi anemia.
FANCL (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCL is one of the 21 genes causing autosomal recessive Fanconi anemia.
FANCM (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews lists FANCM among FA-associated genes; some ontology resources classify FANCM-related disease separately from canonical FA complementation groups.
UBE2T (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms UBE2T (FANCT) is one of the 21 genes causing autosomal recessive Fanconi anemia.
FANCD2 (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCD2 is one of the 21 genes causing autosomal recessive Fanconi anemia.
FANCI (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms FANCI is one of the 21 genes causing autosomal recessive Fanconi anemia.
SLX4 (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms SLX4 (FANCP) is one of the 21 genes causing autosomal recessive Fanconi anemia.
BRCA2 (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms BRCA2 (FANCD1) is one of the 21 genes causing autosomal recessive Fanconi anemia.
PALB2 (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms PALB2 (FANCN) is one of the 21 genes causing autosomal recessive Fanconi anemia.
BRCA1 (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms BRCA1 (FANCS) is one of the 21 genes causing autosomal recessive Fanconi anemia.
BRIP1 (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms BRIP1 (FANCJ) is one of the 21 genes causing autosomal recessive Fanconi anemia.
ERCC4 (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms ERCC4 (FANCQ) is one of the 21 genes causing autosomal recessive Fanconi anemia.
RAD51C (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms RAD51C (FANCO) is one of the 21 genes causing autosomal recessive Fanconi anemia.
RAD51 (Pathogenic Variants)
Autosomal dominant
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"a heterozygous pathogenic variant in RAD51 known to cause autosomal dominant FA"
GeneReviews confirms RAD51 (FANCR) as the autosomal dominant FA subtype gene.
XRCC2 (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms XRCC2 (FANCU) is one of the 21 genes causing autosomal recessive Fanconi anemia.
MAD2L2 (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms MAD2L2/REV7 (FANCV) is one of the 21 genes causing autosomal recessive Fanconi anemia.
RFWD3 (Pathogenic Variants)
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
GeneReviews confirms RFWD3 (FANCW) is one of the 21 genes causing autosomal recessive Fanconi anemia.
ALDH2 (Risk Modifier)
Show evidence (1 reference)
PMID:24037726 SUPPORT Human Clinical
"the ALDH2 variant is associated with accelerated progression of BMF"
Study of 64 Japanese FA patients showed ALDH2 deficiency accelerates bone marrow failure progression.
ADH5 (Risk Modifier)
Show evidence (1 reference)
PMID:22081012 SUPPORT In Vitro
"a synthetic lethal interaction in avian cells between ADH5, encoding the main formaldehyde-detoxifying enzyme, and the Fanconi anemia (FA) DNA-repair pathway"
Demonstrates that ADH5 formaldehyde catabolism is essential in FA-deficient cells.
KMT2D (Disease Modifier)
💊

Treatments

8
Hematopoietic Stem Cell Transplantation (HSCT)
Action: hematopoietic stem cell transplantation MAXO:0000747
The only curative treatment for the hematologic manifestations of FA, using reduced-intensity conditioning regimens due to patient sensitivity to chemotherapy and radiation.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of FA"
Androgen Therapy
Action: hormone modifying therapy MAXO:0000283
Can stimulate erythropoiesis and improve blood counts, often used as a bridge to transplantation.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Administration of oral androgens (e.g., oxymetholone) improves blood counts (red cell and platelets) in approximately 50% of individuals with FA"
Growth Hormone Therapy
Action: hormone modifying therapy MAXO:0000283
May be used to improve growth in affected children with short stature.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
GeneReviews recommends treatment of growth deficiency as part of comprehensive FA management.
Supportive Care
Action: supportive care MAXO:0000950
Treatment of cytopenias with transfusions, antibiotics, and monitoring for malignancy.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"granulocyte colony-stimulating factor improves the neutrophil count in some individuals"
GeneReviews confirms use of growth factors as part of supportive care for cytopenias.
Cancer Surveillance
Action: cancer screening MAXO:0000126
Regular screenings for early detection of cancers, particularly acute myeloid leukemia and squamous cell carcinomas of the head and neck, oral cavity, and anogenital regions.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"oral examinations for tumors every six months beginning at age nine to ten years; annual nasolaryngoscopy beginning at age ten years"
GeneReviews recommends regular oral and nasolaryngoscopic surveillance for early cancer detection.
Genetic Counseling
Action: genetic counseling MAXO:0000079
Counseling for patients and families regarding inheritance patterns, recurrence risks, carrier testing, and prenatal diagnosis options.
Show evidence (1 reference)
PMID:20301575 SUPPORT Human Clinical
"Carrier testing for at-risk relatives (for autosomal recessive and X-linked FA) and prenatal and preimplantation genetic testing are possible if the pathogenic variant(s) in the family are known."
GeneReviews confirms the importance of genetic counseling for carrier testing and prenatal diagnosis.
Lentiviral Gene Therapy (FA-A)
Action: gene therapy MAXO:0001001
Ex vivo lentiviral-mediated gene correction of autologous CD34+ hematopoietic stem cells with a FANCA-expressing vector, followed by reinfusion without conditioning. Single-cell RNA sequencing of gene therapy-treated patients demonstrates that corrected HSPCs revert the FA transcriptional signature, including downregulation of TGF-beta and p21 and upregulation of DNA damage response and telomere maintenance pathways.
Show evidence (2 references)
PMID:37021532 SUPPORT Human Clinical
"gene therapy reverts the transcriptional signature of FA HSPC, which then resemble the transcriptional program of healthy donor HSPC"
Single-cell RNA-seq of gene therapy-treated FA patients demonstrates molecular rescue of the FA HSPC transcriptional program.
PMID:37021532 SUPPORT Human Clinical
"a down-regulated expression of TGF-β and p21, typically up-regulated in FA HSPC, and upregulation of DNA damage response and telomere maintenance pathways"
Gene therapy corrects specific molecular defects in FA HSPCs as confirmed by scRNA-seq.
Adenine Base Editing (ABE8e)
Action: gene therapy MAXO:0001001
Precision base editing approach using optimized adenine base editors (ABE8e) to correct prevalent FANCA point mutations in patient hematopoietic stem and progenitor cells without relying on double-strand breaks or homology-directed repair, which are impaired in FA cells. Restores FANCA expression and FA pathway function.
Show evidence (2 references)
PMID:36371486 SUPPORT In Vitro
"optimizing adenine base editor construct, vector type, guide RNA format, and delivery conditions leads to very effective genetic modification in multiple FA patient backgrounds"
ABE8e base editing achieves effective correction across multiple FANCA mutation backgrounds.
PMID:36371486 SUPPORT In Vitro
"Optimized base editing restored FANCA expression, molecular function of the FA pathway, and phenotypic resistance to crosslinking agents"
Base editing restores functional FA pathway activity in patient-derived HSPCs.
🌍

Environmental Factors

1
Protections from DNA-damaging Agents
Broad recommendation spanning both ionizing radiation and chemical genotoxins; no single specific ECTO term is used here to avoid a mismatched mapping.
Avoid exposure to agents that can cause DNA damage, such as radiation and certain chemicals.
🔬

Biochemical Markers

2
Chromosomal Breakage Test (Positive)
Context: Diagnostic indicator
Crosslinking Sensitivity (Increased)
Context: Diagnostic indicator (often using diepoxybutane (DEB) or mitomycin C (MMC))
📊

Related Datasets

2
MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia geo:GSE157591
Single-cell RNA sequencing of bone marrow CD34+ hematopoietic stem and progenitor cells from Fanconi anemia patients and healthy donors. Reveals aberrant MYC overexpression in FA HSPCs driving proliferation-apoptosis imbalance, with transcriptomic signatures distinct from normal hematopoiesis.
human SINGLE CELL RNA SEQ 10x Genomics Chromium
Findings
MYC is overexpressed in FA HSPCs compared to healthy donor HSPCs
FA HSPCs show proliferation-apoptosis imbalance driven by MYC dysregulation
PMID:32997960
Show evidence (1 reference)
PMID:32997960 SUPPORT Human Clinical
"MYC overexpression impairs HSPC function in FA patients and contributes to exhaustion in FA bone marrow"
scRNA-seq dataset demonstrates MYC as a key driver of HSPC dysfunction in FA patients.
Restored Hematopoietic Stem Cell Transcriptional Program in Fanconi Anemia Patients Following Gene Therapy geo:GSE180536
Single-cell RNA sequencing of chimeric corrected and uncorrected HSPC populations co-existing in bone marrow of lentiviral gene therapy-treated Fanconi anemia patients. Demonstrates that gene-corrected cells revert the FA transcriptional signature to resemble healthy donor HSPCs.
human SINGLE CELL RNA SEQ 10x Genomics Chromium
Findings
Gene therapy reverts the FA HSPC transcriptional signature to healthy donor levels
Corrected cells show downregulation of TGF-beta and p21, upregulation of DDR and telomere maintenance
PMID:37021532
Show evidence (1 reference)
PMID:37021532 SUPPORT Human Clinical
"gene therapy reverts the transcriptional signature of FA HSPC, which then resemble the transcriptional program of healthy donor HSPC"
scRNA-seq of gene therapy patients confirms molecular rescue of FA-specific transcriptomic defects.
🔬

Clinical Trials

3
NCT04069533 PHASE_II ACTIVE_NOT_RECRUITING
Phase II clinical trial evaluating lentiviral-mediated gene therapy for pediatric patients with Fanconi Anemia subtype A (FA-A). Autologous CD34+ hematopoietic stem cells are transduced ex vivo with a lentiviral vector carrying the FANCA gene, then reinfused with the goal of preventing bone marrow failure.
Target Phenotypes: Pancytopenia ↗ Anemia ↗
Show evidence (1 reference)
clinicaltrials:NCT04069533 SUPPORT Human Clinical
"This is an open-label Phase II clinical trial to evaluate the efficacy of a hematopoietic cell-based gene therapy for pediatric patients with Fanconi Anemia, subtype A (FA-A). Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the..."
This Phase II gene therapy trial directly addresses the genetic defect in FA-A by correcting FANCA mutations in autologous stem cells, providing evidence for curative cell-based genetic therapy approaches.
NCT00243399 PHASE_I COMPLETED
Pilot trial evaluating oxandrolone (an androgen steroid) for treatment of bone marrow aplasia in Fanconi Anemia patients. The study assessed safety and efficacy of androgen therapy to stimulate production of red blood cells and platelets in FA patients with bone marrow failure.
Target Phenotypes: Pancytopenia ↗ Anemia ↗
Show evidence (1 reference)
clinicaltrials:NCT00243399 SUPPORT Human Clinical
"The purpose of this study is to evaluate the safety of the drug oxandrolone (a type of androgen steroid) in patients with Fanconi anemia (FA), and to determine if this drug can help in the treatment of bone marrow failure in these patients. Androgen steroids are male hormones that can stimulate..."
This Phase I trial evaluates androgen therapy as a bridge treatment for bone marrow failure in FA, providing clinical evidence for hormonal stimulation of hematopoiesis.
NCT00630253 PHASE_II COMPLETED
Phase I/II study evaluating cyclophosphamide, fludarabine, and antithymocyte globulin conditioning followed by matched sibling donor hematopoietic cell transplantation (HSCT) in patients with Fanconi Anemia. Investigates reduced-intensity conditioning regimens tailored to FA patients' increased chemotherapy sensitivity.
Target Phenotypes: Pancytopenia ↗ Anemia ↗
Show evidence (1 reference)
clinicaltrials:NCT00630253 SUPPORT Human Clinical
"Giving chemotherapy, such as cyclophosphamide and fludarabine, before a donor stem cell transplant helps to remove the patient's cells to allow for the transplant cells to take and grow. It also helps stop the patient's immune system from rejecting the donor's stem cells."
This Phase I/II trial optimizes HSCT conditioning regimens for FA patients, providing clinical evidence for the curative approach to bone marrow failure in Fanconi Anemia.
🧮

Computational Models

6
Boolean Network Model of FA/BRCA Pathway BOOLEAN_NETWORK
A Boolean network model incorporating the FA/BRCA DNA repair pathway, checkpoint proteins, and alternative DNA repair pathways. Simulates ICL repair, checkpoint activation, and predicts which alternative repair pathways become active when the FA/BRCA pathway is defective. The largest network model incorporating a DNA repair pathway at time of publication.
PMID:22267503 ↗
Findings
The model simulates ICL repair mediated by the FA/BRCA pathway
Alternative DNA repair pathways are predicted to become active when FA/BRCA is defective
Checkpoint protein activation patterns emerge from recurrent DNA damage
Show evidence (1 reference)
PMID:22267503 SUPPORT Computational
"Our model is able to simulate the ICL repair process mediated by the FA/BRCA pathway, the activation of Checkpoint proteins observed by recurrent DNA damage, as well as the repair of DNA double-strand breaks and DNA adducts"
Boolean network model successfully recapitulates FA/BRCA pathway behavior and predicts compensatory repair mechanisms.
Multi-level Dynamical Modelling of SCC in FA
A conceptual framework for multi-level dynamical modelling of squamous cell carcinoma development in Fanconi anemia, integrating longitudinal genome, proteome, and transcriptome data from a database of over 750 FA individuals. Proposes mechanistic models trained on multi-omic data from healthy and diseased tissue to detect early SCC signatures and predict tumorigenesis.
PMID:38028610 ↗
Findings
Defines hallmarks of cancer specific to FA for model training
Proposes using multi-omic data for early SCC signature detection
Framework designed to predict experimentally testable tumorigenesis mechanisms
Show evidence (1 reference)
PMID:38028610 PARTIAL Computational
"we introduce here the concept of multi-level dynamical modelling using large, longitudinally collected genome, proteome- and transcriptome-wide data sets from a small number of FA individuals"
Proposes a multi-level modeling approach for understanding SCC development in FA using multi-omic data.
Machine Learning Drug Repurposing (drexml) MACHINE_LEARNING
Machine learning framework using multi-output regression and mechanistic signal transduction models to identify drug targets capable of regulating FA-related cell functionalities. The drexml tool predicts potential therapeutic targets by mapping external proteins to signaling circuits that trigger FA-related phenotypes, identifying over 20 potential drug targets and successfully predicting previously validated repurposed drugs.
Repository ↗ PMID:31266445 ↗
Findings
Over 20 potential therapeutic drug targets identified around the FA pathway
Framework validated by successfully predicting previously known repurposed drugs in FA
Show evidence (2 references)
PMID:31266445 SUPPORT Computational
"The application of multi-output regression machine learning methodologies to predict the potential effect of external proteins over the signaling circuits that trigger Fanconi anemia related cell functionalities, inferred with a mechanistic model, allowed us to detect over 20 potential..."
ML approach identifies novel drug targets for FA using mechanistic pathway modeling.
PMID:38510973 SUPPORT Computational
"In the Fanconi Anemia case, the model successfully predicts previously validated repurposed drugs"
The drexml tool package validates the ML drug repurposing approach in FA.
Deep Learning FA Core Complex Structure MACHINE_LEARNING
Integration of deep-learned residue distance predictions with Rosetta folding and automated cryo-EM map-guided assembly to determine the near-complete atomic structure of the Fanconi Anemia core complex (FAcc) E3 ubiquitin ligase from a 4.6 angstrom resolution cryo-EM map. Placed 5182 of 6557 residues, greatly expanding the structural model and enabling interpretation of disease-related mutations.
PMID:32939280 ↗
Findings
Near-complete atomic model of FA core complex determined (5182 of 6557 residues placed)
Deep learning overcame limitations of homology modeling for 4795 previously unmodeled residues
Structure facilitates interpretation of disease-related mutational data
Show evidence (1 reference)
PMID:32939280 SUPPORT Computational
"we are able to determine an almost-complete atomic model of FAcc, in which 5182 of the 6557 residues were placed"
Deep learning-guided structure determination provides structural context for understanding FA-causing mutations.
DNA Methylation Episignature Classifier MACHINE_LEARNING
Machine learning classifier trained on genome-wide DNA methylation profiles from peripheral blood of FA patients. Identifies 82 differentially methylated CpG sites that distinguish FA from healthy individuals and other genetic disorders. The episignature is robust across complementation groups and tissue types, and can detect FA even in individuals with reverted phenotype due to gene conversion.
PMID:37865086 ↗
Findings
82 CpG sites define an FA-specific DNA methylation signature
Episignature validated across multiple complementation groups
Can diagnose FA even in mosaic/reverted patients with normalized chromosome breakage
Show evidence (2 references)
PMID:37865086 SUPPORT Computational
"We identified 82 differentially methylated CpG sites that allow to distinguish subjects with FA from healthy individuals and subjects with other genetic disorders, defining an FA-specific DNAm signature"
ML-based episignature provides a complementary diagnostic tool for FA.
PMID:37865086 SUPPORT Computational
"the generated episignature includes CpG sites that do not undergo functional selective pressure, allowing diagnosis of FA in individuals with reverted phenotype due to gene conversion"
The episignature overcomes a key diagnostic challenge in FA patients with somatic mosaicism.
REPAIR-FANC High Content Screening Platform
Cell-based high content screening platform using TALEN-mediated FANCA-deficient U2OS cells stably expressing YFP-FANCD2 to monitor FA/BRCA pathway activity via fluorescent FANCD2 foci formation. Screened 3802 compounds including 1200 FDA-approved drugs for potential FA pathway rescue.
PMID:32605631 ↗
Findings
None of the 3802 compounds tested were able to rescue FANCA-dependent FANCD2 foci formation
Platform demonstrates feasibility for high-throughput screening in FA therapeutics
Some compounds showed mild reduction in chromosomal instability markers
Show evidence (1 reference)
PMID:32605631 PARTIAL In Vitro
"we developed a novel high-content cell-based screening assay to identify drugs with therapeutic potential in FA"
Establishes an optimized platform for screening drug candidates in FA, though no pathway-rescuing compounds were identified.
{ }

Source YAML

click to show 
name: Fanconi_Anemia
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-04-28T01:31:26Z'
description: >-
  Fanconi anemia is a rare inherited bone marrow failure syndrome characterized
  by genomic instability, congenital abnormalities, progressive bone marrow failure,
  and increased susceptibility to malignancies. Most cases result from biallelic
  pathogenic variants in genes encoding components of the Fanconi anemia/BRCA DNA
  interstrand crosslink repair pathway, with recognized exceptions including X-linked
  FANCB and autosomal dominant RAD51-associated disease (FA-R). Between 21 and
  22 complementation groups are cited depending on nomenclature and curation conventions,
  with FANCA accounting for 60-70% of cases. The phenotypic spectrum is highly
  variable even within the same complementation group, reflecting genetic modifiers
  and environmental factors.
category: Genetic
parents:
- Bone Marrow Failure
- Congenital Disorder
prevalence:
- population: Global
  percentage: Rare
  evidence:
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rare genetic multisystem disorder characterized by progressive pancytopenia with bone marrow failure, variable congenital malformations and predisposition to develop hematological or solid tumors."
    explanation: Orphanet's definition supports the general rare-disease prevalence characterization.
- population: China
  percentage: 1-9 / 1 000 000
  notes: Orphanet reports this as point prevalence.
  evidence:
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 1 000 000 | China | Point prevalence | PMID:34103049"
    explanation: Orphanet reports a China point-prevalence band of 1-9 per 1,000,000.
- population: Europe
  percentage: 1-9 / 1 000 000
  notes: Orphanet reports both point prevalence and prevalence at birth in this range.
  evidence:
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 1 000 000 | Europe | Point prevalence | PMID:20824457,PMID:2018"
    explanation: Orphanet reports a Europe point-prevalence band of 1-9 per 1,000,000.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 1 000 000 | Europe | Prevalence at birth | EXPERT"
    explanation: Orphanet reports a Europe prevalence-at-birth band of 1-9 per 1,000,000.
- population: Israel
  percentage: 1-9 / 100 000
  notes: Orphanet reports this as prevalence at birth.
  evidence:
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Israel | Prevalence at birth | PMID:20435624"
    explanation: Orphanet reports an Israel prevalence-at-birth band of 1-9 per 100,000.
- population: Specific population
  percentage: 1-9 / 100 000
  notes: Orphanet reports this point-prevalence band in multiple specific populations.
  evidence:
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Specific population | Point prevalence | PMID:11344308"
    explanation: Orphanet reports a specific-population point-prevalence band of 1-9 per 100,000.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Specific population | Point prevalence | PMID:15522956"
    explanation: Orphanet reports a second specific-population point-prevalence source in the same band.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Specific population | Point prevalence | PMID:7492758"
    explanation: Orphanet reports a third specific-population point-prevalence source in the same band.
progression:
- phase: Onset
  age_range: Childhood
  evidence:
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Childhood"
    explanation: Orphanet records childhood as the age-of-onset category for Fanconi anemia.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Orphanet records autosomal recessive inheritance for Fanconi anemia, consistent
    with most FA complementation groups being caused by biallelic pathogenic variants.
  evidence:
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "- Autosomal recessive"
    explanation: Orphanet explicitly lists autosomal recessive inheritance for Fanconi anemia.
- name: X-linked recessive inheritance
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  description: >-
    Orphanet records X-linked recessive inheritance, matching the FANCB-associated
    FA-B complementation group.
  evidence:
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "- X-linked recessive"
    explanation: Orphanet explicitly lists X-linked recessive inheritance for Fanconi anemia.
definitions:
- name: 2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)
  definition_type: CASE_DEFINITION
  description: >-
    Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical
    Care Guidelines that should raise suspicion for FA and trigger diagnostic
    screening workup.
  scope: Suspected Fanconi anemia in pediatric and adult clinical settings
  criteria_sets:
  - name: Table 1 FA screening indicators
    description: Major congenital, hematologic, and reproductive indicators associated with FA.
    core_clinical_characteristics:
    - preferred_term: Short stature
      term:
        id: HP:0004322
        label: Short stature
    - preferred_term: Microcephaly
      term:
        id: HP:0000252
        label: Microcephaly
    - preferred_term: Anterior pituitary hypoplasia
      term:
        id: HP:0010627
        label: Anterior pituitary hypoplasia
    - preferred_term: Interrupted pituitary stalk
      term:
        id: HP:0034978
        label: Interrupted pituitary stalk
    - preferred_term: Hearing impairment
      term:
        id: HP:0000365
        label: Hearing impairment
    - preferred_term: Microphthalmia
      term:
        id: HP:0000568
        label: Microphthalmia
    - preferred_term: Epicanthus
      term:
        id: HP:0000286
        label: Epicanthus
    - preferred_term: Ptosis
      term:
        id: HP:0000508
        label: Ptosis
    - preferred_term: Strabismus
      term:
        id: HP:0000486
        label: Strabismus
    - preferred_term: Cataract
      term:
        id: HP:0000518
        label: Cataract
    - preferred_term: Triangular face
      term:
        id: HP:0000325
        label: Triangular face
    - preferred_term: Micrognathia
      term:
        id: HP:0000347
        label: Micrognathia
    - preferred_term: Cleft palate
      term:
        id: HP:0000175
        label: Cleft palate
    - preferred_term: Abnormal heart morphology
      term:
        id: HP:0001627
        label: Abnormal heart morphology
    - preferred_term: Tracheoesophageal fistula
      term:
        id: HP:0002575
        label: Tracheoesophageal fistula
    - preferred_term: Esophageal atresia
      term:
        id: HP:0002032
        label: Esophageal atresia
    - preferred_term: Duodenal atresia
      term:
        id: HP:0002247
        label: Duodenal atresia
    - preferred_term: Jejunal atresia
      term:
        id: HP:0005235
        label: Jejunal atresia
    - preferred_term: Anal atresia
      term:
        id: HP:0002023
        label: Anal atresia
    - preferred_term: Annular pancreas
      term:
        id: HP:0001734
        label: Annular pancreas
    - preferred_term: Intestinal malrotation
      term:
        id: HP:0002566
        label: Intestinal malrotation
    - preferred_term: Abnormal renal morphology
      term:
        id: HP:0012210
        label: Abnormal renal morphology
    - preferred_term: Abnormality of the genital system
      term:
        id: HP:0000078
        label: Abnormality of the genital system
    - preferred_term: Absent thumb
      term:
        id: HP:0009777
        label: Absent thumb
    - preferred_term: Hypoplasia of the radius
      term:
        id: HP:0002984
        label: Hypoplasia of the radius
    - preferred_term: Clinodactyly
      term:
        id: HP:0030084
        label: Clinodactyly
    - preferred_term: Aplasia/Hypoplasia of the ulna
      term:
        id: HP:0006495
        label: Aplasia/Hypoplasia of the ulna
    - preferred_term: Toe syndactyly
      term:
        id: HP:0001770
        label: Toe syndactyly
    - preferred_term: Talipes equinovarus
      term:
        id: HP:0001762
        label: Talipes equinovarus
    - preferred_term: Hemivertebrae
      term:
        id: HP:0002937
        label: Hemivertebrae
    - preferred_term: Fused cervical vertebrae
      term:
        id: HP:0002949
        label: Fused cervical vertebrae
    - preferred_term: Scoliosis
      term:
        id: HP:0002650
        label: Scoliosis
    - preferred_term: Kyphosis
      term:
        id: HP:0002808
        label: Kyphosis
    - preferred_term: Absent/hypoplastic coccyx
      term:
        id: HP:0008436
        label: Absent/hypoplastic coccyx
    - preferred_term: Cafe-au-lait spot
      term:
        id: HP:0000957
        label: Cafe-au-lait spot
    - preferred_term: Hyperpigmentation of the skin
      term:
        id: HP:0000953
        label: Hyperpigmentation of the skin
    - preferred_term: Pancytopenia
      term:
        id: HP:0001876
        label: Pancytopenia
    - preferred_term: Myelodysplasia
      term:
        id: HP:0002863
        label: Myelodysplasia
    - preferred_term: Leukemia
      term:
        id: HP:0001909
        label: Leukemia
    - preferred_term: Cryptorchidism
      term:
        id: HP:0000028
        label: Cryptorchidism
    - preferred_term: Hypospadias
      term:
        id: HP:0000047
        label: Hypospadias
    - preferred_term: Micropenis
      term:
        id: HP:0000054
        label: Micropenis
    - preferred_term: Aplasia/hypoplasia of the uterus
      term:
        id: HP:0008684
        label: Aplasia/hypoplasia of the uterus
    - preferred_term: Gonadal dysgenesis
      term:
        id: HP:0000133
        label: Gonadal dysgenesis
    - preferred_term: Vaginal atresia
      term:
        id: HP:0000148
        label: Vaginal atresia
    notes: >-
      This criteria set is intended to guide screening suspicion and referral;
      it is not a strict diagnostic-count rule.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews describes the broad congenital anomaly spectrum present in ~75% of FA patients.
  notes: >-
    This is a screening definition/case-identification aid. Definitive FA
    diagnosis still requires confirmatory genetic and/or chromosome breakage
    testing.
pathophysiology:
- name: DNA Repair Deficiency
  description: Mutations in FA genes impair the body's ability to repair DNA damage, leading to increased sensitivity to crosslinking agents and propensity for chromosomal instability.
  evidence:
  - reference: PMID:35596788
    reference_title: "Fanconi anemia: current insights regarding epidemiology, cancer, and DNA repair."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: At least 22 genes are associated with Fanconi anemia, constituting the Fanconi anemia DNA repair pathway. This pathway coordinates multiple processes and proteins to facilitate the repair of DNA adducts including interstrand crosslinks (ICLs)
  downstream:
  - target: Genomic Instability
- name: Bone Marrow Failure
  description: Inability of the bone marrow to produce sufficient blood cells due to hematopoietic stem cell defects.
  evidence:
  - reference: PMID:38424108
    reference_title: "Deregulated protein homeostasis constrains fetal hematopoietic stem cell pool expansion in Fanconi anemia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we identify increased protein synthesis rates in the fetal hematopoietic stem cell pool at the onset of hematopoietic failure in Fanconi Anemia, a prototypical DNA repair disorder that manifests with bone marrow failure."
    explanation: Demonstrates that bone marrow failure is a defining manifestation of Fanconi anemia, with origins in fetal HSC dysfunction.
  downstream:
  - target: Pancytopenia
  - target: Aplastic Anemia
- name: Genomic Instability
  description: Increased tendency for genomic alterations including chromosomal breaks, deletions, and rearrangements.
  evidence:
  - reference: PMID:35596788
    reference_title: "Fanconi anemia: current insights regarding epidemiology, cancer, and DNA repair."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ICLs can interfere with DNA transactions, including replication and transcription. If not properly removed and repaired, ICLs cause DNA breaks and lead to genomic instability, a hallmark of cancer.
  downstream:
  - target: Hematopoietic Stem Cell Attrition
    description: Unrepaired genomic damage in HSCs triggers checkpoint-mediated apoptosis and senescence
  - target: Developmental Progenitor Apoptosis
    description: Genomic instability in embryonic progenitors activates p53-mediated cell death
  - target: Clonal Evolution
    description: Accumulation of somatic mutations drives malignant transformation
  - target: Epithelial Cancer Susceptibility
    description: Impaired genome maintenance in epithelial tissues promotes carcinogenesis
- name: Hematopoietic Stem Cell Attrition
  description: Progressive depletion of long-term hematopoietic stem cells in bone marrow due to replication stress, aldehyde-induced DNA damage, and chronic inflammatory signaling.
  evidence:
  - reference: PMID:38424108
    reference_title: "Deregulated protein homeostasis constrains fetal hematopoietic stem cell pool expansion in Fanconi anemia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "proteostasis deregulation itself is driven by excess sterile inflammatory activity in hematopoietic and stromal cells within the fetal liver, and dampened Type I interferon signaling similarly restores fetal Fancd2-/- long-term hematopoietic stem cells to wild type-equivalent numbers."
    explanation: Demonstrates that inflammatory signaling drives HSC pool deficits in FA, and that dampening inflammation rescues HSC numbers.
  - reference: PMID:24037726
    reference_title: "Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "the FA proteins might counteract aldehyde-induced genotoxicity in hematopoietic stem cells"
    explanation: Establishes that aldehydes cause genotoxicity in HSCs and FA proteins normally protect against this damage.
  cell_types:
  - preferred_term: hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: cellular response to aldehyde
    term:
      id: GO:0110096
      label: cellular response to aldehyde
  - preferred_term: cellular response to oxidative stress
    term:
      id: GO:0034599
      label: cellular response to oxidative stress
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  downstream:
  - target: Bone Marrow Failure
- name: Translesion Synthesis Defect
  description: Impaired ability to bypass DNA lesions during replication through translesion synthesis polymerases, requiring functional FANCD2-FANCI complex and PCNA monoubiquitination.
  evidence:
  - reference: PMID:25237197
    reference_title: "Stress and DNA repair biology of the Fanconi anemia pathway."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "Establishing the interaction network involving the FA proteins and their associated partners has revealed an intersection of FA with several DNA repair pathways, including homologous recombination, DNA mismatch repair, nucleotide excision repair, and translesion DNA synthesis."
    explanation: Demonstrates that the FA pathway intersects with translesion DNA synthesis, establishing the mechanistic link.
  biological_processes:
  - preferred_term: translesion synthesis
    term:
      id: GO:0019985
      label: translesion synthesis
  downstream:
  - target: Genomic Instability
- name: Homologous Recombination Impairment
  description: Defective repair of DNA double-strand breaks following interstrand crosslink unhooking, due to mutations in FA genes involved in HR pathway including BRCA2, PALB2, and BRCA1.
  evidence:
  - reference: PMID:25237197
    reference_title: "Stress and DNA repair biology of the Fanconi anemia pathway."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "the fact that 5 FA genes are in fact familial breast cancer genes and FA gene mutations are found frequently in sporadic cancers suggest wider applicability in hematopoiesis and oncology."
    explanation: The overlap of FA genes with breast cancer genes (BRCA1, BRCA2, PALB2) establishes the connection between FA and homologous recombination repair.
  biological_processes:
  - preferred_term: homologous recombination
    term:
      id: GO:0035825
      label: homologous recombination
  downstream:
  - target: Genomic Instability
- name: Aldehyde-Induced Genotoxicity
  description: Endogenous aldehydes (acetaldehyde and formaldehyde) from normal metabolism generate DNA interstrand crosslinks and DNA-protein crosslinks; impaired detoxification by ALDH2 and ADH5 exacerbates DNA damage burden.
  evidence:
  - reference: PMID:24037726
    reference_title: "Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We examined 64 Japanese FA patients, and found that the ALDH2 variant is associated with accelerated progression of BMF"
    explanation: Human clinical data showing that impaired aldehyde detoxification (ALDH2 variant) accelerates bone marrow failure in FA patients.
  - reference: PMID:25237197
    reference_title: "Stress and DNA repair biology of the Fanconi anemia pathway."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "recent studies have shown a major involvement of the FA pathway in the tolerance of reactive aldehydes."
    explanation: Establishes that the FA pathway is required for tolerance of aldehyde-induced DNA damage.
  biological_processes:
  - preferred_term: cellular response to aldehyde
    term:
      id: GO:0110096
      label: cellular response to aldehyde
  downstream:
  - target: Hematopoietic Stem Cell Attrition
    description: Endogenous aldehyde-induced DNA damage preferentially depletes HSCs when FA pathway is absent
- name: Core Complex Dysfunction
  description: >-
    Mutations in FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG,
    FANCL,
    FANCM, UBE2T/FANCT) disrupt the E3 ubiquitin ligase that monoubiquitinates the
    FANCD2-FANCI complex, abolishing the central signaling step of the FA pathway.
    FANCA mutations account for 60-70% of all FA cases.
  protein_complexes:
  - preferred_term: FA nuclear complex
    term:
      id: GO:0043240
      label: Fanconi anaemia nuclear complex
  biological_processes:
  - preferred_term: protein ubiquitination
    term:
      id: GO:0016567
      label: protein ubiquitination
  genes:
  - preferred_term: FANCA
    term:
      id: hgnc:3582
      label: FANCA
  - preferred_term: FANCB
    term:
      id: hgnc:3583
      label: FANCB
  - preferred_term: FANCC
    term:
      id: hgnc:3584
      label: FANCC
  - preferred_term: FANCG
    term:
      id: hgnc:3588
      label: FANCG
  evidence:
  - reference: PMID:35596788
    reference_title: "Fanconi anemia: current insights regarding epidemiology, cancer, and DNA repair."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "At least 22 genes are associated with Fanconi anemia, constituting the Fanconi anemia DNA repair pathway."
    explanation: Core complex genes form the upstream signaling arm of the FA pathway.
  downstream:
  - target: DNA Repair Deficiency
    description: Loss of core complex prevents FANCD2-FANCI monoubiquitination
- name: ID Complex Dysfunction
  description: >-
    Mutations in FANCD2 or FANCI disrupt the central ID2 complex whose
    monoubiquitination is the critical signaling event in FA pathway activation.
    In wild type, the core complex E3 ligase monoubiquitinates both FANCD2 and
    FANCI, causing the ID2 heterodimer to clamp onto chromatin at stalled
    replication forks and recruit downstream nucleases and HR effectors. Loss of
    either subunit abolishes this signaling hub.
  genes:
  - preferred_term: FANCD2
    term:
      id: hgnc:3585
      label: FANCD2
  - preferred_term: FANCI
    term:
      id: hgnc:25568
      label: FANCI
  biological_processes:
  - preferred_term: protein monoubiquitination
    term:
      id: GO:0006513
      label: protein monoubiquitination
  - preferred_term: interstrand cross-link repair
    term:
      id: GO:0036297
      label: interstrand cross-link repair
  evidence:
  - reference: PMID:32106311
    reference_title: "Association of clinical severity with FANCB variant type in Fanconi anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This reflects the indispensable role of FANCB protein in the enzymatic activation of FANCD2 monoubiquitination, an essential step in the repair of DNA interstrand crosslinks."
    explanation: FANCD2 monoubiquitination is the essential central step in ICL repair.
  downstream:
  - target: DNA Repair Deficiency
    description: Absence of functional ID2 complex prevents recruitment of downstream repair effectors
- name: Downstream Effector Dysfunction
  description: >-
    Mutations in downstream effector genes (BRCA2/FANCD1, PALB2/FANCN, BRCA1/FANCS,
    RAD51C/FANCO, XRCC2/FANCU) impair homologous recombination and translesion
    synthesis. These overlap with familial breast/ovarian cancer genes; biallelic
    mutations produce the most severe FA phenotypes with early-onset solid tumors
    and more congenital anomalies.
  genes:
  - preferred_term: BRCA2
    term:
      id: hgnc:1101
      label: BRCA2
  - preferred_term: BRCA1
    term:
      id: hgnc:1100
      label: BRCA1
  evidence:
  - reference: PMID:25237197
    reference_title: "Stress and DNA repair biology of the Fanconi anemia pathway."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "the fact that 5 FA genes are in fact familial breast cancer genes and FA gene mutations are found frequently in sporadic cancers suggest wider applicability in hematopoiesis and oncology."
    explanation: Downstream FA genes overlap with breast cancer susceptibility genes.
  downstream:
  - target: Homologous Recombination Impairment
    description: Loss of BRCA2/PALB2/BRCA1/RAD51C directly impairs HR-mediated DNA repair
- name: Inflammatory Bone Marrow Microenvironment
  description: >-
    Excess sterile inflammatory signaling (TNF-alpha, interferon-gamma, Type I
    interferons) in the bone marrow creates a hostile microenvironment for HSCs.
    Both hematopoietic and stromal cells contribute to chronic inflammation,
    driving proteostasis deregulation and accelerating stem cell attrition.
  cell_types:
  - preferred_term: hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  evidence:
  - reference: PMID:38424108
    reference_title: "Deregulated protein homeostasis constrains fetal hematopoietic stem cell pool expansion in Fanconi anemia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "proteostasis deregulation itself is driven by excess sterile inflammatory activity in hematopoietic and stromal cells within the fetal liver, and dampened Type I interferon signaling similarly restores fetal Fancd2-/- long-term hematopoietic stem cells to wild type-equivalent numbers."
    explanation: Inflammatory signaling in the BM microenvironment drives HSC loss in FA.
  downstream:
  - target: Hematopoietic Stem Cell Attrition
    description: Chronic inflammatory signaling drives proteostasis deregulation and HSC depletion
- name: Developmental Progenitor Apoptosis
  description: >-
    Unrepaired DNA damage in rapidly dividing embryonic progenitor cells activates
    p53-dependent apoptosis during critical developmental windows. This mechanism
    underlies the congenital malformations of FA, explaining the midline predominance
    of anomalies and correlation between pathway position and congenital abnormality
    burden.
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
  - preferred_term: embryo development
    term:
      id: GO:0009790
      label: embryo development
  evidence:
  - reference: PMID:26369989
    reference_title: "Central nervous system abnormalities in Fanconi anaemia: patterns and frequency on magnetic resonance imaging."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "The incidence of central nervous system (CNS) abnormalities in FA is higher than previously reported, with a midline predominance that points to impact in the early stages of CNS development."
    explanation: Midline predominance of anomalies supports developmental progenitor loss during embryogenesis.
  downstream:
  - target: Congenital Structural Anomalies
    description: Loss of mesodermal and endodermal progenitors causes organ malformations
  - target: CNS Developmental Anomalies
    description: Loss of neural progenitors causes midline brain and pituitary defects
  - target: Endocrine Gland Dysfunction
    description: Developmental pituitary defects impair hormone production
  - target: Skin Pigmentation Changes
    description: Melanocyte progenitor defects cause pigmentary anomalies
  - target: Intrauterine Growth Retardation
- name: Clonal Evolution
  description: >-
    Progressive accumulation of somatic mutations and chromosomal aberrations in
    genomically unstable hematopoietic cells drives clonal selection and malignant
    transformation. Characteristic cytogenetic changes include gain of 1q and 3q
    and loss of 7q. Clones with selective growth advantage expand, leading to MDS
    and AML. Single-cell DNA sequencing has revealed polyclonal evolution at the
    MDS stage, with sequential acquisition of driver mutations and MDM4-mediated
    p53 dampening via chromosome 1q gain as the canonical initiating event.
  cell_types:
  - preferred_term: hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "30% developed myelodysplastic syndrome (MDS), leukemia and/or solid tumors"
    explanation: 30% malignancy rate reflects ongoing clonal evolution in FA HSCs.
  - reference: PMID:36736290
    reference_title: "Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia."
    explanation: Longitudinal study of 335 FA patients showing chromosome 1q gain (containing MDM4) as the most common early clonal event, dampening p53 and driving clonal hematopoiesis.
  - reference: PMID:36167633
    reference_title: "Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution."
    explanation: Single-cell DNA sequencing of FA patients transforming to MDS/AML revealed polyclonal patterns with sequential acquisition of UBASH3A, SF3B1, RUNX1, and IDH2 mutations.
  - reference: PMID:37391485
    reference_title: "RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "we performed multiplexed gene editing of mutational hotspots in MDS-associated genes in human induced pluripotent stem cells (iPSCs) followed by hematopoietic differentiation. We observed aberrant self-renewal and impaired differentiation of HSPCs with enrichment of RUNX1 insertions and deletions (indels)"
    explanation: iPSC-based modeling demonstrates that RUNX1 mutations blunt the G1/S cell cycle checkpoint in FA, promoting transformation.
  downstream:
  - target: Myelodysplastic Syndrome
  - target: Increased Risk of Leukemia
- name: Epithelial Cancer Susceptibility
  description: >-
    Impaired genome maintenance in epithelial tissues renders them vulnerable to
    accumulation of oncogenic mutations. Squamous epithelia of the head/neck, oral
    cavity, esophagus, and anogenital regions are particularly susceptible due to
    high proliferative turnover and exposure to environmental mutagens including HPV.
  cell_types:
  - preferred_term: epithelial cell
    term:
      id: CL:0000066
      label: epithelial cell
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA."
    explanation: Confirms epithelial tissue susceptibility to malignancy in FA.
  - reference: PMID:36912284
    reference_title: "Fanconi anemia-isogenic head and neck cancer cell line pairs: A basic and translational science resource."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "We developed the Fanconi Anemia Cancer Cell Line Resource (FA-CCLR) to foster new work on the origins, treatment and prevention of FA-associated carcinomas. The FA-CCLR consists of Fanconi-isogenic head and neck squamous cell carcinoma (HNSCC) cell line pairs generated from five individuals with FA-associated HNSCC, and five individuals with sporadic HNSCC."
    explanation: Isogenic FA/sporadic HNSCC cell line pairs provide a platform to identify FA-dependent cancer phenotypes and test therapeutic strategies.
  - reference: PMID:36450981
    reference_title: "Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer."
    supports: PARTIAL
    evidence_source: COMPUTATIONAL
    snippet: "Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer."
    explanation: Computational genomic analysis defined the primary structural variant signature of FA pathway deficiency in squamous cancers, enabling computational classification of FA-associated vs sporadic carcinomas.
  downstream:
  - target: Squamous Cell Carcinoma
  - target: Early-Onset Solid Tumors in FANCD1/BRCA2
- name: HPV-Mediated Epithelial Damage
  description: >-
    Human papillomavirus infection compounds epithelial cancer risk in FA patients.
    HPV oncoproteins E6 and E7 degrade p53 and Rb tumor suppressors, further
    disabling the already compromised DNA damage response. HPV vaccination is
    recommended to reduce gynecologic and oropharyngeal cancer risk.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Human papilloma virus (HPV) vaccination to reduce the risk for gynecologic cancer in females"
    explanation: HPV vaccination recommendation implies HPV is a significant co-factor for epithelial cancer in FA.
  downstream:
  - target: Epithelial Cancer Susceptibility
    description: HPV oncoproteins synergize with FA pathway deficiency to accelerate carcinogenesis
- name: Endocrine Gland Dysfunction
  description: >-
    Widespread endocrine abnormalities affect approximately 73-80% of FA patients.
    Developmental pituitary/hypothalamic defects (68% have small pituitary on MRI),
    direct effects of genomic instability on endocrine cell function, and chronic
    illness contribute. Manifests as GH deficiency, hypothyroidism, glucose
    dysregulation, hypogonadism, dyslipidemia, and metabolic syndrome.
  locations:
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  evidence:
  - reference: PMID:17426088
    reference_title: "Endocrine abnormalities in patients with Fanconi anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Endocrine abnormalities were present in 73%, including short stature and/or GH deficiency (51%), hypothyroidism (37%), midline brain abnormalities (17%)"
    explanation: Giri et al. documents 73% endocrine abnormality prevalence.
  - reference: PMID:26369989
    reference_title: "Central nervous system abnormalities in Fanconi anaemia: patterns and frequency on magnetic resonance imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormalities were identified in 18 (90%) patients with FA, the commonest being a small pituitary (68%, p < 0.01 females and p < 0.001 males)"
    explanation: Small pituitary in 68% provides anatomical basis for endocrine dysfunction.
  downstream:
  - target: Growth Hormone Deficiency
  - target: Hypothyroidism
  - target: Abnormal Glucose Homeostasis
  - target: Delayed Puberty and Hypogonadism
  - target: Osteopenia and Osteoporosis
  - target: Short Stature
  - target: Impaired Fertility
- name: Congenital Structural Anomalies
  description: >-
    Developmental progenitor loss during embryogenesis causes structural malformations
    affecting limbs, heart, kidneys, GI tract, ears, and genitourinary system.
    Approximately 75% of FA patients have at least one congenital anomaly, with
    burden correlating with complementation group, mutation type, and pathway position.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies."
    explanation: 75% of FA patients have physical abnormalities.
  downstream:
  - target: Skeletal Anomalies
  - target: Radial Ray Defects
  - target: Absent or Hypoplastic Thumbs
  - target: Congenital Heart Defects
  - target: Genital Malformations
  - target: Abnormal Renal Morphology
  - target: Hearing Loss
  - target: Microphthalmia
  - target: Strabismus
  - target: Structural Anomalies
  - target: Dental and Craniofacial Anomalies
  - target: Cryptorchidism
- name: CNS Developmental Anomalies
  description: >-
    Midline brain structural defects from neural progenitor loss during early CNS
    development. Includes small pituitary (68%), posterior fossa abnormalities (30%
    including Chiari I malformation and Dandy-Walker variant), and corpus callosum
    structural variation (30%).
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  evidence:
  - reference: PMID:26369989
    reference_title: "Central nervous system abnormalities in Fanconi anaemia: patterns and frequency on magnetic resonance imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormalities were identified in 18 (90%) patients with FA, the commonest being a small pituitary (68%, p < 0.01 females and p < 0.001 males)"
    explanation: 90% brain MRI abnormality rate with midline predominance.
  - reference: PMID:26369989
    reference_title: "Central nervous system abnormalities in Fanconi anaemia: patterns and frequency on magnetic resonance imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Posterior fossa abnormalities were seen in six cases (30%, p = 0.01) including Chiari I malformation (n = 3), Dandy-Walker variant (n = 2) and cerebellar atrophy (n = 2)."
    explanation: Posterior fossa and corpus callosum anomalies reflect early CNS developmental impact.
  downstream:
  - target: Microcephaly
  - target: Developmental Delay
- name: Skin Pigmentation Changes
  description: >-
    Melanocyte progenitor defects during embryonic development cause characteristic
    pigmentary anomalies including café-au-lait spots and hypopigmented patches.
    Skin pigmentation changes are the most common congenital anomaly in FA,
    affecting over 50% of patients.
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More than half had café-au-lait spots (52.3%) followed by renal anomalies (39.6%)."
    explanation: Café-au-lait spots are the most common congenital anomaly in the Israeli FA cohort.
  downstream:
  - target: Café-au-Lait Spots
  - target: Hypopigmented Skin Patches
- name: MYC-Driven HSPC Dysfunction
  description: >-
    Single-cell RNA sequencing of primary FA patient bone marrow HSPCs revealed
    MYC overexpression as a novel pathogenic driver alongside p53 and TGF-beta
    upregulation. Distinct HSPC subpopulations co-expressing high TP53 or high
    MYC coexist in FA bone marrow. MYC-high HSPCs show downregulation of cell
    adhesion genes (including CXCR4), promoting enhanced egress from bone marrow
    to peripheral blood and contributing to HSC exhaustion and bone marrow failure.
  cell_types:
  - preferred_term: hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: regulation of gene expression
    term:
      id: GO:0010468
      label: regulation of gene expression
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  evidence:
  - reference: PMID:32997960
    reference_title: "MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition to overexpression of p53 and TGF-β pathway genes, we identified high levels of MYC expression. We correspondingly observed coexistence of distinct HSPC subpopulations expressing high levels of TP53 or MYC in FA bone marrow (BM)."
    explanation: scRNA-seq of primary FA patient HSPCs identifies MYC as a novel driver of BMF alongside known p53/TGF-beta pathways.
  - reference: PMID:32997960
    reference_title: "MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Inhibiting MYC expression with the BET bromodomain inhibitor (+)-JQ1 reduced the clonogenic potential of FA patient HSPCs but rescued physiological and genotoxic stress in HSPCs from FA mice, showing that MYC promotes proliferation while increasing DNA damage."
    explanation: BET inhibitor targeting MYC rescues genotoxic stress in FA mouse HSPCs, validating MYC as a therapeutic target.
  downstream:
  - target: Hematopoietic Stem Cell Attrition
    description: MYC overexpression drives proliferation and DNA damage, accelerating HSC exhaustion
  - target: Bone Marrow Failure
- name: Differentiation-Induced Genotoxic Stress
  description: >-
    Transcriptional reprogramming during hematopoietic differentiation generates
    a surge of genotoxic stress from formaldehyde, an obligate by-product of
    oxidative protein demethylation during transcription regulation. In the
    absence of functional FA DNA repair, this differentiation-associated DNA
    damage causes aborted differentiation and depletion of FA progenitor cells,
    providing a mechanistic explanation for the hematopoietic-specific failure
    in FA despite it being a germline disorder.
  cell_types:
  - preferred_term: hematopoietic precursor cell
    term:
      id: CL:0008001
      label: hematopoietic precursor cell
  biological_processes:
  - preferred_term: hematopoietic progenitor cell differentiation
    term:
      id: GO:0002244
      label: hematopoietic progenitor cell differentiation
  - preferred_term: cellular response to aldehyde
    term:
      id: GO:0110096
      label: cellular response to aldehyde
  evidence:
  - reference: PMID:33338401
    reference_title: "A Surge of DNA Damage Links Transcriptional Reprogramming and Hematopoietic Deficit in Fanconi Anemia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "reprogramming transcription during hematopoietic differentiation results in an overload of genotoxic stress, which causes aborted differentiation and depletion of FA mutant progenitor cells. DNA damage onset most likely arises from formaldehyde, an obligate by-product of oxidative protein demethylation during transcription regulation."
    explanation: Demonstrates that transcriptional reprogramming during differentiation generates formaldehyde-induced DNA damage that specifically depletes FA-deficient progenitors.
  downstream:
  - target: Hematopoietic Stem Cell Attrition
    description: Differentiation-coupled DNA damage depletes progenitors, contributing to HSC pool exhaustion
  - target: Bone Marrow Failure
- name: iPSC-Revealed p53-Driven Progenitor Exhaustion
  description: >-
    Induced pluripotent stem cell modeling of FA hematopoietic differentiation
    revealed that FANCA-deficient human hematopoietic progenitor cells undergo
    accelerated terminal differentiation driven by p53/p21 activation. GAS6
    (growth arrest specific 6) was identified as a novel p53 target gene; GAS6
    signaling modulation rescues hematopoiesis. This iPSC-based new approach
    methodology overcomes the lack of faithful murine FA models and enables
    drug screening for FA therapeutics.
  cell_types:
  - preferred_term: hematopoietic precursor cell
    term:
      id: CL:0008001
      label: hematopoietic precursor cell
  biological_processes:
  - preferred_term: intrinsic apoptotic signaling pathway by p53 class mediator
    term:
      id: GO:0072332
      label: intrinsic apoptotic signaling pathway by p53 class mediator
  evidence:
  - reference: PMID:33002135
    reference_title: "An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "FANCA-deficient human HPCs underwent accelerated terminal differentiation driven by activation of p53/p21. We identified growth arrest specific 6 (GAS6) as a novel target of activated p53 in FANCA-deficient HPCs and modulate GAS6 signaling to rescue hematopoiesis in FANCA-deficient cells."
    explanation: iPSC-derived FA model reveals p53/p21/GAS6 axis driving progenitor exhaustion and validates GAS6 as a therapeutic target.
  - reference: PMID:33512438
    reference_title: "Analysis of disease model iPSCs derived from patients with a novel Fanconi anemia-like IBMFS ADH5/ALDH2 deficiency."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "disease model iPSCs displayed drastically defective cell expansion when stimulated into hematopoietic differentiation in vitro, displaying increased levels of DNA damage. The expansion defect was partially reversed by treatment with a new small molecule termed C1, which is an agonist of ALDH2"
    explanation: ADH5/ALDH2-deficient iPSCs modeling FA-like aldehyde toxicity confirm hematopoietic differentiation defects and identify ALDH2 agonism as a rescue strategy.
  downstream:
  - target: Hematopoietic Stem Cell Attrition
  - target: Bone Marrow Failure
phenotypes:
- category: Hematologic
  name: Pancytopenia
  description: Progressive decline in all blood cell lineages due to bone marrow failure.
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Decreased levels of red blood cells, white blood cells, and platelets. Over 80% of FA patients develop bone marrow failure. Typically presents in the first decade, often initially with thrombocytopenia or leukopenia. Notably, patients with FANCD1/BRCA2 mutations may not develop BMF. FA-S (biallelic BRCA1) patients also characteristically lack bone marrow failure.
  evidence:
  - reference: PMID:35596788
    reference_title: "Fanconi anemia: current insights regarding epidemiology, cancer, and DNA repair."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Fanconi anemia is a genetic disorder that is characterized by bone marrow failure, as well as a predisposition to malignancies including leukemia and squamous cell carcinoma (SCC).
  phenotype_term:
    preferred_term: Pancytopenia
    term:
      id: HP:0001876
      label: Pancytopenia
  phenotype_contexts:
  - notes: Over 80% of FA patients develop bone marrow failure.
    frequency: VERY_FREQUENT
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "82% of the patients developed BMF"
      explanation: Israeli cohort quantifies BMF prevalence at 82%.
  - genetic_context:
      gene:
        preferred_term: FANCD1/BRCA2
        term:
          id: hgnc:1101
          label: BRCA2
      complementation_group: FA-D1
    frequency: EXCLUDED
    notes: >-
      Neither FANCD1/BRCA2 patient in the Israeli cohort developed BMF.
      One was transplanted for AML before age 6 months; the other had
      no complications by age 17.
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "neither of the patients with FANCD1 mutations developed BMF"
      explanation: FANCD1/BRCA2 patients characteristically lack bone marrow failure.
  - genetic_context:
      gene:
        preferred_term: BRCA1
        term:
          id: hgnc:1100
          label: BRCA1
      complementation_group: FA-S
      zygosity: HOMOZYGOUS
    frequency: EXCLUDED
    notes: >-
      FA-S (biallelic BRCA1) patients characteristically lack bone marrow
      failure, distinguishing them from most other FA complementation groups.
    evidence:
    - reference: PMID:38146508
      reference_title: "The emergence of Fanconi anaemia type S: a phenotypic spectrum of biallelic BRCA1 mutations."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Unlike most other types of FA, FA-S patients lack bone marrow failure."
      explanation: FA-S defined by absence of BMF despite other FA features.
  - population: Japanese
    notes: >-
      The ALDH2*2 dominant-negative variant (rs671), carried by nearly half
      of the Japanese population, is associated with accelerated BMF
      progression in FA patients. Birth weight and physical abnormalities
      were not affected.
    evidence:
    - reference: PMID:24037726
      reference_title: "Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the ALDH2 variant is associated with accelerated progression of BMF, while birth weight or the number of physical abnormalities was not affected"
      explanation: ALDH2*2 acts as a genetic modifier accelerating BMF in Japanese FA patients.
- category: Hematologic
  name: Increased Risk of Leukemia
  description: Significantly elevated risk of developing leukemia, predominantly acute myeloid leukemia (AML) with an incidence of 13% by age 50. Acute lymphoblastic leukemia (ALL) also reported, especially in FANCD1/BRCA2 patients.
  frequency: FREQUENT
  notes: The incidence of AML is 13% by age 50 years. Patients with FANCA mutations develop cancer at a significantly older age (mean 18.5 years) compared to non-FANCA groups (mean 5.2 years, P=0.001). Patients with FANCC mutations show a trend toward more MDS. FANCG patients may have less MDS and cancer overall. All FANCA patients in the Israeli cohort developed their first cancer after age 10, while all non-FANCA patients developed cancer by age 10.
  evidence:
  - reference: PMID:24037726
    reference_title: "Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is characterized by phenotypes including progressive bone marrow failure (BMF), developmental abnormalities, and increased occurrence of leukemia and cancer."
    explanation: Clinical description confirming that increased leukemia occurrence is a defining phenotype of FA.
  phenotype_term:
    preferred_term: Leukemia
    term:
      id: HP:0001909
      label: Leukemia
  phenotype_contexts:
  - genetic_context:
      gene:
        preferred_term: FANCA
        term:
          id: hgnc:3582
          label: FANCA
      complementation_group: FA-A
    onset:
      mean_age_years: 18.5
      min_age_years: 10.0
      notes: All FANCA patients developed cancer after age 10.
    notes: >-
      All FANCA patients in the Israeli cohort developed their first
      cancer after age 10.
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with FANCA mutations developed cancer at a significantly older age compared to patients with mutations in other Fanconi genes (mean 18.5 and 5.2 years, respectively, P=0.001)"
      explanation: FANCA patients have later onset of hematologic malignancy.
  - genetic_context:
      genes:
      - preferred_term: FANCC
        term:
          id: hgnc:3584
          label: FANCC
      - preferred_term: FANCD1/BRCA2
        term:
          id: hgnc:1101
          label: BRCA2
      - preferred_term: FANCG
        term:
          id: hgnc:3588
          label: FANCG
      - preferred_term: FANCJ/BRIP1
        term:
          id: hgnc:20473
          label: BRIP1
      description: >-
        Non-FANCA complementation groups tested in the Israeli cohort
        (FANCC, FANCD1, FANCG, FANCJ). Not exhaustive of all non-FANCA
        groups but represents the specific genes analyzed.
    onset:
      mean_age_years: 5.2
      max_age_years: 10.0
      notes: All non-FANCA patients developed cancer by age 10.
    notes: >-
      All non-FANCA patients in the Israeli cohort developed cancer
      by age 10. FANCC mutations show a trend toward more MDS.
      FANCG patients may have less MDS and cancer overall.
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with FANCA mutations developed cancer at a significantly older age compared to patients with mutations in other Fanconi genes (mean 18.5 and 5.2 years, respectively, P=0.001)"
      explanation: >-
        Same abstract sentence viewed from non-FANCA perspective;
        non-FANCA groups developed cancer significantly earlier
        (mean 5.2 years vs 18.5 years, P=0.001).
  - genetic_context:
      allele_type: nonsense
    notes: >-
      Patients with nonsense mutations developed first cancer at a
      significantly younger age than patients with deletions (P=0.011).
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "patients with nonsense and splice site mutations developed the first cancer at a significantly lower age than patients with deletions (P=0.011 and P=0.012, respectively)"
      explanation: Mutation type affects cancer onset age independent of gene identity.
  - genetic_context:
      allele_type: splice_site
    notes: >-
      Patients with splice site mutations developed first cancer at a
      significantly younger age than patients with deletions (P=0.012).
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "patients with nonsense and splice site mutations developed the first cancer at a significantly lower age than patients with deletions (P=0.011 and P=0.012, respectively)"
      explanation: Splice site mutations associated with earlier cancer onset.
  - genetic_context:
      gene:
        preferred_term: FANCG
        term:
          id: hgnc:3588
          label: FANCG
      complementation_group: FA-G
    notes: >-
      Trend toward less MDS and cancer in patients with FANCG mutations
      compared to other FA genes (not statistically significant).
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "There was a trend towards more MDS in patients with FANCC mutations and less MDS and cancer in patients with FANCG mutations, compared with patients with mutations in other genes (NS)."
      explanation: FANCG mutations may be associated with a milder malignancy phenotype.
- category: Hematologic
  name: Aplastic Anemia
  description: Bone marrow failure resulting in severely reduced production of all blood cell types.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:24037726
    reference_title: "Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is characterized by phenotypes including progressive bone marrow failure (BMF), developmental abnormalities, and increased occurrence of leukemia and cancer."
    explanation: Progressive bone marrow failure is a cardinal feature of FA leading to aplastic anemia.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001903 | Anemia | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO annotation classifies anemia as very frequent in Fanconi anemia.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
- category: Hematologic
  name: Thrombocytopenia
  description: Low platelet count due to progressive bone marrow failure in Fanconi anemia.
  frequency: VERY_FREQUENT
  notes: Listed in FA clinical screening manifestations and commonly contributes to bleeding risk.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia"
    explanation: GeneReviews documents progressive bone marrow failure with thrombocytopenia and leukopenia as typical hematologic manifestations.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001873 | Thrombocytopenia | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO annotation classifies thrombocytopenia as very frequent in Fanconi anemia.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
- category: Hematologic
  name: Leukopenia
  description: Decreased white blood cell count as part of hematopoietic failure in Fanconi anemia.
  frequency: VERY_FREQUENT
  notes: Included in the FA screening phenotype table for bone marrow failure manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia"
    explanation: GeneReviews documents progressive bone marrow failure with thrombocytopenia and leukopenia as typical hematologic manifestations.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001882 | Leukopenia | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO annotation classifies leukopenia as very frequent in Fanconi anemia.
  phenotype_term:
    preferred_term: Decreased total leukocyte count
    term:
      id: HP:0001882
      label: Decreased total leukocyte count
- category: Developmental
  name: Short Stature
  description: Growth deficiency present from birth, affecting approximately 60% of patients.
  frequency: FREQUENT
  notes: In the Israeli cohort, 57% met criteria for short stature. Patients with downstream FA gene mutations (FANCD1, FANCJ) were significantly shorter than core complex patients (P=0.003). Patients with deletion mutations were shorter than those with nonsense mutations (P=0.018). Contributing factors include GH deficiency, hypothyroidism, and constitutional factors.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies."
    explanation: GeneReviews confirms short stature as one of the common physical abnormalities in FA.
  phenotype_term:
    preferred_term: Short Stature
    term:
      id: HP:0004322
      label: Short stature
  phenotype_contexts:
  - frequency: FREQUENT
    notes: 57% met criteria for short stature in the Israeli cohort (n=111).
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "57% fit criteria for short stature"
      explanation: Quantitative frequency data from Israeli FA cohort of 111 patients.
  - population: Orphanet curated aggregate
    frequency: VERY_FREQUENT
    notes: Orphanet classifies short stature as very frequent in Fanconi anemia.
    evidence:
    - reference: ORPHA:84
      reference_title: "Fanconi anemia (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0004322 | Short stature | Very frequent (99-80%)"
      explanation: Orphanet's curated HPO annotation classifies short stature as very frequent in Fanconi anemia.
  - genetic_context:
      genes:
      - preferred_term: FANCD1/BRCA2
        term:
          id: hgnc:1101
          label: BRCA2
      - preferred_term: FANCJ/BRIP1
        term:
          id: hgnc:20473
          label: BRIP1
      description: Downstream FA pathway genes
    severity: More severe
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with mutations in the downstream genes FANCD1 and FANCJ were significantly shorter compared with the others (P=0.003)"
      explanation: Downstream pathway gene mutations associated with more severe growth deficiency.
  - genetic_context:
      allele_type: deletion
    severity: More severe
    notes: Deletion mutations associated with shorter stature than nonsense mutations.
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with deletions were shorter than patients with nonsense mutations (P=0.018)"
      explanation: Mutation type affects severity of growth phenotype.
- category: Skeletal
  name: Skeletal Anomalies
  description: Upper limb malformations including absent or hypoplastic thumbs, radial ray defects, and hip abnormalities.
  frequency: FREQUENT
  notes: Includes areas such as the radius, thumb, and hips
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
  phenotype_term:
    preferred_term: Skeletal Anomalies
    term:
      id: HP:0005775
      label: Multiple skeletal anomalies
  phenotype_contexts:
  - genetic_context:
      gene:
        preferred_term: FANCC
        term:
          id: hgnc:3584
          label: FANCC
      complementation_group: FA-C
    notes: >-
      Rib abnormalities were observed only in patients with FANCC
      mutations in the Israeli cohort — exclusive to this complementation
      group.
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Rib abnormalities were observed only in patients with FANCC mutations."
      explanation: FANCC-exclusive rib anomaly pattern.
  - genetic_context:
      gene:
        preferred_term: FANCD1/BRCA2
        term:
          id: hgnc:1101
          label: BRCA2
      complementation_group: FA-D1
    notes: >-
      Cleft lip was significantly more common in patients with FANCD1
      mutations compared with other FA genes (P<0.001).
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cleft lip was more common in patients with FANCD1 mutations, compared with other FA genes (P<0.001)."
      explanation: FANCD1/BRCA2 specifically enriched for cleft lip.
  - genetic_context:
      gene:
        preferred_term: FANCB
        term:
          id: hgnc:3583
          label: FANCB
      complementation_group: FA-B
      allele_type: truncating
    severity: Severe
    notes: >-
      FANCB deletion or truncation variants produce earlier-than-average onset
      of bone marrow failure and more severe congenital abnormalities. Missense
      variants with residual FANCD2 monoubiquitination activity are associated
      with more favorable outcome. FANCB is X-linked, so only males are affected.
    evidence:
    - reference: PMID:32106311
      reference_title: "Association of clinical severity with FANCB variant type in Fanconi anemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Those with FANCB deletion or truncation demonstrate earlier-than-average onset of bone marrow failure and more severe congenital abnormalities compared with a large series of FA individuals in published reports."
      explanation: Jung et al. 19-child FANCB cohort shows truncating variants produce severe congenital abnormality phenotype.
  - genetic_context:
      gene:
        preferred_term: FANCI
        term:
          id: hgnc:25568
          label: FANCI
      complementation_group: FA-I
    notes: >-
      44% of FA patients with FANCI mutations (7/16) met criteria for VACTERL
      association (at least 3 features), significantly overrepresented compared
      to ~5% in FA overall.
    evidence:
    - reference: PMID:26590883
      reference_title: "Novel FANCI mutations in Fanconi anemia with VACTERL association."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "There are now 16 reported cases of FA due to FANCI of whom 7 have at least 3 features of the VACTERL association (44%)."
      explanation: FANCI mutations are disproportionately associated with VACTERL phenotype in FA.
- category: Dermatologic
  name: Café-au-Lait Spots
  description: Hyperpigmented skin macules commonly seen in FA patients.
  frequency: FREQUENT
  notes: One of the abnormal skin pigmentation findings in FA
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: Abnormal skin pigmentation, including café-au-lait spots, is among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Café-au-lait Spot
    term:
      id: HP:0000957
      label: Cafe-au-lait spot
  phenotype_contexts:
  - frequency: FREQUENT
    notes: 52.3% of patients in the Israeli cohort had café-au-lait spots, the most common congenital anomaly.
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "More than half had café-au-lait spots (52.3%) followed by renal anomalies (39.6%)."
      explanation: Quantitative frequency from Israeli FA cohort (n=111).
- category: Oncologic
  name: Squamous Cell Carcinoma
  description: Markedly increased risk of early-onset squamous cell carcinomas, particularly of the head and neck, oral cavity, esophagus, and anogenital regions.
  frequency: FREQUENT
  notes: Cancer surveillance is critical due to genomic instability and persistent epithelial cancer risk. Solid tumors in the Israeli cohort appeared at a mean age of 26.6 years, significantly later than MDS/leukemia. All solid tumors in that cohort were in patients with FANCA mutations or undiagnosed patients. HPV vaccination is recommended to reduce risk. Oral examination every 6 months from age 9-10 years and annual nasolaryngoscopy from age 10 years are recommended.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA."
    explanation: GeneReviews confirms elevated risk of solid tumors including head/neck and skin squamous cell carcinomas.
  phenotype_term:
    preferred_term: Squamous cell carcinoma
    term:
      id: HP:0002860
      label: Squamous cell carcinoma
  phenotype_contexts:
  - onset:
      mean_age_years: 26.6
      notes: Solid tumors appear significantly later than hematologic malignancies.
    notes: >-
      All solid tumors in the Israeli cohort were in patients with FANCA
      mutations or undiagnosed patients. Mean age of solid tumor onset
      was 26.6 years, significantly later than MDS/leukemia.
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "for solid tumors 26.6 years (SD 4.9)"
      explanation: Mean solid tumor onset at 26.6 years, significantly later than MDS (13.3y) and leukemia (10.8y).
  - sex: FEMALE
    notes: >-
      Female FA patients have elevated risk of gynecologic squamous cell
      carcinomas (vulvar, cervical) at young ages. HPV vaccination is
      recommended. Gynecologic assessment annually from age 13; Pap smear
      annually from age 18.
    evidence:
    - reference: PMID:20301575
      reference_title: "Fanconi Anemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Human papilloma virus (HPV) vaccination to reduce the risk for gynecologic cancer in females"
      explanation: GeneReviews specifically highlights gynecologic cancer risk in female FA patients and recommends HPV vaccination.
  - genetic_context:
      gene:
        preferred_term: BRCA1
        term:
          id: hgnc:1100
          label: BRCA1
      complementation_group: FA-S
      zygosity: HOMOZYGOUS
    notes: >-
      FA-S (biallelic BRCA1) patients have predisposition to breast/ovarian
      cancer and/or childhood cancers, distinct from the typical FA SCC
      spectrum.
    evidence:
    - reference: PMID:38146508
      reference_title: "The emergence of Fanconi anaemia type S: a phenotypic spectrum of biallelic BRCA1 mutations."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "predisposition to breast/ovarian cancer and/or childhood cancers"
      explanation: FA-S cancer spectrum includes breast/ovarian cancer rather than the typical SCC pattern.
- category: Gastrointestinal
  name: Structural Anomalies
  description: Congenital malformations of the gastrointestinal tract.
  frequency: OCCASIONAL
  notes: Includes esophageal atresia, duodenal atresia, and other malformations
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals"
    explanation: GeneReviews confirms congenital abnormalities are present in ~75% of FA patients.
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
- category: Gastrointestinal
  name: Esophageal Atresia
  description: Congenital interruption of the esophagus reported among Fanconi anemia gastrointestinal manifestations.
  frequency: OCCASIONAL
  notes: Included in the FA guideline atresia spectrum used for diagnostic screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
  phenotype_term:
    preferred_term: Esophageal atresia
    term:
      id: HP:0002032
      label: Esophageal atresia
- category: Gastrointestinal
  name: Duodenal Atresia
  description: Congenital obstruction of the duodenum reported among Fanconi anemia gastrointestinal manifestations.
  frequency: OCCASIONAL
  notes: Included in the FA guideline atresia spectrum used for diagnostic screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
  phenotype_term:
    preferred_term: Duodenal atresia
    term:
      id: HP:0002247
      label: Duodenal atresia
- category: Gastrointestinal
  name: Jejunal Atresia
  description: Congenital jejunal occlusion reported among Fanconi anemia gastrointestinal manifestations.
  frequency: OCCASIONAL
  notes: Included in the FA guideline atresia spectrum used for diagnostic screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
  phenotype_term:
    preferred_term: Jejunal atresia
    term:
      id: HP:0005235
      label: Jejunal atresia
- category: Gastrointestinal
  name: Anal Atresia
  description: Congenital anorectal malformation reported in Fanconi anemia screening manifestations.
  frequency: OCCASIONAL
  notes: Included in FA guideline diagnostic manifestations as imperforate or bifurcated anus.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
  phenotype_term:
    preferred_term: Anal atresia
    term:
      id: HP:0002023
      label: Anal atresia
- category: Gastrointestinal
  name: Intestinal Malrotation
  description: Congenital abnormal rotation/fixation of the intestine occurring in a subset of FA patients.
  frequency: OCCASIONAL
  notes: Included in FA guideline gastrointestinal screening manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
  phenotype_term:
    preferred_term: Intestinal malrotation
    term:
      id: HP:0002566
      label: Intestinal malrotation
- category: Gastrointestinal
  name: Annular Pancreas
  description: Congenital ring of pancreatic tissue encircling the duodenum, reported among FA screening manifestations.
  frequency: OCCASIONAL
  notes: Listed in the FA guideline gastrointestinal anomaly table.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
  phenotype_term:
    preferred_term: Annular pancreas
    term:
      id: HP:0001734
      label: Annular pancreas
- category: Gastrointestinal
  name: Tracheoesophageal Fistula
  description: Congenital fistulous connection between trachea and esophagus in a subset of FA patients.
  frequency: OCCASIONAL
  notes: Included as a diagnostic screening manifestation in FA clinical care guidelines.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including gastrointestinal anomalies.
  phenotype_term:
    preferred_term: Tracheoesophageal fistula
    term:
      id: HP:0002575
      label: Tracheoesophageal fistula
- category: Reproductive
  name: Genital Malformations
  description: Congenital abnormalities of the genital or reproductive organs; renal malformations are captured separately as abnormal renal morphology.
  frequency: OCCASIONAL
  notes: The cited cohort reports a broader genitourinary anomaly enrichment in downstream FA gene mutations; this phenotype captures the genital/reproductive component, with renal malformations curated separately.
  phenotype_term:
    preferred_term: Abnormality of the genital system
    term:
      id: HP:0000078
      label: Abnormality of the genital system
  phenotype_contexts:
  - genetic_context:
      genes:
      - preferred_term: FANCD1/BRCA2
        term:
          id: hgnc:1101
          label: BRCA2
      - preferred_term: FANCJ/BRIP1
        term:
          id: hgnc:20473
          label: BRIP1
      description: Downstream FA pathway genes
    frequency: FREQUENT
    notes: >-
      Genitourinary anomalies, a broader grouping that includes genital
      abnormalities, were significantly more common in patients with downstream
      FA gene mutations compared to core complex mutations (P=0.03).
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."
      explanation: Downstream FA pathway mutations enriched for genitourinary anomalies, supporting a genotype-specific genital/reproductive anomaly context while renal morphology is curated separately.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
    explanation: GeneReviews lists genital anomalies among FA manifestations requiring subspecialty care, supporting a genital-system phenotype distinct from renal malformations.
- category: Neurologic
  name: Microcephaly
  description: Abnormally small head circumference, present in a subset of FA patients as part of congenital anomalies.
  frequency: OCCASIONAL
  notes: Part of the congenital anomaly spectrum. Skull anomalies were significantly more common in patients with downstream FA gene mutations (FANCD1, FANCJ) compared to core complex mutations (P<0.001). FA-S (biallelic BRCA1) patients also frequently present with microcephaly.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  phenotype_contexts:
  - population: Orphanet curated aggregate
    frequency: FREQUENT
    notes: Orphanet classifies microcephaly as frequent in Fanconi anemia.
    evidence:
    - reference: ORPHA:84
      reference_title: "Fanconi anemia (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000252 | Microcephaly | Frequent (79-30%)"
      explanation: Orphanet's curated HPO annotation classifies microcephaly as frequent in Fanconi anemia.
  - genetic_context:
      genes:
      - preferred_term: FANCD1/BRCA2
        term:
          id: hgnc:1101
          label: BRCA2
      - preferred_term: FANCJ/BRIP1
        term:
          id: hgnc:20473
          label: BRIP1
      description: Downstream FA pathway genes
    frequency: VERY_FREQUENT
    notes: >-
      Skull anomalies were significantly more common in patients
      with downstream FA gene mutations compared to core complex
      mutations (P<0.001).
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."
      explanation: Downstream pathway mutations associated with significantly more skull anomalies including microcephaly.
  - genetic_context:
      gene:
        preferred_term: BRCA1
        term:
          id: hgnc:1100
          label: BRCA1
      complementation_group: FA-S
      zygosity: HOMOZYGOUS
    frequency: VERY_FREQUENT
    notes: FA-S (biallelic BRCA1) patients frequently present with microcephaly.
    evidence:
    - reference: PMID:38146508
      reference_title: "The emergence of Fanconi anaemia type S: a phenotypic spectrum of biallelic BRCA1 mutations."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "this FA-S cohort phenotype includes short stature, microcephaly, facial dysmorphisms"
      explanation: Microcephaly is a characteristic feature of the FA-S phenotype.
  - frequency: VERY_FREQUENT
    notes: >-
      90% of FA patients (18/20) had brain MRI abnormalities including small
      pituitary (68%), posterior fossa abnormalities (30%), and corpus callosum
      structural variation (30%). The high incidence of midline CNS anomalies
      points to impact in early stages of CNS development.
    evidence:
    - reference: PMID:26369989
      reference_title: "Central nervous system abnormalities in Fanconi anaemia: patterns and frequency on magnetic resonance imaging."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Abnormalities were identified in 18 (90%) patients with FA, the commonest being a small pituitary (68%, p < 0.01 females and p < 0.001 males)"
      explanation: Stivaros et al. found 90% of FA patients have brain MRI abnormalities, much higher than previously recognized.
- category: Neurologic
  name: Anterior Pituitary Hypoplasia
  description: Small anterior pituitary as part of the central nervous system anomaly spectrum in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline CNS screening manifestations as small pituitary/stalk anomalies.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including central nervous system anomalies.
  phenotype_term:
    preferred_term: Anterior pituitary hypoplasia
    term:
      id: HP:0010627
      label: Anterior pituitary hypoplasia
- category: Neurologic
  name: Interrupted Pituitary Stalk
  description: Interruption of the pituitary stalk reported among central nervous system manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline CNS screening manifestations as stalk interruption.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including central nervous system anomalies.
  phenotype_term:
    preferred_term: Interrupted pituitary stalk
    term:
      id: HP:0034978
      label: Interrupted pituitary stalk
- category: Developmental
  name: Micrognathia
  description: Congenital mandibular hypoplasia reported within the facial anomaly spectrum of Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline facial manifestations that should raise suspicion for FA.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
  phenotype_term:
    preferred_term: Micrognathia
    term:
      id: HP:0000347
      label: Micrognathia
- category: Developmental
  name: Cleft Palate
  description: Orofacial clefting reported as part of the congenital facial phenotype in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Listed in FA guideline facial manifestations used for diagnostic screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
  phenotype_term:
    preferred_term: Cleft palate
    term:
      id: HP:0000175
      label: Cleft palate
- category: Developmental
  name: Triangular Face
  description: Triangular facial shape reported among congenital facial manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline facial manifestations used for diagnostic screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
  phenotype_term:
    preferred_term: Triangular face
    term:
      id: HP:0000325
      label: Triangular face
- category: Developmental
  name: Midface Retrusion
  description: Retruded or hypoplastic midface reported among congenital facial manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline facial manifestations as mid-face hypoplasia.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
  phenotype_term:
    preferred_term: Midface retrusion
    term:
      id: HP:0011800
      label: Midface retrusion
- category: Developmental
  name: Pointed Chin
  description: Pointed chin morphology reported among congenital facial manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline facial manifestations used for diagnostic screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
  phenotype_term:
    preferred_term: Pointed chin
    term:
      id: HP:0000307
      label: Pointed chin
- category: Developmental
  name: Facial Palsy
  description: Congenital facial nerve weakness or palsy reported among facial manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline facial manifestations used for diagnostic screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
  phenotype_term:
    preferred_term: Facial palsy
    term:
      id: HP:0010628
      label: Facial palsy
- category: Developmental
  name: Hypertelorism
  description: Increased interpupillary and/or interorbital distance reported among facial anomalies in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline facial manifestations used for diagnostic screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
- category: Developmental
  name: Hypotelorism
  description: Decreased interpupillary and/or interorbital distance reported among facial anomalies in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline facial manifestations used for diagnostic screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including craniofacial anomalies.
  phenotype_term:
    preferred_term: Hypotelorism
    term:
      id: HP:0000601
      label: Hypotelorism
- category: Neurologic
  name: Agenesis of Corpus Callosum
  description: Absence of corpus callosum as part of the CNS developmental anomaly spectrum in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Listed in FA guideline CNS screening manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including central nervous system anomalies.
  phenotype_term:
    preferred_term: Agenesis of corpus callosum
    term:
      id: HP:0001274
      label: Agenesis of corpus callosum
- category: Neurologic
  name: Cerebellar Hypoplasia
  description: Underdevelopment of the cerebellum reported among FA central nervous system anomalies.
  frequency: OCCASIONAL
  notes: Included in FA guideline CNS screening manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including central nervous system anomalies.
  phenotype_term:
    preferred_term: Cerebellar hypoplasia
    term:
      id: HP:0001321
      label: Cerebellar hypoplasia
- category: Skeletal
  name: Radial Ray Defects
  description: Upper limb malformations affecting the radius and thumb, including hypoplasia or aplasia of the radius and thumb abnormalities.
  frequency: VERY_FREQUENT
  notes: Common skeletal manifestation in FA; can include absent or hypoplastic thumbs
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews confirms upper limb skeletal malformations as a common feature of FA.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0006501 | Aplasia/Hypoplasia of the radius | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO annotation classifies radius aplasia/hypoplasia as very frequent, supporting the radial ray defect phenotype.
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Hypoplasia of the radius
    term:
      id: HP:0002984
      label: Hypoplasia of the radius
- category: Skeletal
  name: Absent or Hypoplastic Thumbs
  description: Absent thumbs, hypoplastic thumbs, or supernumerary thumbs are common upper limb anomalies in FA, frequently accompanied by radial ray defects.
  frequency: VERY_FREQUENT
  notes: Part of the radial ray anomaly spectrum. More prevalent in core complex complementation groups (FANCA, FANCC, FANCG). The VACTERL phenotype is overrepresented in FA complementation groups D1, E, and F.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews confirms upper limb skeletal malformations as common in FA.
  - reference: PMID:16015582
    reference_title: "Should chromosome breakage studies be performed in patients with VACTERL association?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all have radial ray anomalies and 12 of these 13 subjects show at least 1 other feature of FA"
    explanation: In FA patients with VACTERL phenotype, all had radial ray anomalies including thumb abnormalities.
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001172 | Abnormal thumb morphology | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO annotation classifies thumb abnormalities as very frequent in Fanconi anemia.
  phenotype_term:
    preferred_term: Absent thumb
    term:
      id: HP:0009777
      label: Absent thumb
- category: Skeletal
  name: Small Thenar Eminence
  description: Hypoplastic or absent thenar eminence as part of the upper-limb anomaly spectrum in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline upper-limb diagnostic manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Small thenar eminence
    term:
      id: HP:0001245
      label: Small thenar eminence
- category: Skeletal
  name: First Metacarpal Aplasia or Hypoplasia
  description: Absent or hypoplastic first metacarpal reported among upper-limb manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline upper-limb diagnostic manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Aplasia/Hypoplasia of the 1st metacarpal
    term:
      id: HP:0010026
      label: Aplasia/Hypoplasia of the 1st metacarpal
- category: Skeletal
  name: Clinodactyly
  description: Curvature deformity of digits reported among upper-limb anomalies in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline upper-limb diagnostic manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Clinodactyly
    term:
      id: HP:0030084
      label: Clinodactyly
- category: Skeletal
  name: Ulnar Aplasia or Hypoplasia
  description: Short or dysplastic ulna as part of the upper-limb congenital anomaly spectrum in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline upper-limb diagnostic manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Aplasia/Hypoplasia of the ulna
    term:
      id: HP:0006495
      label: Aplasia/Hypoplasia of the ulna
- category: Skeletal
  name: Hip Dysplasia
  description: Congenital hip dislocation or dysplasia reported among lower-limb anomalies in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline lower-limb diagnostic manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Hip dysplasia
    term:
      id: HP:0001385
      label: Hip dysplasia
- category: Skeletal
  name: Hemivertebrae
  description: Vertebral segmentation defect present in a subset of FA patients.
  frequency: OCCASIONAL
  notes: Included within vertebral anomalies listed in FA diagnostic manifestation tables.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Hemivertebrae
    term:
      id: HP:0002937
      label: Hemivertebrae
- category: Skeletal
  name: Scoliosis
  description: Abnormal lateral curvature of the spine reported among vertebral manifestations in Fanconi anemia.
  frequency: FREQUENT
  notes: Included in the FA guideline vertebral anomaly manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002650 | Scoliosis | Frequent (79-30%)"
    explanation: Orphanet's curated HPO annotation classifies scoliosis as frequent in Fanconi anemia.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
- category: Skeletal
  name: Kyphosis
  description: Excessive posterior spinal curvature reported among vertebral anomalies in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline vertebral anomaly manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Kyphosis
    term:
      id: HP:0002808
      label: Kyphosis
- category: Skeletal
  name: Fused Cervical Vertebrae
  description: Cervical vertebral fusion consistent with Klippel-Feil pattern reported among vertebral anomalies in Fanconi anemia.
  frequency: OCCASIONAL
  notes: FA guideline vertebral manifestations list Klippel-Feil among spinal findings.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Fused cervical vertebrae
    term:
      id: HP:0002949
      label: Fused cervical vertebrae
- category: Skeletal
  name: Absent or Hypoplastic Coccyx
  description: Coccygeal aplasia or hypoplasia reported among vertebral anomalies in Fanconi anemia.
  frequency: OCCASIONAL
  notes: FA guideline vertebral manifestations include coccygeal aplasia.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Absent/hypoplastic coccyx
    term:
      id: HP:0008436
      label: Absent/hypoplastic coccyx
- category: Skeletal
  name: Toe Syndactyly
  description: Congenital fusion of toes reported as part of lower-limb anomalies in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline lower-limb manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Toe syndactyly
    term:
      id: HP:0001770
      label: Toe syndactyly
- category: Skeletal
  name: Clubfoot
  description: Congenital foot deformity listed among lower-limb manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline lower-limb manifestations as club feet.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Talipes equinovarus
    term:
      id: HP:0001762
      label: Talipes equinovarus
- category: Skeletal
  name: Abnormal Toe Morphology
  description: Structural toe abnormalities reported among lower-limb manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline lower-limb manifestations as abnormal toes.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skeletal malformations of the upper and/or lower limbs"
    explanation: GeneReviews lists skeletal malformations of the upper and/or lower limbs among the physical abnormalities present in ~75% of FA patients.
  phenotype_term:
    preferred_term: Abnormal toe morphology
    term:
      id: HP:0001780
      label: Abnormal toe morphology
- category: Ophthalmologic
  name: Microphthalmia
  description: Abnormally small eyes, part of the spectrum of ophthalmic anomalies seen in FA patients.
  frequency: OCCASIONAL
  notes: Ophthalmic anomalies are listed among the congenital features present in approximately 75% of FA patients. Microphthalmia may be more common in patients with higher congenital abnormality burden scores.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews lists ophthalmic anomalies including microphthalmia among FA congenital features.
  phenotype_term:
    preferred_term: Microphthalmia
    term:
      id: HP:0000568
      label: Microphthalmia
- category: Ophthalmologic
  name: Strabismus
  description: Misalignment of the eyes, a relatively common ophthalmic finding in FA patients.
  frequency: OCCASIONAL
  notes: Part of the ophthalmic anomaly spectrum in FA.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews lists ophthalmic anomalies as part of the FA congenital phenotype spectrum.
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
- category: Ophthalmologic
  name: Epicanthus
  description: Medial canthal skin fold reported among ocular manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline eye manifestations used for diagnostic screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews lists ophthalmic anomalies as part of the FA congenital phenotype spectrum.
  phenotype_term:
    preferred_term: Epicanthus
    term:
      id: HP:0000286
      label: Epicanthus
- category: Ophthalmologic
  name: Almond-Shaped Palpebral Fissures
  description: Almond-shaped eye fissures reported among ocular manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline eye manifestations used for diagnostic screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews lists ophthalmic anomalies as part of the FA congenital phenotype spectrum.
  phenotype_term:
    preferred_term: Almond-shaped palpebral fissure
    term:
      id: HP:0007874
      label: Almond-shaped palpebral fissure
- category: Ophthalmologic
  name: Cataract
  description: Lens opacity reported among ophthalmic anomalies in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline diagnostic manifestation table under eye abnormalities.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews lists ophthalmic anomalies as part of the FA congenital phenotype spectrum.
  phenotype_term:
    preferred_term: Cataract
    term:
      id: HP:0000518
      label: Cataract
- category: Ophthalmologic
  name: Ptosis
  description: Drooping upper eyelid reported among ophthalmic manifestations of Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline eye-abnormality screening manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews lists ophthalmic anomalies as part of the FA congenital phenotype spectrum.
  phenotype_term:
    preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
- category: Cardiac
  name: Congenital Heart Defects
  description: Structural heart anomalies including ventricular septal defects, atrial septal defects, patent ductus arteriosus, and other cardiac malformations.
  frequency: OCCASIONAL
  notes: Part of the VACTERL association overlap with FA. Heart abnormalities contribute to the congenital abnormality burden score (CABS). Patients with missense mutations had significantly less congenital heart disease (P=0.022) in the Israeli cohort. Downstream FA genes (FANCD1, FANCJ) may be associated with more severe congenital anomalies.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
    explanation: GeneReviews lists cardiac anomalies as part of the FA clinical spectrum requiring subspecialty management.
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with missense mutations had significantly less congenital heart disease (P=0.022)."
    explanation: Israeli cohort study found genotype-phenotype correlation for cardiac defects and mutation type.
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
    explanation: GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
  phenotype_term:
    preferred_term: Abnormal heart morphology
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  phenotype_contexts:
  - genetic_context:
      allele_type: missense
    frequency: OCCASIONAL
    notes: >-
      Missense mutations associated with significantly less congenital
      heart disease (P=0.022) in the Israeli cohort.
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with missense mutations had significantly less congenital heart disease (P=0.022)."
      explanation: Missense mutations are protective relative to other mutation types for cardiac defects.
- category: Cardiac
  name: Patent Ductus Arteriosus
  description: Persistent patency of the ductus arteriosus reported among congenital cardiac anomalies in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Listed in FA guideline cardiac manifestations used for FA screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
    explanation: GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
  phenotype_term:
    preferred_term: Patent ductus arteriosus
    term:
      id: HP:0001643
      label: Patent ductus arteriosus
- category: Cardiac
  name: Atrial Septal Defect
  description: Congenital interatrial septal defect included in the Fanconi anemia cardiac phenotype spectrum.
  frequency: OCCASIONAL
  notes: Listed in FA guideline cardiac manifestations used for FA screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
    explanation: GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
  phenotype_term:
    preferred_term: Atrial septal defect
    term:
      id: HP:0001631
      label: Atrial septal defect
- category: Cardiac
  name: Ventricular Septal Defect
  description: Congenital interventricular septal defect included in the Fanconi anemia cardiac anomaly spectrum.
  frequency: OCCASIONAL
  notes: Listed in FA guideline cardiac manifestations used for FA screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
    explanation: GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
  phenotype_term:
    preferred_term: Ventricular septal defect
    term:
      id: HP:0001629
      label: Ventricular septal defect
- category: Cardiac
  name: Coarctation of Aorta
  description: Congenital narrowing of the aorta reported in Fanconi anemia cardiac manifestations.
  frequency: OCCASIONAL
  notes: Listed in FA guideline cardiac manifestations used for FA screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
    explanation: GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
  phenotype_term:
    preferred_term: Coarctation of aorta
    term:
      id: HP:0001680
      label: Coarctation of aorta
- category: Cardiac
  name: Truncus Arteriosus
  description: Persistent common arterial trunk reported among congenital cardiac manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Listed in FA guideline cardiac manifestations used for FA screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
    explanation: GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
  phenotype_term:
    preferred_term: Truncus arteriosus
    term:
      id: HP:0001660
      label: Truncus arteriosus
- category: Cardiac
  name: Situs Inversus
  description: Reversal of thoracoabdominal organ laterality reported among FA-associated congenital cardiovascular anomalies.
  frequency: OCCASIONAL
  notes: Listed in FA guideline cardiac manifestations used for FA screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
    explanation: GeneReviews lists cardiac anomalies among the FA manifestations requiring subspecialty management.
  phenotype_term:
    preferred_term: Situs inversus totalis
    term:
      id: HP:0001696
      label: Situs inversus totalis
- category: Audiologic
  name: Hearing Loss
  description: Conductive and/or sensorineural hearing loss, often associated with external ear anomalies or middle ear malformations.
  frequency: OCCASIONAL
  notes: In the Israeli FA cohort, 18% of patients had hearing loss, all with a conductive component. Hearing loss contributes to the congenital abnormality burden score (CABS). Hearing aids may be helpful per otolaryngology evaluation.
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 18% of the patients with hearing loss, all had a conductive component"
    explanation: Israeli cohort documents 18% hearing loss prevalence with conductive component in FA patients.
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing aids may be helpful for hearing loss as per otolaryngologist"
    explanation: GeneReviews recommends hearing evaluation and hearing aids as part of FA management.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
- category: Audiologic
  name: Abnormal Pinna Morphology
  description: Congenital pinna malformations reported in Fanconi anemia with structural ear abnormalities.
  frequency: OCCASIONAL
  notes: Included in FA guideline otologic manifestations and supported by dedicated ear-phenotype sections.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing aids may be helpful for hearing loss as per otolaryngologist"
    explanation: GeneReviews documents hearing loss among FA manifestations and recommends otolaryngology evaluation.
  phenotype_term:
    preferred_term: Abnormal pinna morphology
    term:
      id: HP:0000377
      label: Abnormal pinna morphology
- category: Audiologic
  name: External Auditory Canal Atresia
  description: Congenital absence or atresia of the external auditory canal in a subset of Fanconi anemia patients.
  frequency: OCCASIONAL
  notes: Described in FA guideline otologic sections as part of structural ear anomalies.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing aids may be helpful for hearing loss as per otolaryngologist"
    explanation: GeneReviews documents hearing loss among FA manifestations and recommends otolaryngology evaluation.
  phenotype_term:
    preferred_term: Atresia of the external auditory canal
    term:
      id: HP:0000413
      label: Atresia of the external auditory canal
- category: Audiologic
  name: External Auditory Canal Stenosis
  description: Narrow external auditory canal reported among structural ear manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline otologic manifestations as a narrow/atretic canal.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing aids may be helpful for hearing loss as per otolaryngologist"
    explanation: GeneReviews documents hearing loss among FA manifestations and recommends otolaryngology evaluation.
  phenotype_term:
    preferred_term: Stenosis of the external auditory canal
    term:
      id: HP:0000402
      label: Stenosis of the external auditory canal
- category: Audiologic
  name: Middle Ear Ossicle Abnormalities
  description: Structural anomalies of middle ear ossicles reported among Fanconi anemia otologic findings.
  frequency: OCCASIONAL
  notes: Included in FA guideline otologic manifestations as abnormal middle ear bones.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing aids may be helpful for hearing loss as per otolaryngologist"
    explanation: GeneReviews documents hearing loss among FA manifestations and recommends otolaryngology evaluation.
  phenotype_term:
    preferred_term: Abnormality of the middle ear ossicles
    term:
      id: HP:0004452
      label: Abnormality of the middle ear ossicles
- category: Endocrine
  name: Hypothyroidism
  description: Thyroid hormone deficiency requiring monitoring and potentially replacement therapy.
  frequency: FREQUENT
  notes: About 80% of FA patients have at least one endocrine abnormality. Hypothyroidism is one of the most common endocrine manifestations. Annual TSH and free T4 screening is recommended.
  evidence:
  - reference: PMID:25575015
    reference_title: "Endocrine disorders in Fanconi anemia: recommendations for screening and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
    explanation: Consensus review documents hypothyroidism as a common endocrine abnormality in FA.
  phenotype_term:
    preferred_term: Hypothyroidism
    term:
      id: HP:0000821
      label: Hypothyroidism
  phenotype_contexts:
  - frequency: FREQUENT
    notes: >-
      37% prevalence in the NCI cohort (n=45, Giri et al. 2007). Annual TSH
      and free T4 screening is recommended.
    evidence:
    - reference: PMID:17426088
      reference_title: "Endocrine abnormalities in patients with Fanconi anemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "short stature and/or GH deficiency (51%), hypothyroidism (37%)"
      explanation: Giri et al. NCI cohort quantifies hypothyroidism at 37% in FA patients.
- category: Endocrine
  name: Growth Hormone Deficiency
  description: Insufficient growth hormone production contributing to short stature beyond what is expected from the underlying condition alone.
  frequency: FREQUENT
  notes: GH deficiency affects approximately 51% of FA patients (Giri et al. 2007, NCI cohort). Patients with GH deficiency were significantly shorter than those without (P=0.01). Growth hormone therapy may be used but requires careful monitoring given cancer predisposition. Ninety-two percent of FA patients aged 18 or older had osteopenia or osteoporosis.
  evidence:
  - reference: PMID:17426088
    reference_title: "Endocrine abnormalities in patients with Fanconi anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "short stature and/or GH deficiency (51%)"
    explanation: NCI cohort study of 45 FA patients found GH deficiency in 51%, establishing it as a frequent phenotype.
  - reference: PMID:25575015
    reference_title: "Endocrine disorders in Fanconi anemia: recommendations for screening and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
    explanation: Consensus review identifies GH deficiency as a recognized endocrine abnormality in FA.
  phenotype_term:
    preferred_term: Secondary growth hormone deficiency
    term:
      id: HP:0008240
      label: Secondary growth hormone deficiency
  phenotype_contexts:
  - frequency: FREQUENT
    notes: >-
      51% of FA patients had short stature and/or GH deficiency in the NCI
      cohort (n=45). Only GH deficiency correlated significantly with short
      stature (P=0.01). Midline brain abnormalities were found in 17% of
      patients, and 60% of those were GH-deficient.
    evidence:
    - reference: PMID:17426088
      reference_title: "Endocrine abnormalities in patients with Fanconi anemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "short stature and/or GH deficiency (51%), hypothyroidism (37%), midline brain abnormalities (17%) (these patients had very short stature and 60% were GH-deficient)"
      explanation: Giri et al. NCI cohort quantifies GH deficiency at 51% with pituitary abnormality association.
- category: Endocrine
  name: Abnormal Glucose Homeostasis
  description: Abnormal glucose and insulin metabolism including insulin resistance, impaired glucose tolerance, and diabetes mellitus.
  frequency: OCCASIONAL
  notes: Part of the metabolic/endocrine abnormalities seen in up to 80% of FA patients. Two-hour glucose tolerance testing and insulin levels are recommended as part of annual endocrine surveillance.
  evidence:
  - reference: PMID:25575015
    reference_title: "Endocrine disorders in Fanconi anemia: recommendations for screening and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
    explanation: Consensus review identifies abnormal glucose/insulin metabolism as part of the FA endocrine phenotype.
  phenotype_term:
    preferred_term: Abnormal glucose homeostasis
    term:
      id: HP:0011014
      label: Abnormal glucose homeostasis
  phenotype_contexts:
  - frequency: FREQUENT
    notes: >-
      39% of FA patients had abnormal glucose/insulin metabolism in the NCI
      cohort (Giri et al. 2007). 21% met criteria for metabolic syndrome.
    evidence:
    - reference: PMID:17426088
      reference_title: "Endocrine abnormalities in patients with Fanconi anemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "abnormal glucose/insulin metabolism (39%)"
      explanation: Giri et al. NCI cohort quantifies glucose/insulin abnormalities at 39%.
- category: Endocrine
  name: Delayed Puberty and Hypogonadism
  description: Delayed onset of puberty and hypogonadism affecting both sexes, with males commonly showing cryptorchidism and females showing ovarian insufficiency.
  frequency: FREQUENT
  notes: Pubertal delay and hypogonadism are among the most common endocrine abnormalities in FA (present in up to 80% of patients with at least one endocrine abnormality). Pubertal staging and hormone levels should be assessed at puberty and every two years until complete.
  evidence:
  - reference: PMID:25575015
    reference_title: "Endocrine disorders in Fanconi anemia: recommendations for screening and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
    explanation: Consensus review identifies pubertal delay and hypogonadism as prominent endocrine features of FA.
  phenotype_term:
    preferred_term: Delayed puberty
    term:
      id: HP:0000823
      label: Delayed puberty
  phenotype_contexts:
  - frequency: VERY_FREQUENT
    notes: >-
      65% of peripubertal or postpubertal FA patients had gonadal dysfunction
      in the NCI cohort (Giri et al. 2007).
    evidence:
    - reference: PMID:17426088
      reference_title: "Endocrine abnormalities in patients with Fanconi anemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "65% of peripubertal or postpubertal patients had gonadal dysfunction"
      explanation: Giri et al. NCI cohort quantifies gonadal dysfunction at 65% in peripubertal/postpubertal FA patients.
- category: Reproductive
  name: Impaired Fertility
  description: Reduced fertility in both sexes, with males often showing azoospermia or oligospermia due to gonadal failure, and females showing diminished ovarian reserve and premature menopause.
  frequency: FREQUENT
  notes: Male infertility is very common due to primary gonadal failure. Female fertility is reduced but pregnancies have been reported. Fertility preservation counseling should be offered early.
  evidence:
  - reference: PMID:25575015
    reference_title: "Endocrine disorders in Fanconi anemia: recommendations for screening and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
    explanation: Impaired fertility is listed as a key endocrine abnormality in FA patients.
  phenotype_term:
    preferred_term: Infertility
    term:
      id: HP:0000789
      label: Infertility
  phenotype_contexts:
  - sex: MALE
    frequency: VERY_FREQUENT
    notes: Near-universal azoospermia due to primary gonadal failure.
    evidence:
    - reference: PMID:25575015
      reference_title: "Endocrine disorders in Fanconi anemia: recommendations for screening and treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
      explanation: Male infertility in FA is near-universal due to gonadal failure and azoospermia.
  - sex: FEMALE
    frequency: FREQUENT
    notes: Reduced fertility with diminished ovarian reserve and premature menopause, but pregnancies have been reported.
    evidence:
    - reference: PMID:25575015
      reference_title: "Endocrine disorders in Fanconi anemia: recommendations for screening and treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility."
      explanation: Female fertility is reduced but not absent; successful pregnancies have been documented.
- category: Reproductive
  name: Cryptorchidism
  description: Undescended testes, a common genitourinary malformation in male FA patients.
  frequency: OCCASIONAL
  notes: Part of the genitourinary anomaly spectrum. Genital anomalies were significantly more common in patients with downstream FA gene mutations (FANCD1, FANCJ) compared to core complex mutations in the Israeli cohort.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews lists genitourinary anomalies including genital anomalies as part of FA.
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."
    explanation: Israeli cohort found genitourinary anomalies enriched in downstream FA gene mutations (FANCD1, FANCJ).
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000028 | Cryptorchidism | Occasional (29-5%)"
    explanation: Orphanet specifically lists cryptorchidism as an occasional phenotype in Fanconi anemia.
  phenotype_term:
    preferred_term: Cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
  phenotype_contexts:
  - genetic_context:
      genes:
      - preferred_term: FANCD1/BRCA2
        term:
          id: hgnc:1101
          label: BRCA2
      - preferred_term: FANCJ/BRIP1
        term:
          id: hgnc:20473
          label: BRIP1
      description: Downstream FA pathway genes
    frequency: FREQUENT
    notes: >-
      Genitourinary anomalies including cryptorchidism were significantly
      more common in downstream FA gene mutations (P=0.03).
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."
      explanation: Downstream pathway mutations enriched for genitourinary anomalies including cryptorchidism.
- category: Reproductive
  name: Testicular Aplasia or Hypoplasia
  description: Small or absent testes reported among male genital manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline male genital manifestations used for diagnostic screening.
  evidence:
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000035 | Abnormal testis morphology | Occasional (29-5%)"
    explanation: Orphanet lists abnormal testis morphology as an occasional phenotype in Fanconi anemia; aplasia/hypoplasia of the testes is a specific subtype.
  phenotype_term:
    preferred_term: Aplasia/Hypoplasia of the testes
    term:
      id: HP:0010468
      label: Aplasia/Hypoplasia of the testes
- category: Reproductive
  name: Hypospadias
  description: Ventral displacement of the urethral meatus as part of male genital anomalies in FA.
  frequency: OCCASIONAL
  notes: Listed in FA guideline male genital manifestations used for diagnostic screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews lists genitourinary tract anomalies as part of the FA congenital phenotype spectrum.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000047 | Hypospadias | Occasional (29-5%)"
    explanation: Orphanet specifically lists hypospadias as an occasional phenotype in Fanconi anemia.
  phenotype_term:
    preferred_term: Hypospadias
    term:
      id: HP:0000047
      label: Hypospadias
- category: Reproductive
  name: Micropenis
  description: Congenital small phallus reported among male genital manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in FA guideline male genital manifestations used for diagnostic screening. GeneReviews lists genitourinary tract anomalies broadly in FA; micropenis is a specific subtype reported in the FA clinical care guidelines but not individually named in available PubMed abstracts.
  phenotype_term:
    preferred_term: Micropenis
    term:
      id: HP:0000054
      label: Micropenis
- category: Reproductive
  name: Bicornuate Uterus
  description: Congenital uterine malformation reported among female genital manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline female-genital manifestations used for FA screening.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
    explanation: GeneReviews lists genital anomalies among the FA manifestations requiring subspecialty management.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000813 | Bicornuate uterus | Occasional (29-5%)"
    explanation: Orphanet specifically lists bicornuate uterus as an occasional phenotype in Fanconi anemia.
  phenotype_term:
    preferred_term: Bicornuate uterus
    term:
      id: HP:0000813
      label: Bicornuate uterus
- category: Reproductive
  name: Uterine Aplasia or Hypoplasia
  description: Hypoplastic or absent uterus reported among female genital manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline female-genital manifestations used for FA screening.
  evidence:
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000130 | Abnormality of the uterus | Occasional (29-5%)"
    explanation: Orphanet lists abnormality of the uterus as an occasional phenotype in FA; aplasia/hypoplasia of the uterus is a specific subtype.
  phenotype_term:
    preferred_term: Aplasia/hypoplasia of the uterus
    term:
      id: HP:0008684
      label: Aplasia/hypoplasia of the uterus
- category: Reproductive
  name: Gonadal Dysgenesis
  description: Gonadal developmental abnormality reported among female genital manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline female-genital manifestations used for FA screening. GeneReviews lists genital anomalies broadly as an FA manifestation; gonadal dysgenesis as a specific subtype is documented in the FA clinical care guidelines but not individually named in available PubMed abstracts.
  phenotype_term:
    preferred_term: Gonadal dysgenesis
    term:
      id: HP:0000133
      label: Gonadal dysgenesis
- category: Reproductive
  name: Ovarian Hypoplasia
  description: Small or underdeveloped ovaries reported in female Fanconi anemia manifestations.
  frequency: OCCASIONAL
  notes: Included in the FA guideline female-genital manifestations as small ovaries. GeneReviews lists genital anomalies broadly as an FA manifestation; ovarian hypoplasia as a specific subtype is documented in the FA clinical care guidelines but not individually named in available PubMed abstracts.
  phenotype_term:
    preferred_term: Aplasia/Hypoplasia of the ovary
    term:
      id: HP:0010462
      label: Aplasia/Hypoplasia of the ovary
- category: Reproductive
  name: Rectovaginal Fistula
  description: Congenital fistulous communication between rectum and vagina reported in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline female-genital manifestations used for FA screening. GeneReviews lists genital anomalies broadly as an FA manifestation; rectovaginal fistula as a specific subtype is documented in the FA clinical care guidelines but not individually named in available PubMed abstracts.
  phenotype_term:
    preferred_term: Rectovaginal fistula
    term:
      id: HP:0000143
      label: Rectovaginal fistula
- category: Reproductive
  name: Vaginal Atresia
  description: Congenital vaginal canal atresia reported among female genital manifestations in Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline female-genital manifestations used for FA screening. GeneReviews lists genital anomalies broadly as an FA manifestation; vaginal atresia as a specific subtype is documented in the FA clinical care guidelines but not individually named in available PubMed abstracts.
  phenotype_term:
    preferred_term: Vaginal atresia
    term:
      id: HP:0000148
      label: Vaginal atresia
- category: Reproductive
  name: Delayed Menarche
  description: Later-than-expected onset of menarche reported in female Fanconi anemia manifestations.
  frequency: OCCASIONAL
  notes: Included in the FA guideline female-genital and endocrine-reproductive manifestation spectrum. GeneReviews lists genital anomalies broadly as an FA manifestation; delayed menarche as a specific feature is documented in the FA clinical care guidelines but not individually named in available PubMed abstracts.
  phenotype_term:
    preferred_term: Delayed menarche
    term:
      id: HP:0012569
      label: Delayed menarche
- category: Reproductive
  name: Premature Ovarian Insufficiency
  description: Early loss of ovarian function corresponding to early menopause in female Fanconi anemia.
  frequency: OCCASIONAL
  notes: Included in the FA guideline female-genital manifestations as early menopause. GeneReviews lists genital anomalies broadly as an FA manifestation; premature ovarian insufficiency as a specific feature is documented in the FA clinical care guidelines but not individually named in available PubMed abstracts.
  phenotype_term:
    preferred_term: Premature ovarian insufficiency
    term:
      id: HP:0008209
      label: Premature ovarian insufficiency
- category: Renal
  name: Abnormal Renal Morphology
  description: Congenital kidney malformations including ectopic kidneys, horseshoe kidneys, renal agenesis, or hypoplastic kidneys.
  frequency: FREQUENT
  notes: In the Israeli FA cohort, 39.6% of patients had renal anomalies, making it the second most common congenital anomaly after skin pigmentation changes. Renal anomalies contribute to the congenital abnormality burden score.
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More than half had café-au-lait spots (52.3%) followed by renal anomalies (39.6%)."
    explanation: Israeli cohort found renal anomalies in nearly 40% of FA patients.
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews lists genitourinary tract anomalies as part of the FA congenital spectrum.
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
    explanation: GeneReviews lists renal malformations among the FA manifestations requiring subspecialty management.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012210 | Abnormal renal morphology | Frequent (79-30%)"
    explanation: Orphanet's curated HPO annotation classifies abnormal renal morphology as frequent in Fanconi anemia.
  phenotype_term:
    preferred_term: Abnormal renal morphology
    term:
      id: HP:0012210
      label: Abnormal renal morphology
- category: Developmental
  name: Intrauterine Growth Retardation
  description: Low birth weight for gestational age, reflecting prenatal growth restriction.
  frequency: OCCASIONAL
  notes: In the Israeli cohort, 20% of FA patients were born small for gestational age. Growth deficiency often begins prenatally and continues postnatally.
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "20% were born small for the gestational age, and 57% fit criteria for short stature."
    explanation: Israeli cohort documents 20% small for gestational age prevalence in FA.
  phenotype_term:
    preferred_term: Intrauterine growth retardation
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  phenotype_contexts:
  - frequency: OCCASIONAL
    notes: >-
      20% born SGA in the Israeli cohort. ALDH2*2 variant did not affect
      birth weight in Japanese FA patients, suggesting prenatal growth
      restriction is independent of aldehyde-mediated damage.
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "20% were born small for the gestational age, and 57% fit criteria for short stature."
      explanation: 20% SGA prevalence in Israeli FA cohort.
    - reference: PMID:24037726
      reference_title: "Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the ALDH2 variant is associated with accelerated progression of BMF, while birth weight or the number of physical abnormalities was not affected"
      explanation: Birth weight unaffected by ALDH2 status, suggesting different mechanism for prenatal growth restriction.
- category: Neurologic
  name: Developmental Delay
  description: Cognitive and/or motor developmental delays present in a subset of FA patients.
  frequency: OCCASIONAL
  notes: Developmental delay contributes to the congenital abnormality burden score. Patients with splice site mutations had significantly more CNS anomalies and developmental delay (P=0.038) compared with other mutation types. Patients with downstream FA gene mutations (FANCD1, FANCJ) had significantly more CNS abnormalities (P=0.005). FA-S (biallelic BRCA1) patients frequently present with intellectual disability.
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with splice site mutations had significantly more CNS anomalies and developmental delay, compared with the other patients (P=0.03 and P=0.038, respectively)."
    explanation: Israeli cohort found developmental delay associated with splice site mutations in FA.
  - reference: PMID:38146508
    reference_title: "The emergence of Fanconi anaemia type S: a phenotypic spectrum of biallelic BRCA1 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "this FA-S cohort phenotype includes short stature, microcephaly, facial dysmorphisms, hypo/hyperpigmented lesions, intellectual disability, chromosomal sensitivity to crosslinking agents and predisposition to breast/ovarian cancer and/or childhood cancers"
    explanation: FA-S (BRCA1 biallelic) patients commonly present with intellectual disability.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  phenotype_contexts:
  - population: Orphanet curated aggregate
    frequency: FREQUENT
    notes: Orphanet classifies intellectual disability and global developmental delay as frequent in Fanconi anemia.
    evidence:
    - reference: ORPHA:84
      reference_title: "Fanconi anemia (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001249 | Intellectual disability | Frequent (79-30%)"
      explanation: Orphanet's curated HPO annotation classifies intellectual disability as frequent in Fanconi anemia.
    - reference: ORPHA:84
      reference_title: "Fanconi anemia (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001263 | Global developmental delay | Frequent (79-30%)"
      explanation: Orphanet's curated HPO annotation classifies global developmental delay as frequent in Fanconi anemia.
  - genetic_context:
      allele_type: splice_site
    frequency: FREQUENT
    notes: >-
      Patients with splice site mutations had significantly more CNS
      anomalies and developmental delay (P=0.038) compared with other
      mutation types.
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with splice site mutations had significantly more CNS anomalies and developmental delay, compared with the other patients (P=0.03 and P=0.038, respectively)."
      explanation: Splice site mutations specifically associated with developmental delay in FA.
  - genetic_context:
      genes:
      - preferred_term: FANCD1/BRCA2
        term:
          id: hgnc:1101
          label: BRCA2
      - preferred_term: FANCJ/BRIP1
        term:
          id: hgnc:20473
          label: BRIP1
      description: Downstream FA pathway genes
    frequency: FREQUENT
    notes: >-
      Downstream FA gene mutations associated with significantly more
      CNS abnormalities (P=0.005) compared to core complex mutations.
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."
      explanation: Downstream pathway mutations enriched for CNS abnormalities.
  - genetic_context:
      gene:
        preferred_term: BRCA1
        term:
          id: hgnc:1100
          label: BRCA1
      complementation_group: FA-S
      zygosity: HOMOZYGOUS
    frequency: VERY_FREQUENT
    notes: >-
      FA-S (biallelic BRCA1) patients frequently present with intellectual
      disability as part of the characteristic FA-S phenotypic spectrum.
    evidence:
    - reference: PMID:38146508
      reference_title: "The emergence of Fanconi anaemia type S: a phenotypic spectrum of biallelic BRCA1 mutations."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "this FA-S cohort phenotype includes short stature, microcephaly, facial dysmorphisms, hypo/hyperpigmented lesions, intellectual disability"
      explanation: Intellectual disability is a defining feature of the FA-S subtype.
- category: Neurologic
  name: Hydrocephalus
  description: Ventricular enlargement and cerebrospinal fluid accumulation reported among FA CNS anomalies.
  frequency: OCCASIONAL
  notes: Included in the FA guideline central nervous system screening manifestations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including central nervous system anomalies.
  phenotype_term:
    preferred_term: Hydrocephalus
    term:
      id: HP:0000238
      label: Hydrocephalus
- category: Neurologic
  name: Ventriculomegaly
  description: Dilatation of the cerebral ventricles reported in the FA central nervous system anomaly spectrum.
  frequency: OCCASIONAL
  notes: Included in the FA guideline CNS screening manifestations as dilated ventricles.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies"
    explanation: GeneReviews documents that physical abnormalities are present in approximately 75% of FA patients, including central nervous system anomalies.
  phenotype_term:
    preferred_term: Ventriculomegaly
    term:
      id: HP:0002119
      label: Ventriculomegaly
- category: Dermatologic
  name: Hypopigmented Skin Patches
  description: Areas of decreased skin pigmentation, often in combination with hyperpigmented lesions such as café-au-lait spots.
  frequency: VERY_FREQUENT
  notes: The combination of hypo- and hyperpigmented skin lesions is characteristic of FA. In the Israeli cohort, skin pigmentation changes (café-au-lait spots) were the most common congenital anomaly (52.3%).
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "abnormal skin pigmentation"
    explanation: GeneReviews lists abnormal skin pigmentation among the physical abnormalities present in ~75% of FA patients.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001053 | Hypopigmented skin patches | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO annotation classifies hypopigmented skin patches as very frequent in Fanconi anemia.
  phenotype_term:
    preferred_term: Hypopigmented skin patches
    term:
      id: HP:0001053
      label: Hypopigmented skin patches
- category: Dermatologic
  name: Hyperpigmentation
  description: Generalized or patchy increased skin pigmentation in the Fanconi anemia congenital anomaly spectrum.
  frequency: VERY_FREQUENT
  notes: Included in FA guideline skin findings and commonly co-occurs with hypopigmented lesions.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "abnormal skin pigmentation"
    explanation: GeneReviews lists abnormal skin pigmentation among the physical abnormalities present in ~75% of FA patients.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007400 | Irregular hyperpigmentation | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO annotation classifies irregular hyperpigmentation as very frequent in Fanconi anemia.
  phenotype_term:
    preferred_term: Hyperpigmentation of the skin
    term:
      id: HP:0000953
      label: Hyperpigmentation of the skin
- category: Skeletal
  name: Osteopenia and Osteoporosis
  description: Reduced bone mineral density affecting the majority of adult FA patients, likely related to endocrine dysfunction, chronic illness, and potentially direct effects of FA pathway deficiency on osteoblast function.
  frequency: VERY_FREQUENT
  notes: 92% of FA patients aged 18 or older had osteopenia or osteoporosis in the NCI cohort (Giri et al. 2007). May be compounded by GH deficiency, hypogonadism, and post-HSCT conditioning effects.
  evidence:
  - reference: PMID:17426088
    reference_title: "Endocrine abnormalities in patients with Fanconi anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ninety-two percent of the patients 18 yr or older had osteopenia or osteoporosis."
    explanation: Near-universal bone density loss in adult FA patients.
  phenotype_term:
    preferred_term: Osteopenia
    term:
      id: HP:0000938
      label: Osteopenia
- category: Dental
  name: Dental and Craniofacial Anomalies
  description: Dental anomalies including tooth agenesis, root abnormalities, tooth rotation, enamel defects, and craniofacial dysmorphisms.
  frequency: FREQUENT
  notes: In a systematic review with 46 additional Brazilian cases, 93.5% of FA patients exhibited dental/craniofacial anomalies. Root abnormalities (69.6%), tooth rotation (54.3%), and tooth agenesis (26%) were most common. Anomalies in tooth size and shape were more prevalent in patients who underwent HSCT at age 14 or older.
  evidence:
  - reference: PMID:39568270
    reference_title: "Dental and Craniofacial Anomalies in Fanconi Anemia: A Systematic Review and Additional 46 Reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In our cohort, 93.5% of patients exhibited anomalies, primarily root abnormalities (69.6%), tooth rotation (54.3%), and tooth agenesis (26%)."
    explanation: Systematic review demonstrates very high prevalence of dental anomalies in FA patients.
  phenotype_term:
    preferred_term: Abnormality of the dentition
    term:
      id: HP:0000164
      label: Abnormality of the dentition
- category: Hematologic
  name: Myelodysplastic Syndrome
  description: Clonal hematopoietic disorder with dysplastic bone marrow and cytopenias, frequently preceding progression to acute myeloid leukemia.
  frequency: FREQUENT
  notes: In the Israeli cohort, 30% of patients developed MDS, leukemia, and/or solid tumors. Patients with non-FANCA mutations (FANCC, FANCD1, FANCG, FANCJ) developed first cancer (including MDS) significantly earlier than FANCA patients (mean 5.2 vs 18.5 years, P=0.001). There was a trend toward more MDS in FANCC patients.
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "30% developed myelodysplastic syndrome (MDS), leukemia and/or solid tumors"
    explanation: Israeli cohort documents that 30% of FA patients developed MDS, leukemia, and/or solid tumors.
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean age of the first cancer was 18.5 years (SD 6.3 years) for patients with FANCA, relative to 5.2 years (SD 3.7 years) for patients with FANCC, FANCD1, FANCG and FANCJ mutations, with a statistically significant difference (P=0.001)."
    explanation: Demonstrates significantly earlier cancer onset in non-FANCA complementation groups.
  phenotype_term:
    preferred_term: Myelodysplasia
    term:
      id: HP:0002863
      label: Myelodysplasia
  phenotype_contexts:
  - onset:
      mean_age_years: 13.3
    notes: >-
      Mean age of first MDS event was 13.3 years in the Israeli cohort.
      There was a trend toward more MDS in FANCC patients.
    evidence:
    - reference: PMID:31558676
      reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "30% developed myelodysplastic syndrome (MDS), leukemia and/or solid tumors"
      explanation: Israeli cohort documents MDS as part of the 30% cancer rate in FA patients.
- category: Oncologic
  name: Early-Onset Solid Tumors in FANCD1/BRCA2
  description: Patients with biallelic FANCD1/BRCA2 mutations have a uniquely severe cancer predisposition with early-onset solid tumors in childhood, including medulloblastoma, Wilms tumor, and neuroblastoma, distinct from the typical FA tumor spectrum.
  frequency: VERY_FREQUENT
  subtype: FA-D1
  notes: FANCD1/BRCA2 and FANCN/PALB2 patients have the most severe cancer phenotype with near-invariable early-onset malignancy. In the Israeli cohort, one FANCD1 patient developed medulloblastoma at age 3. These patients require cancer screening from a very young age. Neither FANCD1 patient in the Israeli cohort developed BMF, distinguishing this subtype. FA-S (biallelic BRCA1) patients also lack bone marrow failure but have cancer predisposition.
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with FANCD1 mutations have been previously described as uniquely developing solid tumors early in life"
    explanation: Confirms early-onset solid tumor predisposition unique to FANCD1/BRCA2 subtype.
  - reference: PMID:38146508
    reference_title: "The emergence of Fanconi anaemia type S: a phenotypic spectrum of biallelic BRCA1 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unlike most other types of FA, FA-S patients lack bone marrow failure."
    explanation: FA-S (biallelic BRCA1) patients have cancer predisposition but lack BMF, similar to FANCD1.
biochemical:
- name: Chromosomal Breakage Test
  presence: Positive
  context: Diagnostic indicator
- name: Crosslinking Sensitivity
  presence: Increased
  context: Diagnostic indicator (often using diepoxybutane (DEB) or mitomycin C (MMC))
genetic:
- name: FANCA
  association: Pathogenic Variants
  notes: Most common FA gene, accounting for approximately 60-70% of cases.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCA is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: FANCB
  association: Pathogenic Variants
  inheritance:
  - name: X-linked
  notes: Component of FA core complex; X-linked inheritance pattern.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a hemizygous pathogenic variant in FANCB known to cause X-linked FA"
    explanation: GeneReviews confirms FANCB causes X-linked Fanconi anemia.
- name: FANCC
  association: Pathogenic Variants
  notes: Second most common FA gene in certain populations.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCC is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: FANCE
  association: Pathogenic Variants
  notes: Component of FA core complex.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCE is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: FANCF
  association: Pathogenic Variants
  notes: Component of FA core complex.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCF is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: FANCG
  association: Pathogenic Variants
  notes: Associated with more severe phenotype requiring earlier intervention.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCG is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: FANCL
  association: Pathogenic Variants
  notes: E3 ubiquitin ligase component of FA core complex that monoubiquitinates FANCD2-FANCI complex.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCL is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: FANCM
  association: Pathogenic Variants
  notes: >-
    DNA translocase that recognizes stalled replication forks and recruits the FA
    core complex. FANCM has historically been proposed as FA-M in some sources,
    but classification differs across curation resources.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews lists FANCM among FA-associated genes; some ontology resources classify FANCM-related disease separately from canonical FA complementation groups.
- name: UBE2T
  association: Pathogenic Variants
  notes: Also known as FANCT; E2 ubiquitin-conjugating enzyme that works with FANCL to monoubiquitinate FANCD2-FANCI.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms UBE2T (FANCT) is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: FANCD2
  association: Pathogenic Variants
  notes: Forms complex with FANCI; monoubiquitination is central to FA pathway activation and DNA repair.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCD2 is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: FANCI
  association: Pathogenic Variants
  notes: Forms complex with FANCD2; phosphorylation and monoubiquitination regulate ICL repair.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCI is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: SLX4
  association: Pathogenic Variants
  notes: Also known as FANCP; nuclease scaffold protein that coordinates multiple nucleases for DNA unhooking.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms SLX4 (FANCP) is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: BRCA2
  association: Pathogenic Variants
  notes: Also known as FANCD1; essential for homologous recombination repair downstream of ICL unhooking.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms BRCA2 (FANCD1) is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: PALB2
  association: Pathogenic Variants
  notes: Also known as FANCN; partner and localizer of BRCA2, required for HR repair.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms PALB2 (FANCN) is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: BRCA1
  association: Pathogenic Variants
  notes: Also known as FANCS; involved in homologous recombination and DNA damage response.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms BRCA1 (FANCS) is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: BRIP1
  association: Pathogenic Variants
  notes: Also known as FANCJ/BACH1; BRCA1-interacting helicase involved in homologous recombination.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms BRIP1 (FANCJ) is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: ERCC4
  association: Pathogenic Variants
  notes: Also known as FANCQ/XPF; structure-specific nuclease with roles in interstrand crosslink and nucleotide excision repair.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms ERCC4 (FANCQ) is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: RAD51C
  association: Pathogenic Variants
  notes: Also known as FANCO; RAD51 paralog essential for homologous recombination.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms RAD51C (FANCO) is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: RAD51
  association: Pathogenic Variants
  inheritance:
  - name: Autosomal dominant
  notes: Also known as FANCR; dominant-negative heterozygous variants cause the autosomal dominant FA-R subtype.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a heterozygous pathogenic variant in RAD51 known to cause autosomal dominant FA"
    explanation: GeneReviews confirms RAD51 (FANCR) as the autosomal dominant FA subtype gene.
- name: XRCC2
  association: Pathogenic Variants
  notes: Also known as FANCU; involved in homologous recombination repair.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms XRCC2 (FANCU) is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: MAD2L2
  association: Pathogenic Variants
  notes: Also known as REV7 and FANCV; component of DNA polymerase zeta for translesion synthesis.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms MAD2L2/REV7 (FANCV) is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: RFWD3
  association: Pathogenic Variants
  notes: Also known as FANCW; E3 ubiquitin ligase active at stalled replication forks that supports homologous recombination.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms RFWD3 (FANCW) is one of the 21 genes causing autosomal recessive Fanconi anemia.
- name: ALDH2
  association: Risk Modifier
  notes: Aldehyde dehydrogenase 2; detoxifies acetaldehyde. ALDH2*2 variant accelerates bone marrow failure progression in FA patients.
  evidence:
  - reference: PMID:24037726
    reference_title: "Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the ALDH2 variant is associated with accelerated progression of BMF"
    explanation: Study of 64 Japanese FA patients showed ALDH2 deficiency accelerates bone marrow failure progression.
- name: ADH5
  association: Risk Modifier
  notes: Alcohol dehydrogenase 5; detoxifies formaldehyde, providing tier-1 protection against aldehyde-induced DNA damage.
  evidence:
  - reference: PMID:22081012
    reference_title: "Formaldehyde catabolism is essential in cells deficient for the Fanconi anemia DNA-repair pathway."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "a synthetic lethal interaction in avian cells between ADH5, encoding the main formaldehyde-detoxifying enzyme, and the Fanconi anemia (FA) DNA-repair pathway"
    explanation: Demonstrates that ADH5 formaldehyde catabolism is essential in FA-deficient cells.
- name: KMT2D
  association: Disease Modifier
  notes: Histone methyltransferase; loss in squamous cell carcinomas can epigenetically suppress FA/BRCA gene expression under metabolic stress.
diagnosis:
- name: Chromosomal Breakage Test
  notes: Measures sensitivity to DNA crosslinking agents
- name: Chromosomal Breakage Test (DEB)
  description: >-
    Auerbach's gold-standard primary diagnostic for Fanconi anemia. Peripheral
    blood lymphocytes (or cultured fibroblasts for confirmation in suspected
    hematopoietic mosaicism) are incubated with a T-cell mitogen and the DNA
    interstrand crosslinker diepoxybutane (DEB; CHEBI:23704); metaphases are
    then scored for chromosomal breaks, gaps, and radial figures. FA cells
    show pathognomonically elevated breakage compared with controls. DEB is
    the preferred clastogen because it has lower rates of false-positive and
    false-negative results than other crosslinking agents.
  diagnosis_term:
    preferred_term: chromosomal breakage analysis (DEB)
    term:
      id: MAXO:0000746
      label: chromosomal breakage analysis
  presence: Positive
  results: >-
    Increased breaks per cell, breaks per aberrant cell, and proportion of
    cells with any aberration relative to unaffected controls and relatives;
    radial figures are highly characteristic.
  evidence:
  - reference: PMID:18428345
    reference_title: "Diagnosis of fanconi anemia by diepoxybutane analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diepoxybutane (DEB) analysis is the preferred test for FA because
      other agents have higher rates of false-positive and false-negative results."
    explanation: Auerbach's published Curr Protoc Hum Genet protocol establishes
      DEB as the preferred clastogen for the FA diagnostic chromosomal breakage
      assay over other agents.
  - reference: PMID:19622403
    reference_title: "Fanconi anemia and its diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "laboratory study of chromosomal breakage induced by diepoxybutane
      (DEB) or other crosslinking agents provides a unique cellular marker for
      the diagnosis of the disorder either prenatally or postnatally."
    explanation: Auerbach review confirms the DEB-induced chromosomal breakage
      assay as the defining cellular marker for FA diagnosis, applicable both
      prenatally and postnatally.
  - reference: PMID:19622403
    reference_title: "Fanconi anemia and its diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients in the IFAR have had the diagnosis confirmed by chromosomal
      breakage studies, mostly using the DNA crosslinking agent diepoxybutane (DEB)"
    explanation: Documents that the International Fanconi Anemia Registry (IFAR)
      relies primarily on DEB-induced chromosomal breakage for confirmed FA
      diagnosis, establishing DEB as the dominant clinical clastogen.
  - reference: PMID:25227706
    reference_title: "Comparison of chromosome breakage in non-mosaic and mosaic
      patients with Fanconi anemia, relatives, and patients with other inherited
      bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnostic feature of FA is increased chromosomal breakage in
      blood lymphocytes cultured with diepoxybutane or mitomycin C."
    explanation: Fargo/Giri/Alter NCI cohort study confirms DEB-treated lymphocyte
      chromosomal breakage as the diagnostic readout for FA.
  notes: >-
    May be performed on peripheral blood lymphocytes for postnatal diagnosis or
    on cultured fibroblasts, chorionic villus, or amniocyte preparations for
    prenatal diagnosis. Hematopoietic mosaicism can yield discordant blood
    versus fibroblast results — confirmation on skin fibroblasts is recommended
    when the blood-lymphocyte breakage result is borderline.
- name: Chromosomal Breakage Test (MMC)
  description: >-
    Alternative form of the FA chromosomal breakage assay using mitomycin C
    (MMC; CHEBI:27504) as the clastogen instead of diepoxybutane. Cells are
    exposed to MMC and metaphases scored for breaks and radial figures. MMC
    is the preferred clastogen in some laboratories (notably in Europe) and
    is functionally equivalent to DEB for FA diagnosis; the choice of agent
    is laboratory-dependent. The assay also enables a quantitative estimate
    of the degree of mosaicism in the lymphocyte compartment.
  diagnosis_term:
    preferred_term: chromosomal breakage analysis (MMC)
    term:
      id: MAXO:0000746
      label: chromosomal breakage analysis
  presence: Positive
  results: >-
    Increased breaks per cell, breaks per aberrant cell, and proportion of
    cells with any aberration; radial figures are highly characteristic.
    Quantitative readout estimates the proportion of MMC-resistant
    (revertant/mosaic) lymphocytes.
  evidence:
  - reference: PMID:25227706
    reference_title: "Comparison of chromosome breakage in non-mosaic and mosaic
      patients with Fanconi anemia, relatives, and patients with other inherited
      bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lymphocytes were treated with diepoxybutane or mitomycin C, and
      metaphases scored for breaks and radials."
    explanation: Fargo/Giri/Alter NCI IBMFS cohort applies both DEB and MMC
      chromosomal breakage assays as parallel diagnostics for FA, supporting
      MMC as a valid alternative clastogen.
  - reference: PMID:25227706
    reference_title: "Comparison of chromosome breakage in non-mosaic and mosaic
      patients with Fanconi anemia, relatives, and patients with other inherited
      bone marrow failure syndromes."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "The choices of clastogen are laboratory-dependent, but there was
      no method or analysis of lymphocytes that clearly distinguished all
      individuals mosaic for FA from relatives or patients with other IBMFS."
    explanation: PARTIAL because while MMC (and DEB) reliably identify non-mosaic
      FA, neither clastogen unambiguously resolves all mosaic FA patients from
      relatives or other inherited bone marrow failure syndromes — a known
      limitation that motivates fibroblast confirmation and genotyping.
  - reference: PMID:22693659
    reference_title: "Diagnosis of fanconi anemia: chromosomal breakage analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cells derived from FA patients are-by definition-hypersensitive to
      DNA cross-linking agents, such as mitomycin C, diepoxybutane, or
      cisplatinum, which becomes manifest as excessive growth inhibition, cell
      cycle arrest, and chromosomal breakage upon cellular exposure to these drugs."
    explanation: Oostra et al. canonical MMC protocol paper confirms that FA
      cellular hypersensitivity to MMC manifests as chromosomal breakage,
      providing the mechanistic basis for the MMC-based assay.
  - reference: PMID:22693659
    reference_title: "Diagnosis of fanconi anemia: chromosomal breakage analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here we provide a detailed laboratory protocol for the accurate
      assessment of the FA diagnosis as based on mitomycin C-induced chromosomal
      breakage analysis in whole-blood cultures."
    explanation: Establishes a published, detailed laboratory protocol for
      MMC-induced chromosomal breakage analysis as a primary FA diagnostic in
      whole-blood culture, including quantitative mosaicism estimation.
  notes: >-
    Used in laboratories where MMC is the standard clastogen. The NCI/IBMFS
    cohort showed individual overlap between mosaic FA patients and relatives
    or non-FA IBMFS patients with both DEB and MMC, so genotyping remains the
    gold standard for resolving ambiguous cases. The Oostra protocol enables
    quantitative mosaicism estimation in the lymphocyte compartment.
- name: Genetic Testing
  notes: Identifies pathogenic variants in FA genes
- name: Bone Marrow Examination
  notes: Assesses degree of bone marrow failure
environmental:
- name: Protections from DNA-damaging Agents
  description: Avoid exposure to agents that can cause DNA damage, such as radiation and certain chemicals.
  notes: Broad recommendation spanning both ionizing radiation and chemical genotoxins; no single specific ECTO term is used here to avoid a mismatched mapping.
treatments:
- name: Hematopoietic Stem Cell Transplantation (HSCT)
  description: The only curative treatment for the hematologic manifestations of FA, using reduced-intensity conditioning regimens due to patient sensitivity to chemotherapy and radiation.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of FA
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
- name: Androgen Therapy
  description: Can stimulate erythropoiesis and improve blood counts, often used as a bridge to transplantation.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Administration of oral androgens (e.g., oxymetholone) improves blood counts (red cell and platelets) in approximately 50% of individuals with FA
  treatment_term:
    preferred_term: hormone modifying therapy
    term:
      id: MAXO:0000283
      label: hormone modifying therapy
- name: Growth Hormone Therapy
  description: May be used to improve growth in affected children with short stature.
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."
    explanation: GeneReviews recommends treatment of growth deficiency as part of comprehensive FA management.
  treatment_term:
    preferred_term: hormone modifying therapy
    term:
      id: MAXO:0000283
      label: hormone modifying therapy
- name: Supportive Care
  description: Treatment of cytopenias with transfusions, antibiotics, and monitoring for malignancy.
  notes: Includes blood transfusions, growth factor support, and infection prophylaxis
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "granulocyte colony-stimulating factor improves the neutrophil count in some individuals"
    explanation: GeneReviews confirms use of growth factors as part of supportive care for cytopenias.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Cancer Surveillance
  description: Regular screenings for early detection of cancers, particularly acute myeloid leukemia and squamous cell carcinomas of the head and neck, oral cavity, and anogenital regions.
  notes: Required due to markedly increased risk of developing malignancies, especially squamous cell carcinomas at young ages
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "oral examinations for tumors every six months beginning at age nine to ten years; annual nasolaryngoscopy beginning at age ten years"
    explanation: GeneReviews recommends regular oral and nasolaryngoscopic surveillance for early cancer detection.
  treatment_term:
    preferred_term: cancer screening
    term:
      id: MAXO:0000126
      label: cancer screening
- name: Genetic Counseling
  description: Counseling for patients and families regarding inheritance patterns, recurrence risks, carrier testing, and prenatal diagnosis options.
  notes: Essential for family planning and understanding autosomal recessive and X-linked inheritance patterns
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Carrier testing for at-risk relatives (for autosomal recessive and X-linked FA) and prenatal and preimplantation genetic testing are possible if the pathogenic variant(s) in the family are known."
    explanation: GeneReviews confirms the importance of genetic counseling for carrier testing and prenatal diagnosis.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
- name: Lentiviral Gene Therapy (FA-A)
  description: >-
    Ex vivo lentiviral-mediated gene correction of autologous CD34+ hematopoietic
    stem cells
    with a FANCA-expressing vector, followed by reinfusion without conditioning. Single-cell
    RNA sequencing of gene therapy-treated patients demonstrates that corrected HSPCs
    revert
    the FA transcriptional signature, including downregulation of TGF-beta and p21
    and
    upregulation of DNA damage response and telomere maintenance pathways.
  evidence:
  - reference: PMID:37021532
    reference_title: "Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gene therapy reverts the transcriptional signature of FA HSPC, which then resemble the transcriptional program of healthy donor HSPC"
    explanation: Single-cell RNA-seq of gene therapy-treated FA patients demonstrates molecular rescue of the FA HSPC transcriptional program.
  - reference: PMID:37021532
    reference_title: "Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a down-regulated expression of TGF-β and p21, typically up-regulated in FA HSPC, and upregulation of DNA damage response and telomere maintenance pathways"
    explanation: Gene therapy corrects specific molecular defects in FA HSPCs as confirmed by scRNA-seq.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
- name: Adenine Base Editing (ABE8e)
  description: >-
    Precision base editing approach using optimized adenine base editors (ABE8e) to
    correct
    prevalent FANCA point mutations in patient hematopoietic stem and progenitor cells
    without relying on double-strand breaks or homology-directed repair, which are
    impaired
    in FA cells. Restores FANCA expression and FA pathway function.
  evidence:
  - reference: PMID:36371486
    reference_title: "Adenine base editing efficiently restores the function of Fanconi anemia hematopoietic stem and progenitor cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "optimizing adenine base editor construct, vector type, guide RNA format, and delivery conditions leads to very effective genetic modification in multiple FA patient backgrounds"
    explanation: ABE8e base editing achieves effective correction across multiple FANCA mutation backgrounds.
  - reference: PMID:36371486
    reference_title: "Adenine base editing efficiently restores the function of Fanconi anemia hematopoietic stem and progenitor cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Optimized base editing restored FANCA expression, molecular function of the FA pathway, and phenotypic resistance to crosslinking agents"
    explanation: Base editing restores functional FA pathway activity in patient-derived HSPCs.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
clinical_trials:
- name: NCT04069533
  phase: PHASE_II
  status: ACTIVE_NOT_RECRUITING
  description: Phase II clinical trial evaluating lentiviral-mediated gene therapy for pediatric patients with Fanconi Anemia subtype A (FA-A). Autologous CD34+ hematopoietic stem cells are transduced ex vivo with a lentiviral vector carrying the FANCA gene, then reinfused with the goal of preventing bone marrow failure.
  target_phenotypes:
  - preferred_term: Pancytopenia
    term:
      id: HP:0001876
      label: Pancytopenia
  - preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: clinicaltrials:NCT04069533
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is an open-label Phase II clinical trial to evaluate the efficacy of a hematopoietic cell-based gene therapy for pediatric patients with Fanconi Anemia, subtype A (FA-A). Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the FANCA gene."
    explanation: This Phase II gene therapy trial directly addresses the genetic defect in FA-A by correcting FANCA mutations in autologous stem cells, providing evidence for curative cell-based genetic therapy approaches.
- name: NCT00243399
  phase: PHASE_I
  status: COMPLETED
  description: Pilot trial evaluating oxandrolone (an androgen steroid) for treatment of bone marrow aplasia in Fanconi Anemia patients. The study assessed safety and efficacy of androgen therapy to stimulate production of red blood cells and platelets in FA patients with bone marrow failure.
  target_phenotypes:
  - preferred_term: Pancytopenia
    term:
      id: HP:0001876
      label: Pancytopenia
  - preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: clinicaltrials:NCT00243399
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to evaluate the safety of the drug oxandrolone (a type of androgen steroid) in patients with Fanconi anemia (FA), and to determine if this drug can help in the treatment of bone marrow failure in these patients. Androgen steroids are male hormones that can stimulate the production of red blood cells (the cells which carry oxygen in the blood) and platelets (cells that help blood clot)."
    explanation: This Phase I trial evaluates androgen therapy as a bridge treatment for bone marrow failure in FA, providing clinical evidence for hormonal stimulation of hematopoiesis.
- name: NCT00630253
  phase: PHASE_II
  status: COMPLETED
  description: Phase I/II study evaluating cyclophosphamide, fludarabine, and antithymocyte globulin conditioning followed by matched sibling donor hematopoietic cell transplantation (HSCT) in patients with Fanconi Anemia. Investigates reduced-intensity conditioning regimens tailored to FA patients' increased chemotherapy sensitivity.
  target_phenotypes:
  - preferred_term: Pancytopenia
    term:
      id: HP:0001876
      label: Pancytopenia
  - preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: clinicaltrials:NCT00630253
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Giving chemotherapy, such as cyclophosphamide and fludarabine, before a donor stem cell transplant helps to remove the patient's cells to allow for the transplant cells to take and grow. It also helps stop the patient's immune system from rejecting the donor's stem cells."
    explanation: This Phase I/II trial optimizes HSCT conditioning regimens for FA patients, providing clinical evidence for the curative approach to bone marrow failure in Fanconi Anemia.
datasets:
- accession: geo:GSE157591
  title: MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia
  description: >-
    Single-cell RNA sequencing of bone marrow CD34+ hematopoietic stem and progenitor
    cells
    from Fanconi anemia patients and healthy donors. Reveals aberrant MYC overexpression
    in FA HSPCs driving proliferation-apoptosis imbalance, with transcriptomic signatures
    distinct from normal hematopoiesis.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  platform: 10x Genomics Chromium
  publication: PMID:32997960
  findings:
  - statement: MYC is overexpressed in FA HSPCs compared to healthy donor HSPCs
  - statement: FA HSPCs show proliferation-apoptosis imbalance driven by MYC dysregulation
  evidence:
  - reference: PMID:32997960
    reference_title: "MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MYC overexpression impairs HSPC function in FA patients and contributes to exhaustion in FA bone marrow"
    explanation: scRNA-seq dataset demonstrates MYC as a key driver of HSPC dysfunction in FA patients.
- accession: geo:GSE180536
  title: Restored Hematopoietic Stem Cell Transcriptional Program in Fanconi Anemia Patients Following Gene Therapy
  description: >-
    Single-cell RNA sequencing of chimeric corrected and uncorrected HSPC populations
    co-existing in bone marrow of lentiviral gene therapy-treated Fanconi anemia patients.
    Demonstrates that gene-corrected cells revert the FA transcriptional signature
    to
    resemble healthy donor HSPCs.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  platform: 10x Genomics Chromium
  publication: PMID:37021532
  findings:
  - statement: Gene therapy reverts the FA HSPC transcriptional signature to healthy donor levels
  - statement: Corrected cells show downregulation of TGF-beta and p21, upregulation of DDR and telomere maintenance
  evidence:
  - reference: PMID:37021532
    reference_title: "Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gene therapy reverts the transcriptional signature of FA HSPC, which then resemble the transcriptional program of healthy donor HSPC"
    explanation: scRNA-seq of gene therapy patients confirms molecular rescue of FA-specific transcriptomic defects.
computational_models:
- name: Boolean Network Model of FA/BRCA Pathway
  description: >-
    A Boolean network model incorporating the FA/BRCA DNA repair pathway, checkpoint
    proteins,
    and alternative DNA repair pathways. Simulates ICL repair, checkpoint activation,
    and
    predicts which alternative repair pathways become active when the FA/BRCA pathway
    is
    defective. The largest network model incorporating a DNA repair pathway at time
    of publication.
  model_type: BOOLEAN_NETWORK
  publication: PMID:22267503
  findings:
  - statement: The model simulates ICL repair mediated by the FA/BRCA pathway
  - statement: Alternative DNA repair pathways are predicted to become active when FA/BRCA is defective
  - statement: Checkpoint protein activation patterns emerge from recurrent DNA damage
  evidence:
  - reference: PMID:22267503
    reference_title: "A Boolean network model of the FA/BRCA pathway."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Our model is able to simulate the ICL repair process mediated by the FA/BRCA pathway, the activation of Checkpoint proteins observed by recurrent DNA damage, as well as the repair of DNA double-strand breaks and DNA adducts"
    explanation: Boolean network model successfully recapitulates FA/BRCA pathway behavior and predicts compensatory repair mechanisms.
- name: Multi-level Dynamical Modelling of SCC in FA
  description: >-
    A conceptual framework for multi-level dynamical modelling of squamous cell carcinoma
    development in Fanconi anemia, integrating longitudinal genome, proteome, and
    transcriptome
    data from a database of over 750 FA individuals. Proposes mechanistic models trained
    on
    multi-omic data from healthy and diseased tissue to detect early SCC signatures
    and
    predict tumorigenesis.
  publication: PMID:38028610
  findings:
  - statement: Defines hallmarks of cancer specific to FA for model training
  - statement: Proposes using multi-omic data for early SCC signature detection
  - statement: Framework designed to predict experimentally testable tumorigenesis mechanisms
  evidence:
  - reference: PMID:38028610
    reference_title: "Concepts of multi-level dynamical modelling: understanding mechanisms of squamous cell carcinoma development in Fanconi anemia."
    supports: PARTIAL
    evidence_source: COMPUTATIONAL
    snippet: "we introduce here the concept of multi-level dynamical modelling using large, longitudinally collected genome, proteome- and transcriptome-wide data sets from a small number of FA individuals"
    explanation: Proposes a multi-level modeling approach for understanding SCC development in FA using multi-omic data.
- name: Machine Learning Drug Repurposing (drexml)
  description: >-
    Machine learning framework using multi-output regression and mechanistic signal
    transduction
    models to identify drug targets capable of regulating FA-related cell functionalities.
    The drexml tool predicts potential therapeutic targets by mapping external proteins
    to
    signaling circuits that trigger FA-related phenotypes, identifying over 20 potential
    drug targets and successfully predicting previously validated repurposed drugs.
  model_type: MACHINE_LEARNING
  repository_url: https://github.com/loucerac/drexml
  publication: PMID:31266445
  findings:
  - statement: Over 20 potential therapeutic drug targets identified around the FA pathway
  - statement: Framework validated by successfully predicting previously known repurposed drugs in FA
  evidence:
  - reference: PMID:31266445
    reference_title: "Exploring the druggable space around the Fanconi anemia pathway using machine learning and mechanistic models."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "The application of multi-output regression machine learning methodologies to predict the potential effect of external proteins over the signaling circuits that trigger Fanconi anemia related cell functionalities, inferred with a mechanistic model, allowed us to detect over 20 potential therapeutic targets"
    explanation: ML approach identifies novel drug targets for FA using mechanistic pathway modeling.
  - reference: PMID:38510973
    reference_title: "drexml: A command line tool and Python package for drug repurposing."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "In the Fanconi Anemia case, the model successfully predicts previously validated repurposed drugs"
    explanation: The drexml tool package validates the ML drug repurposing approach in FA.
- name: Deep Learning FA Core Complex Structure
  description: >-
    Integration of deep-learned residue distance predictions with Rosetta folding
    and automated
    cryo-EM map-guided assembly to determine the near-complete atomic structure of
    the Fanconi
    Anemia core complex (FAcc) E3 ubiquitin ligase from a 4.6 angstrom resolution
    cryo-EM map.
    Placed 5182 of 6557 residues, greatly expanding the structural model and enabling
    interpretation of disease-related mutations.
  model_type: MACHINE_LEARNING
  publication: PMID:32939280
  findings:
  - statement: Near-complete atomic model of FA core complex determined (5182 of 6557 residues placed)
  - statement: Deep learning overcame limitations of homology modeling for 4795 previously unmodeled residues
  - statement: Structure facilitates interpretation of disease-related mutational data
  evidence:
  - reference: PMID:32939280
    reference_title: "Deep learning enables the atomic structure determination of the Fanconi Anemia core complex from cryoEM."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "we are able to determine an almost-complete atomic model of FAcc, in which 5182 of the 6557 residues were placed"
    explanation: Deep learning-guided structure determination provides structural context for understanding FA-causing mutations.
- name: DNA Methylation Episignature Classifier
  description: >-
    Machine learning classifier trained on genome-wide DNA methylation profiles from
    peripheral
    blood of FA patients. Identifies 82 differentially methylated CpG sites that distinguish
    FA from healthy individuals and other genetic disorders. The episignature is robust
    across
    complementation groups and tissue types, and can detect FA even in individuals
    with
    reverted phenotype due to gene conversion.
  model_type: MACHINE_LEARNING
  publication: PMID:37865086
  findings:
  - statement: 82 CpG sites define an FA-specific DNA methylation signature
  - statement: Episignature validated across multiple complementation groups
  - statement: Can diagnose FA even in mosaic/reverted patients with normalized chromosome breakage
  evidence:
  - reference: PMID:37865086
    reference_title: "Identification of a robust DNA methylation signature for Fanconi anemia."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "We identified 82 differentially methylated CpG sites that allow to distinguish subjects with FA from healthy individuals and subjects with other genetic disorders, defining an FA-specific DNAm signature"
    explanation: ML-based episignature provides a complementary diagnostic tool for FA.
  - reference: PMID:37865086
    reference_title: "Identification of a robust DNA methylation signature for Fanconi anemia."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "the generated episignature includes CpG sites that do not undergo functional selective pressure, allowing diagnosis of FA in individuals with reverted phenotype due to gene conversion"
    explanation: The episignature overcomes a key diagnostic challenge in FA patients with somatic mosaicism.
- name: REPAIR-FANC High Content Screening Platform
  description: >-
    Cell-based high content screening platform using TALEN-mediated FANCA-deficient
    U2OS cells
    stably expressing YFP-FANCD2 to monitor FA/BRCA pathway activity via fluorescent
    FANCD2
    foci formation. Screened 3802 compounds including 1200 FDA-approved drugs for
    potential
    FA pathway rescue.
  publication: PMID:32605631
  findings:
  - statement: None of the 3802 compounds tested were able to rescue FANCA-dependent FANCD2 foci formation
  - statement: Platform demonstrates feasibility for high-throughput screening in FA therapeutics
  - statement: Some compounds showed mild reduction in chromosomal instability markers
  evidence:
  - reference: PMID:32605631
    reference_title: "High content drug screening for Fanconi anemia therapeutics."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "we developed a novel high-content cell-based screening assay to identify drugs with therapeutic potential in FA"
    explanation: Establishes an optimized platform for screening drug candidates in FA, though no pathway-rescuing compounds were identified.
has_subtypes:
# Pathway tier classification
- name: Core Complex Subtypes
  classification: pathway_tier
  description: >-
    FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCT/UBE2T)
    encode
    the E3 ubiquitin ligase complex that monoubiquitinates the FANCD2-FANCI heterodimer.
    Patients with
    core complex mutations generally have a later age of cancer onset compared to
    downstream pathway
    defects.
  children:
  - FA-A
  - FA-B
  - FA-C
  - FA-E
  - FA-F
  - FA-G
  - FA-L
  - FA-T
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with FANCA mutations developed cancer at a significantly older age compared to patients with mutations in other Fanconi genes (mean 18.5 and 5.2 years, respectively, P=0.001)"
    explanation: Israeli cohort demonstrates later cancer onset in core complex (FANCA) vs downstream gene mutations.
- name: ID Complex Subtypes
  classification: pathway_tier
  description: >-
    The FANCD2-FANCI heterodimer is monoubiquitinated by the core complex and recruited
    to DNA damage
    sites. Mutations in these genes cause intermediate-severity FA phenotypes.
  children:
  - FA-D2
  - FA-I
- name: Downstream Effector Subtypes
  classification: pathway_tier
  description: >-
    Downstream effector genes (BRCA2/FANCD1, BRIP1/FANCJ, PALB2/FANCN, RAD51C/FANCO,
    RAD51/FANCR,
    BRCA1/FANCS, SLX4/FANCP, ERCC4/FANCQ, XRCC2/FANCU, MAD2L2/FANCV, RFWD3/FANCW)
    mediate
    homologous recombination repair downstream of FANCD2-FANCI. Patients with FANCD1/BRCA2
    and
    FANCN/PALB2 mutations have notably earlier cancer onset and increased risk of
    childhood solid tumors
    including medulloblastoma and Wilms tumor.
  children:
  - FA-D1
  - FA-J
  - FA-N
  - FA-O
  - FA-P
  - FA-Q
  - FA-R
  - FA-S
  - FA-U
  - FA-V
  - FA-W
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."
    explanation: Israeli cohort demonstrates more severe congenital anomaly profile in downstream pathway gene mutations.
# Complementation group classification
- name: FA-A
  classification: complementation_group
  description: >-
    Most common complementation group, accounting for 60-70% of all FA cases. FANCA
    is a component of
    the FA core complex. Patients tend to develop cancer at a later age compared to
    other FA subtypes.
  subtype_term:
    preferred_term: Fanconi anemia complementation group A
    term:
      id: MONDO:0009215
      label: Fanconi anemia complementation group A
  genes:
  - preferred_term: FANCA
    term:
      id: hgnc:3582
      label: FANCA
  subtype_frequency: "60-70%"
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "two-thirds of genetically diagnosed patients had biallelic FANCA mutations. These numbers are similar to the International Fanconi Anemia Registry, in which 60% of the diagnosed patients had FANCA mutations"
    explanation: Israeli cohort confirms FANCA accounts for approximately 60-70% of FA cases.
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCA causes autosomal recessive FA.
- name: FA-B
  classification: complementation_group
  description: >-
    X-linked FA subtype caused by hemizygous FANCB mutations. FANCB is part of the
    FA core complex.
    Affected males may have more severe congenital anomalies including VACTERL association.
  subtype_term:
    preferred_term: Fanconi anemia complementation group B
    term:
      id: MONDO:0010351
      label: Fanconi anemia complementation group B
  genes:
  - preferred_term: FANCB
    term:
      id: hgnc:3583
      label: FANCB
  subtype_frequency: "<1%"
  inheritance:
  - name: X-linked recessive
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a hemizygous pathogenic variant in FANCB known to cause X-linked FA"
    explanation: GeneReviews confirms FANCB causes X-linked Fanconi anemia.
- name: FA-C
  classification: complementation_group
  description: >-
    Second or third most common FA complementation group depending on population.
    FANCC is a component
    of the FA core complex. Common Ashkenazi Jewish founder mutation (IVS4+4A>T).
  subtype_term:
    preferred_term: Fanconi anemia complementation group C
    term:
      id: MONDO:0009213
      label: Fanconi anemia complementation group C
  genes:
  - preferred_term: FANCC
    term:
      id: hgnc:3584
      label: FANCC
  subtype_frequency: "~10-15%"
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)"
    explanation: Israeli cohort shows FANCC accounts for 13% of genetically diagnosed FA cases.
- name: FA-D1
  classification: complementation_group
  description: >-
    Caused by biallelic BRCA2 mutations. Associated with very early-onset malignancies
    including
    medulloblastoma, Wilms tumor, and AML, typically before age 5. Distinct from heterozygous
    BRCA2 carriers who develop breast/ovarian cancer.
  subtype_term:
    preferred_term: Fanconi anemia complementation group D1
    term:
      id: MONDO:0011584
      label: Fanconi anemia complementation group D1
  genes:
  - preferred_term: BRCA2
    term:
      id: hgnc:1101
      label: BRCA2
  subtype_frequency: "~2%"
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "one patient with a FANCD1 mutation developed medulloblastoma at the age of 3 years. Patients with FANCD1 mutations have been previously described as uniquely developing solid tumors early in life"
    explanation: Confirms early-onset solid tumors in FANCD1/BRCA2 patients.
- name: FA-D2
  classification: complementation_group
  description: >-
    FANCD2 is one of two components of the ID complex that is monoubiquitinated by
    the core complex.
    FANCD2 mutations cause a moderate FA phenotype.
  subtype_term:
    preferred_term: Fanconi anemia complementation group D2
    term:
      id: MONDO:0009214
      label: Fanconi anemia complementation group D2
  genes:
  - preferred_term: FANCD2
    term:
      id: hgnc:3585
      label: FANCD2
  subtype_frequency: "~3%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCD2 causes autosomal recessive FA.
- name: FA-E
  classification: complementation_group
  description: >-
    FANCE is a component of the FA core complex that directly interacts with FANCD2.
  subtype_term:
    preferred_term: Fanconi anemia complementation group E
    term:
      id: MONDO:0010953
      label: Fanconi anemia complementation group E
  genes:
  - preferred_term: FANCE
    term:
      id: hgnc:3586
      label: FANCE
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCE causes autosomal recessive FA.
- name: FA-F
  classification: complementation_group
  description: >-
    FANCF is a core complex adaptor protein required for complex assembly and stability.
  subtype_term:
    preferred_term: Fanconi anemia complementation group F
    term:
      id: MONDO:0011325
      label: Fanconi anemia complementation group F
  genes:
  - preferred_term: FANCF
    term:
      id: hgnc:3587
      label: FANCF
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCF causes autosomal recessive FA.
- name: FA-G
  classification: complementation_group
  description: >-
    Third most common complementation group in some populations, accounting for up
    to 14% of cases.
    FANCG/XRCC9 is a component of the FA core complex.
  subtype_term:
    preferred_term: Fanconi anemia complementation group G
    term:
      id: MONDO:0013565
      label: Fanconi anemia complementation group G
  genes:
  - preferred_term: FANCG
    term:
      id: hgnc:3588
      label: FANCG
  subtype_frequency: "~10%"
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)"
    explanation: Israeli cohort shows FANCG accounts for 14% of genetically diagnosed FA cases.
- name: FA-I
  classification: complementation_group
  description: >-
    FANCI forms the ID heterodimer with FANCD2. The complex is monoubiquitinated by
    the core complex
    and recruited to sites of DNA interstrand crosslinks.
  subtype_term:
    preferred_term: Fanconi anemia complementation group I
    term:
      id: MONDO:0012186
      label: Fanconi anemia complementation group I
  genes:
  - preferred_term: FANCI
    term:
      id: hgnc:25568
      label: FANCI
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCI causes autosomal recessive FA.
- name: FA-J
  classification: complementation_group
  description: >-
    Caused by biallelic mutations in BRIP1 (BACH1), a BRCA1-interacting helicase involved
    in
    homologous recombination repair. Heterozygous BRIP1 mutations confer increased
    breast cancer risk.
  subtype_term:
    preferred_term: Fanconi anemia complementation group J
    term:
      id: MONDO:0012187
      label: Fanconi anemia complementation group J
  genes:
  - preferred_term: BRIP1
    term:
      id: hgnc:20473
      label: BRIP1
  subtype_frequency: "~3%"
  evidence:
  - reference: PMID:31558676
    reference_title: "Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)"
    explanation: Israeli cohort shows FANCJ accounts for 3% of genetically diagnosed FA cases.
- name: FA-L
  classification: complementation_group
  description: >-
    FANCL is the E3 ubiquitin ligase of the FA core complex responsible for monoubiquitinating
    FANCD2 and FANCI.
  subtype_term:
    preferred_term: Fanconi anemia complementation group L
    term:
      id: MONDO:0013566
      label: Fanconi anemia complementation group L
  genes:
  - preferred_term: FANCL
    term:
      id: hgnc:20748
      label: FANCL
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms FANCL causes autosomal recessive FA.
- name: FA-N
  classification: complementation_group
  description: >-
    Caused by biallelic PALB2 mutations. Like FA-D1 (BRCA2), associated with very
    early-onset
    childhood malignancies. Heterozygous PALB2 mutations are a moderate-penetrance
    breast cancer
    susceptibility allele.
  subtype_term:
    preferred_term: Fanconi anemia complementation group N
    term:
      id: MONDO:0012565
      label: Fanconi anemia complementation group N
  genes:
  - preferred_term: PALB2
    term:
      id: hgnc:26144
      label: PALB2
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms PALB2/FANCN causes autosomal recessive FA.
- name: FA-O
  classification: complementation_group
  description: >-
    Caused by biallelic RAD51C mutations. RAD51C functions in homologous recombination
    downstream
    of FANCD2. Heterozygous RAD51C mutations confer ovarian cancer susceptibility.
  subtype_term:
    preferred_term: Fanconi anemia complementation group O
    term:
      id: MONDO:0013248
      label: Fanconi anemia complementation group O
  genes:
  - preferred_term: RAD51C
    term:
      id: hgnc:9820
      label: RAD51C
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms RAD51C/FANCO causes autosomal recessive FA.
- name: FA-P
  classification: complementation_group
  description: >-
    Caused by biallelic SLX4 mutations. SLX4 is a scaffold protein that coordinates
    multiple
    structure-specific endonucleases for interstrand crosslink repair.
  subtype_term:
    preferred_term: Fanconi anemia complementation group P
    term:
      id: MONDO:0013499
      label: Fanconi anemia complementation group P
  genes:
  - preferred_term: SLX4
    term:
      id: hgnc:23845
      label: SLX4
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms SLX4/FANCP causes autosomal recessive FA.
- name: FA-Q
  classification: complementation_group
  description: >-
    Caused by biallelic ERCC4/XPF mutations. ERCC4 is a structure-specific endonuclease
    also
    implicated in nucleotide excision repair, creating a phenotypic overlap with xeroderma
    pigmentosum and Cockayne syndrome.
  subtype_term:
    preferred_term: Fanconi anemia complementation group Q
    term:
      id: MONDO:0014108
      label: Fanconi anemia complementation group Q
  genes:
  - preferred_term: ERCC4
    term:
      id: hgnc:3436
      label: ERCC4
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms ERCC4/FANCQ causes autosomal recessive FA.
- name: FA-R
  classification: complementation_group
  description: >-
    Caused by heterozygous dominant-negative RAD51 mutations. The only autosomal dominant
    form of FA.
    All reported cases arise de novo.
  subtype_term:
    preferred_term: Fanconi anemia complementation group R
    term:
      id: MONDO:0014986
      label: Fanconi anemia complementation group R
  genes:
  - preferred_term: RAD51
    term:
      id: hgnc:9817
      label: RAD51
  subtype_frequency: "<1%"
  inheritance:
  - name: Autosomal dominant
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a heterozygous pathogenic variant in RAD51 known to cause autosomal dominant FA"
    explanation: GeneReviews confirms RAD51/FANCR causes autosomal dominant FA via de novo mutations.
- name: FA-S
  classification: complementation_group
  description: >-
    Caused by biallelic BRCA1 mutations. Extremely rare, with phenotypic overlap with
    both FA and
    hereditary breast/ovarian cancer syndrome. Heterozygous BRCA1 carriers have high
    breast and
    ovarian cancer risk.
  subtype_term:
    preferred_term: Fanconi anemia, complementation group S
    term:
      id: MONDO:0054748
      label: Fanconi anemia, complementation group S
  genes:
  - preferred_term: BRCA1
    term:
      id: hgnc:1100
      label: BRCA1
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms BRCA1/FANCS causes autosomal recessive FA.
- name: FA-T
  classification: complementation_group
  description: >-
    Caused by biallelic UBE2T mutations. UBE2T is the E2 ubiquitin-conjugating enzyme
    that works
    with the FANCL E3 ligase to monoubiquitinate the ID complex.
  subtype_term:
    preferred_term: Fanconi anemia complementation group T
    term:
      id: MONDO:0014638
      label: Fanconi anemia complementation group T
  genes:
  - preferred_term: UBE2T
    term:
      id: hgnc:25009
      label: UBE2T
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms UBE2T/FANCT causes autosomal recessive FA.
- name: FA-U
  classification: complementation_group
  description: >-
    Caused by biallelic XRCC2 mutations. XRCC2 is a RAD51 paralog involved in homologous
    recombination repair.
  subtype_term:
    preferred_term: Fanconi anemia complementation group U
    term:
      id: MONDO:0014987
      label: Fanconi anemia complementation group U
  genes:
  - preferred_term: XRCC2
    term:
      id: hgnc:12829
      label: XRCC2
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms XRCC2/FANCU causes autosomal recessive FA.
- name: FA-V
  classification: complementation_group
  description: >-
    Caused by biallelic MAD2L2/REV7 mutations. MAD2L2 functions in translesion synthesis
    and
    also plays roles in mitotic checkpoint signaling.
  subtype_term:
    preferred_term: Fanconi anemia complementation group V
    term:
      id: MONDO:0014985
      label: Fanconi anemia complementation group V
  genes:
  - preferred_term: MAD2L2
    term:
      id: hgnc:6764
      label: MAD2L2
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms MAD2L2/FANCV causes autosomal recessive FA.
- name: FA-W
  classification: complementation_group
  description: >-
    Caused by biallelic RFWD3 mutations. RFWD3 is an E3 ubiquitin ligase that ubiquitinates
    RPA at stalled replication forks to promote homologous recombination.
  subtype_term:
    preferred_term: Fanconi anemia, complementation group W
    term:
      id: MONDO:0044325
      label: Fanconi anemia, complementation group W
  genes:
  - preferred_term: RFWD3
    term:
      id: hgnc:25539
      label: RFWD3
  subtype_frequency: "<1%"
  evidence:
  - reference: PMID:20301575
    reference_title: "Fanconi Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"
    explanation: GeneReviews confirms RFWD3/FANCW causes autosomal recessive FA.
notes: Fanconi Anemia is a complex condition that requires multidisciplinary management and regular monitoring to address both hematologic and systemic complications.
disease_term:
  preferred_term: Fanconi anemia
  term:
    id: MONDO:0019391
    label: Fanconi anemia
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0019391
      label: Fanconi anemia
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet ORPHA:84
    mapping_justification: >-
      Orphanet ORPHA:84 lists MONDO:0019391 as an exact cross-reference for
      Fanconi anemia.
external_assertions:
- name: Orphanet Fanconi anemia structured record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:84
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=84
  description: >-
    Orphanet ORPHA:84 is the structured-database record for Fanconi anemia and
    lists exact cross-references including MONDO:0019391 and OMIM:227650.
  evidence:
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0019391 | Exact"
    explanation: Orphanet lists MONDO:0019391 as an exact cross-reference for Fanconi anemia.
  - reference: ORPHA:84
    reference_title: "Fanconi anemia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:227650 | Exact"
    explanation: Orphanet lists OMIM:227650 as an exact cross-reference for Fanconi anemia.
classifications:
  harrisons_chapter:
  - classification_value: hematologic disorder
  - classification_value: hereditary disease
references:
- reference: PMID:20301575
  title: "Fanconi Anemia."
  tags:
  - GeneReviews
  findings: []
- reference: DOI:10.1038/s41467-024-46159-1
  title: Deregulated protein homeostasis constrains fetal hematopoietic stem cell pool expansion in Fanconi anemia
  findings: []
- reference: DOI:10.1038/s41467-024-50861-5
  title: Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma
  findings: []
- reference: DOI:10.1093/pnasnexus/pgae242
  title: Dual role of proliferating cell nuclear antigen monoubiquitination in facilitating Fanconi anemia-mediated interstrand crosslink repair
  findings: []
- reference: DOI:10.1146/annurev-pathmechdis-111523-023420
  title: 'Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications'
  findings: []
- reference: DOI:10.1182/blood-2013-06-507962
  title: Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients
  findings: []
- reference: DOI:10.1182/blood-2014-04-526293
  title: Stress and DNA repair biology of the Fanconi anemia pathway
  findings: []
- reference: DOI:10.1186/s13023-025-03896-w
  title: 'Comprehensive review on Fanconi anemia: insights into DNA interstrand cross-links, repair pathways, and associated tumors'
  findings: []
- reference: DOI:10.3390/cells13090733
  title: Crosstalk between DNA Damage Repair and Metabolic Regulation in Hematopoietic Stem Cells
  findings: []
- reference: DOI:10.3390/ijms252111619
  title: 'New Insights into the Fanconi Anemia Pathogenesis: A Crosstalk Between Inflammation and Oxidative Stress'
  findings: []
📚

References & Deep Research

References

10
PMID:20301575
Fanconi Anemia.
No top-level findings curated for this source.
DOI:10.1038/s41467-024-46159-1
Deregulated protein homeostasis constrains fetal hematopoietic stem cell pool expansion in Fanconi anemia
No top-level findings curated for this source.
DOI:10.1038/s41467-024-50861-5
Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma
No top-level findings curated for this source.
DOI:10.1093/pnasnexus/pgae242
Dual role of proliferating cell nuclear antigen monoubiquitination in facilitating Fanconi anemia-mediated interstrand crosslink repair
No top-level findings curated for this source.
DOI:10.1146/annurev-pathmechdis-111523-023420
Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications
No top-level findings curated for this source.
DOI:10.1182/blood-2013-06-507962
Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients
No top-level findings curated for this source.
DOI:10.1182/blood-2014-04-526293
Stress and DNA repair biology of the Fanconi anemia pathway
No top-level findings curated for this source.
DOI:10.1186/s13023-025-03896-w
Comprehensive review on Fanconi anemia: insights into DNA interstrand cross-links, repair pathways, and associated tumors
No top-level findings curated for this source.
DOI:10.3390/cells13090733
Crosstalk between DNA Damage Repair and Metabolic Regulation in Hematopoietic Stem Cells
No top-level findings curated for this source.
DOI:10.3390/ijms252111619
New Insights into the Fanconi Anemia Pathogenesis: A Crosstalk Between Inflammation and Oxidative Stress
No top-level findings curated for this source.

Deep Research

3
Cyberian ▸
Introduction
deep-research 35 citations 2026-02-08T10:19:52.670309

Introduction

Fanconi anemia (FA; MONDO:0019391) is a rare inherited genome‑instability disorder. A recent review summarizes its core definition: “Fanconi anemia (FA) is a rare genetic disorder caused by defects in the repair of DNA interstrand crosslinks (ICLs)”—lesions that block replication and transcription and drive genome instability.[fang-2025-fanconi-review][mondo-fanconi-anemia] Clinically, FA manifests with bone‑marrow failure, congenital anomalies, and cancer predisposition, especially myeloid leukemia and squamous cell carcinomas, which links the molecular repair defect to multi‑system pathology.[fang-2025-fanconi-review]

Core Pathophysiology

ICLs are among the most toxic DNA lesions because they covalently tether both strands and stall replication forks. The FA pathway coordinates their recognition and repair, and its central effector is the FANCI–FANCD2 (ID) complex. The structural primary literature emphasizes that “Central to this pathway is the FANCI‑FANCD2 (ID) complex, which is activated by DNA damage‑induced phosphorylation and monoubiquitination,” and that the ID complex recognizes DNA structures associated with replication forks encountering ICLs.[joo-2011-id2-structure] Reviews of the FA/BRCA pathway further place ICL repair at the intersection of nucleolytic processing, translesion synthesis, and homologous recombination.[kim-2012-genesdev-icls] The FA pathway is activated when replication forks encounter ICLs, leading to ID2 activation and recruitment to chromatin at damage foci; disruption of this activation step underlies the canonical FA cellular phenotype of ICL hypersensitivity and chromosomal breakage.[joo-2011-id2-structure][alpi-2015-ube2t-deficiency]

Molecular Players and Pathway Architecture

FA genes encode proteins that operate in DNA damage repair pathways, “particularly in the repair of interstrand crosslinks (ICLs).”[fang-2025-fanconi-review] Current syntheses place at least 22 FA proteins in the pathway, organized into core complex, ID2, and downstream effector modules.[fang-2025-fanconi-review] At the core, FANCA (HGNC:3582), FANCL (HGNC:20748), and the E2 enzyme UBE2T (HGNC:25009; FANC‑T) cooperate to monoubiquitinate FANCD2 (HGNC:3585) and FANCI (HGNC:25568), an essential activation step for ICL repair.[ncbi-fanca-hgnc3582][ncbi-fancl-hgnc20748][encode-ube2t-hgnc25009][ncbi-fancd2-hgnc3585][ncbi-fanci-hgnc25568][machida-2007-ube2t-chromatin] Mechanistically, the FA core complex and UBE2T “are required for the S phase and DNA damage‑restricted monoubiquitination of FANCD2,” and UBE2T‑deficient patient cells lose FANCD2/FANCI monoubiquitination and become hypersensitive to crosslinking agents, demonstrating causality in FA‑T.[machida-2007-ube2t-chromatin][alpi-2015-ube2t-deficiency]

Downstream of ID2, monoubiquitinated FANCD2 acts as a recruitment hub for nucleases and repair factors. The FAN1 nuclease (HGNC:26672) “interacts with, and is recruited to sites of DNA damage by, the monoubiquitinated form of FANCD2,” and its loss causes ICL sensitivity and genome instability.[mackay-2013-fan1-nuclease][ncbi-fan1-hgnc26672] SLX4/FANCP (HGNC:23845) is a scaffold for structure‑specific nucleases; its UBZ domain “was required for interaction of SLX4 with ubiquitylated FANCD2” and for recruitment to ICL‑induced damage foci, linking ID2 ubiquitination to endonuclease deployment.[yamamoto-2011-slx4-icls][ncbi-slx4-hgnc23845] Structural work further shows that “recruitment of the [FANCD2–FANCI] complex to a stalled replication fork serves as the trigger for the activating monoubiquitination event,” establishing the order of activation and recruitment at ICL‑stalled forks.[rajan-2016-id2-recruitment] These modules ultimately coordinate incision/unhooking, translesion synthesis, and homologous recombination to restore replication, processes that align with the pathway’s role in DNA interstrand crosslink repair.[mackay-2013-fan1-nuclease][yamamoto-2011-slx4-icls]

Cellular Processes and Components

The FA pathway maps to defined GO biological processes, including DNA interstrand crosslink repair (GO:0036297), DNA repair (GO:0006281), DNA damage response (GO:0006974), homologous recombination (GO:0000724), and translesion synthesis (GO:0019985).[go-icls-repair][go-dna-repair][go-dna-damage-response][go-homologous-recombination][go-translesion-synthesis] The cellular context is largely nuclear, with repair machinery operating on chromatin (GO:0000785) at replication forks (GO:0005657) inside the nucleus (GO:0005634).[go-chromatin][go-replication-fork][go-nucleus] FA proteins assemble at DNA‑damage foci on chromatin after monoubiquitination, emphasizing chromatin‑localized repair factories rather than cytoplasmic signaling.[machida-2007-ube2t-chromatin][joo-2011-id2-structure]

Disease Progression

A plausible sequence begins with endogenous or exogenous ICLs (including aldehyde‑derived lesions), which stall replication forks and recruit the ID2 complex. In FA, pathogenic variants disrupt core complex assembly or E2/E3 activity, impairing FANCD2/FANCI monoubiquitination and preventing orderly recruitment of FAN1, SLX4, and other nucleases needed for unhooking and repair.[machida-2007-ube2t-chromatin][alpi-2015-ube2t-deficiency][mackay-2013-fan1-nuclease][yamamoto-2011-slx4-icls] In model systems, SLX4 loss produces cell death with extensive chromosomal aberrations, illustrating how incomplete repair converts replication‑associated lesions into chromosome breaks.[yamamoto-2011-slx4-icls] Persistent DNA damage activates p53‑dependent surveillance; in hematopoietic stem cells, “deletion of p53 completely rescues the survival of aldehyde‑stressed and mutated haematopoietic stem cells,” demonstrating that damage‑response pathways drive stem‑cell attrition.[garaycoechea-2018-aldehydes-hsc] The combined result is progressive bone‑marrow failure from stem‑cell depletion plus clonal evolution of surviving cells with genomic instability, yielding leukemia and solid‑tumor risk.[fang-2025-fanconi-review][garaycoechea-2018-aldehydes-hsc]

Clinical Phenotypes, Cell Types, and Anatomy

The most vulnerable cell population is the hematopoietic stem cell (CL:0000037) within the hematopoietic system (UBERON:0002390), which sustains lifelong blood production in bone marrow (UBERON:0002371) and blood (UBERON:0000178).[cl-hematopoietic-stem-cell][uberon-hematopoietic-system][uberon-bone-marrow][uberon-blood] Clinically, FA is characterized by bone‑marrow hypocellularity (HP:0005528) and aplastic anemia (HP:0001915), reflecting stem‑cell loss and defective regeneration.[hp-bone-marrow-hypocellularity][hp-aplastic-anemia] Developmental phenotypes such as short stature (HP:0004322) are common, consistent with genome‑maintenance defects during embryogenesis.[hp-short-stature] The cancer‑predisposition phenotype includes acute myeloid leukemia (HP:0004808), consistent with ICL‑repair failure, mutational accumulation, and selection.[hp-aml][fang-2025-fanconi-review]

Chemical and Environmental Modifiers

Endogenous aldehydes such as acetaldehyde (CHEBI:15343) and formaldehyde (CHEBI:16842) are physiologic genotoxins that generate DNA damage; acetaldehyde‑driven DNA damage in stem cells is documented in vivo, and FA pathway defects heighten susceptibility to such insults.[chebi-acetaldehyde][chebi-formaldehyde][garaycoechea-2018-aldehydes-hsc] Clinically and experimentally, FA cells display hypersensitivity to ICL‑inducing agents such as mitomycin C (CHEBI:27504) and cisplatin (CHEBI:27899), which is diagnostically leveraged in chromosome‑breakage testing and mechanistically reflects failure of the FA ICL repair cascade.[chebi-mitomycin-c][chebi-cisplatin][alpi-2015-ube2t-deficiency][yamamoto-2011-slx4-icls]

Open Questions

Important unresolved questions include how tissue‑specific aldehyde loads and detoxification capacity set the threshold for FA pathway failure in different organs, and how the balance between p53‑mediated attrition and clonal escape determines cancer risk trajectories. Another gap is the precise ordering and kinetics of nuclease recruitment and translesion synthesis at ICL‑stalled forks in human cells, which could identify therapeutic windows to protect hematopoietic stem cells without increasing mutational burden.

References

fang-2025-fanconi-review — Fang C, et al. “Comprehensive review on Fanconi anemia: insights into DNA interstrand cross-links, repair pathways, and associated tumors.” Orphanet J Rare Dis. 2025 Jul 30;20:389. DOI: 10.1186/s13023-025-03896-w. PMCID: PMC12312369. PMID: 40739565. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12312369/ kim-2012-genesdev-icls — Kim H, D’Andrea AD. “Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway.” Genes Dev. 2012 Jul 1;26(13):1393–1408. DOI: 10.1101/gad.195248.112. PMCID: PMC3403008. PMID: 22751496. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3403008/ joo-2011-id2-structure — Joo W, et al. “Structure of the FANCI-FANCD2 Complex: Insights into the Fanconi Anemia DNA Repair Pathway.” Science. 2011;333(6040):312–316. DOI: 10.1126/science.1205805. PMCID: PMC3310437. PMID: 21764741. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3310437/ rajan-2016-id2-recruitment — Rajan A, et al. “The FANCD2–FANCI complex is recruited to DNA interstrand crosslinks before monoubiquitination of FANCD2.” Nat Commun. 2016 Jul 13;7:12124. DOI: 10.1038/ncomms12124. PMCID: PMC4947157. PMID: 27405460. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4947157/ machida-2007-ube2t-chromatin — Machida YJ, et al. “UBE2T, the Fanconi Anemia Core Complex, and FANCD2 Are Recruited Independently to Chromatin: a Basis for the Regulation of FANCD2 Monoubiquitination.” Mol Cell Biol. 2007 Oct 15;27(24):8421–8430. DOI: 10.1128/MCB.00504-07. PMCID: PMC2169426. PMID: 17938197. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC2169426/ alpi-2015-ube2t-deficiency — Alpi AF, et al. “Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA‑T subtype of Fanconi anemia.” Cell Rep. 2015;12(1):35–45. DOI: 10.1016/j.celrep.2015.06.014. PMCID: PMC4497947. PMID: 26119737. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4497947/ mackay-2013-fan1-nuclease — MacKay C, et al. “Identification of KIAA1018/FAN1, a DNA Repair Nuclease Recruited to DNA Damage by Monoubiquitinated FANCD2.” Cell. 2010 Jul 9;142(1):65–76. DOI: 10.1016/j.cell.2010.06.021. PMCID: PMC3710700. PMID: 20603015. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3710700/ yamamoto-2011-slx4-icls — Yamamoto KN, et al. “Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway.” Proc Natl Acad Sci U S A. 2011 Apr 4;108(16):6492–6496. DOI: 10.1073/pnas.1018487108. PMCID: PMC3080998. PMID: 21464321. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3080998/ garaycoechea-2018-aldehydes-hsc — Garaycoechea JI, et al. “Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells.” Nature. 2018;553(7687):171–177. DOI: 10.1038/nature25154. PMCID: PMC6047743. PMID: 29323295. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6047743/ mondo-fanconi-anemia — MONDO:0019391 “Fanconi anemia.” BioPortal. URL: https://bioportal.bioontology.org/ontologies/MONDO/?p=classes&conceptid=MONDO:0019391 ncbi-fanca-hgnc3582 — FANCA (HGNC:3582) in NCBI Gene. URL: https://www.ncbi.nlm.nih.gov/gene/2176 ncbi-fancd2-hgnc3585 — FANCD2 (HGNC:3585) in NCBI Gene. URL: https://www.ncbi.nlm.nih.gov/gene/2177 ncbi-fanci-hgnc25568 — FANCI (HGNC:25568) in NCBI Gene. URL: https://www.ncbi.nlm.nih.gov/gene/55215 ncbi-fancl-hgnc20748 — FANCL (HGNC:20748) in NCBI Gene. URL: https://www.ncbi.nlm.nih.gov/gene/55120 encode-ube2t-hgnc25009 — UBE2T (HGNC:25009) in ENCODE gene summary. URL: https://www.encodeproject.org/search/?searchTerm=UBE2T ncbi-fan1-hgnc26672 — FAN1 (HGNC:26672) in NCBI Gene. URL: https://www.ncbi.nlm.nih.gov/gene/22909 ncbi-slx4-hgnc23845 — SLX4 (HGNC:23845) in NCBI Gene. URL: https://www.ncbi.nlm.nih.gov/gene/80206 go-icls-repair — GO:0036297 “DNA interstrand cross-link repair.” AmiGO 2. URL: http://amigo.geneontology.org/amigo/term/GO:0036297 go-dna-repair — GO:0006281 “DNA repair.” AmiGO 2. URL: http://amigo.geneontology.org/amigo/term/GO:0006281 go-dna-damage-response — GO:0006974 “cellular response to DNA damage stimulus.” AmiGO 2. URL: http://amigo.geneontology.org/amigo/term/GO:0006974 go-homologous-recombination — GO:0000724 “double-strand break repair via homologous recombination.” AmiGO 2. URL: http://amigo.geneontology.org/amigo/term/GO:0000724 go-translesion-synthesis — GO:0019985 “translesion synthesis.” AmiGO 2. URL: http://amigo.geneontology.org/amigo/term/GO:0019985 go-replication-fork — GO:0005657 “replication fork.” AmiGO 2. URL: http://amigo.geneontology.org/amigo/term/GO:0005657 go-nucleus — GO:0005634 “nucleus.” SGD GO term page. URL: https://www.yeastgenome.org/go/GO:0005634 go-chromatin — GO:0000785 “chromatin.” AmiGO 2. URL: http://amigo.geneontology.org/amigo/term/GO:0000785 cl-hematopoietic-stem-cell — CL:0000037 “hematopoietic stem cell.” ZFIN. URL: https://zfin.org/action/ontology/term/CL:0000037 uberon-bone-marrow — UBERON:0002371 “bone marrow.” BioPortal. URL: https://bioportal.bioontology.org/ontologies/UBERON/?p=classes&conceptid=UBERON:0002371 uberon-blood — UBERON:0000178 “blood.” BioPortal. URL: https://bioportal.bioontology.org/ontologies/UBERON/?p=classes&conceptid=UBERON:0000178 uberon-hematopoietic-system — UBERON:0002390 “hematopoietic system.” ZFIN. URL: https://zfin.org/action/ontology/term/UBERON:0002390 hp-bone-marrow-hypocellularity — HP:0005528 “Bone marrow hypocellularity.” Orphanet. URL: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=HP:0005528 hp-aplastic-anemia — HP:0001915 “Aplastic anemia.” MSigDB. URL: https://www.gsea-msigdb.org/gsea/msigdb/geneset_page.jsp?geneSetName=HP_APLASTIC_ANEMIA hp-aml — HP:0004808 “Acute myeloid leukemia.” MSigDB. URL: https://www.gsea-msigdb.org/gsea/msigdb/geneset_page.jsp?geneSetName=HP_ACUTE_MYELOID_LEUKEMIA hp-short-stature — HP:0004322 “Short stature.” Mendelian Genomics Research Program HPO features table. URL: https://mendelian.genome.wustl.edu/cmg/feature_table chebi-formaldehyde — CHEBI:16842 “formaldehyde.” ChEBI. URL: https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16842 chebi-cisplatin — CHEBI:27899 “cisplatin.” ChEBI. URL: https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:27899 chebi-mitomycin-c — CHEBI:27504 “mitomycin C.” ChEBI. URL: https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:27504 chebi-acetaldehyde — CHEBI:15343 “acetaldehyde.” SGD chemical page. URL: https://www.yeastgenome.org/chemical/CHEBI:15343

Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 28 citations 2026-02-14T10:37:06.559130

Disease Pathophysiology Research Report

Target Disease

  • Disease Name: Fanconi Anemia (FA)
  • MONDO ID: MONDO:0019391
  • Category: Genetic (DNA repair disorder)

Pathophysiology Description (Narrative)

Fanconi anemia is a genomic instability syndrome caused by biallelic pathogenic variants in genes encoding the FA/BRCA DNA interstrand crosslink (ICL) repair pathway. The central biochemical lesion is the DNA ICL, which stalls replication and transcription, provoking replication fork collapse, chromosomal breakage, and activation of checkpoint signaling. The FA core complex (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, plus FAAPs) recognizes ICL-stalled forks and catalyzes the monoubiquitination of the FANCD2–FANCI (I-D2) complex via the E3 ligase FANCL and the E2 UBE2T (FANCT). Monoubiquitinated I-D2 localizes to damaged chromatin and orchestrates nuclease-mediated “unhooking” (e.g., SLX4/FANCP scaffolding XPF–ERCC1 and SLX1), translesion synthesis (TLS, Polζ with FANCV/REV7), and homologous recombination (HR) to complete repair; the cycle is reset by USP1-mediated deubiquitination. FA proteins also protect stressed forks, interface with ATR/CHK1 signaling, and contribute to mitotic integrity (ultrafine bridges), explaining the broad chromosomal instability and cancer predisposition in FA (URL: https://doi.org/10.1182/blood-2014-04-526293; Oct 2014) (longerich2014stressanddna pages 4-5, longerich2014stressanddna pages 7-8). Recent work further shows that PCNA monoubiquitination at K164 is critical to canalize ICL repair toward canonical FA/TLS: in its absence, MSH2–MSH6 mismatch repair is mis-recruited to ICLs, and combined PcnaK164R and FA deficiency is embryonic lethal, highlighting a dual role of PCNA-Ub in polymerase switching and pathway choice (URL: https://doi.org/10.1093/pnasnexus/pgae242; Jun 2024) (shah2024dualroleof pages 1-2).

Endogenous aldehydes are major physiological sources of crosslinking and DNA–protein crosslink damage in hematopoietic stem cells (HSCs). A two-tier protection model has emerged: tier-1 detoxification by ADH5 (formaldehyde) and ALDH2 (acetaldehyde), and tier-2 removal of aldehyde-induced lesions by the FA repair pathway. In humans with FA, the dominant-negative ALDH2*2 variant accelerates progression of bone marrow failure, underscoring aldehyde burden as a disease modifier and therapeutic target (URL: https://doi.org/10.1182/blood-2013-06-507962; Oct 2013) (hira2013variantaldh2is pages 1-2). Reviews and mechanistic syntheses concur that aldehyde genotoxicity, replication stress with ATR activation, and chronic inflammatory/oxidative milieus converge to drive HSC attrition, myelodysplasia/AML, and squamous carcinogenesis (URLs: https://doi.org/10.3390/ijms252111619; Oct 2024; https://doi.org/10.1146/annurev-pathmechdis-111523-023420; Jan 2025; https://doi.org/10.1186/s13023-025-03896-w; Jul 2025) (repczynska2024newinsightsinto pages 9-13, repczynska2024newinsightsinto pages 13-17, liu2025inheritedpredispositionsto pages 13-15, fang2025comprehensivereviewon pages 1-3).

Two 2024 advances refine FA pathophysiology and therapeutic angles: (1) fetal HSC failure originates in the fetal liver from inflammation-driven ER stress and proteostasis disruption in LT-HSCs; restoring protein folding with the chemical chaperone TUDCA and dampening type I interferon signaling rescue fetal Fancd2−/− LT-HSC pool size, identifying proteostasis/inflammation as actionable nodes (URL: https://doi.org/10.1038/s41467-024-46159-1; Feb 2024) (kovuru2024deregulatedproteinhomeostasis pages 10-11). (2) In head and neck squamous cell carcinoma (HNSCC), KMT2D loss increases glycolysis and, under glycolytic inhibition, epigenetically suppresses FA/BRCA gene expression by converting FA gene promoters/enhancers to inactive states; combining 2-deoxyglucose with DNA crosslinkers or PARP inhibitors preferentially suppresses KMT2D-deficient tumors, linking metabolic state, chromatin, and FA pathway competence (URL: https://doi.org/10.1038/s41467-024-50861-5; Aug 2024) (liu2024histonemethyltransferasekmt2ddeficiency pages 1-2).

1. Core Pathophysiology

  • Primary mechanisms: Defective ICL repair at stalled replication forks with failure of FANCD2–FANCI monoubiquitination dynamics, aberrant nuclease unhooking, faulty TLS, and impaired HR. Consequences include replication fork collapse, chromosomal breakage, anaphase bridge formation, and checkpoint activation defects (URLs: 2014 Blood review; 2025 Annual Review) (longerich2014stressanddna pages 4-5, longerich2014stressanddna pages 7-8, liu2025inheritedpredispositionsto pages 13-15).
  • Dysregulated molecular pathways: FA/BRCA ICL repair axis; ATR/ATM–CHK1 signaling coupling to FANCI phosphorylation and FANCD2 activity; PCNA-Ub-dependent damage tolerance steering TLS vs. MMR at ICLs (URL: 2024 PNAS Nexus) (longerich2014stressanddna pages 7-8, shah2024dualroleof pages 1-2).
  • Affected cellular processes: HSC quiescence maintenance fails under chronic replication stress and inflammatory ROS; mitotic integrity is compromised (ultrafine bridges/cytokinesis failure), leading to clonal evolution (URLs: 2014 Blood; 2025 Annual Review) (longerich2014stressanddna pages 7-8, liu2025inheritedpredispositionsto pages 13-15).

2. Key Molecular Players

  • Genes/Proteins (HGNC):
  • FA core and I-D2: FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, UBE2T (FANCT), FANCD2, FANCI; E3 ligase–E2 module FANCL–UBE2T (URLs: 2014 Blood; 2024 IJMS review) (longerich2014stressanddna pages 4-5, repczynska2024newinsightsinto pages 9-13).
  • Nucleases/scaffold: SLX4/FANCP, XPF–ERCC1, SLX1; FAN1 recruits to Ub-FANCD2 (URL: 2014 Blood) (longerich2014stressanddna pages 4-5).
  • TLS: REV1, POLζ (REV3L/REV7 [FANCV]); PCNA-Ub; RAD6–RAD18 (URL: 2024 PNAS Nexus) (shah2024dualroleof pages 1-2).
  • HR: BRCA2/FANCD1, PALB2/FANCN, BRCA1/FANCS, RAD51/RAD51C (FANCO), XRCC2 (FANCU), RFWD3 (URLs: 2024 IJMS review; 2025 Annual Review) (repczynska2024newinsightsinto pages 9-13, liu2025inheritedpredispositionsto pages 13-15).
  • Signaling: ATR–ATRIP, CHK1; FANCI phosphorylation “switch” (URL: 2014 Blood) (longerich2014stressanddna pages 7-8).
  • Aldehyde detoxification: ALDH2, ADH5 (URL: 2013 Blood) (hira2013variantaldh2is pages 1-2).
  • Epigenetic-metabolic regulator in SCC: KMT2D (H3K4 methyltransferase) modulating FA gene chromatin under glycolytic stress (URL: 2024 Nat Commun) (liu2024histonemethyltransferasekmt2ddeficiency pages 1-2).
  • Chemical Entities (CHEBI): acetaldehyde (CHEBI:15343), formaldehyde (CHEBI:16842); mitomycin C (CHEBI:50684), diepoxybutane (CHEBI:42680); 2-deoxy-D-glucose (CHEBI:17698); tauroursodeoxycholic acid (TUDCA; bile acid derivative, CHEBI:132954) (hira2013variantaldh2is pages 1-2, liu2024histonemethyltransferasekmt2ddeficiency pages 1-2, kovuru2024deregulatedproteinhomeostasis pages 10-11).
  • Cell Types (CL): long-term hematopoietic stem cells (LT-HSCs; CL:0000037), hematopoietic progenitors (CL:0000038), mesenchymal stromal cells (CL:0000134); inflammatory macrophages/Kupffer cells (CL:0000706) are implicated as niche sources of sterile inflammation in fetal liver (kovuru2024deregulatedproteinhomeostasis pages 10-11).
  • Anatomical Locations (UBERON): bone marrow (UBERON:0002371); fetal liver (UBERON:0002107); oral cavity mucosa (UBERON:0001729) and esophagus (UBERON:0001043) as SCC sites (fang2025comprehensivereviewon pages 1-3).

3. Biological Processes (GO terms; disrupted in FA)

  • DNA interstrand cross-link repair (GO:0036297): core FA/BRCA function (longerich2014stressanddna pages 4-5, liu2025inheritedpredispositionsto pages 13-15).
  • DNA damage tolerance via translesion synthesis (GO:0043085) and PCNA monoubiquitination (GO:0008630 for DNA damage response ubiquitination): pathway choice at ICLs (shah2024dualroleof pages 1-2).
  • DNA double-strand break repair via homologous recombination (GO:0000724): post-unhooking repair (longerich2014stressanddna pages 4-5, liu2025inheritedpredispositionsto pages 13-15).
  • ATR signaling pathway (GO:0038061) and checkpoint signaling (GO:0000077): coupling to FANCI/FANCD2 (longerich2014stressanddna pages 7-8).
  • Response to aldehyde (GO:0043437) and detoxification (GO:0098754): ADH5/ALDH2 tier-1 protection (hira2013variantaldh2is pages 1-2, repczynska2024newinsightsinto pages 13-17).
  • Cellular response to oxidative stress (GO:0034599) and ER stress/protein folding (GO:0034976; GO:0006457): fetal HSC proteostasis defect (kovuru2024deregulatedproteinhomeostasis pages 10-11, repczynska2024newinsightsinto pages 9-13).
  • Regulation of chromosomal stability/mitotic cytokinesis (e.g., chromosome segregation GO:0007059): ultrafine bridges in FA (longerich2014stressanddna pages 4-5).

4. Cellular Components (GO CC)

  • Nuclear chromatin and replication forks: site of I-D2 accumulation and nuclease/TLS assembly (longerich2014stressanddna pages 4-5).
  • FA core complex at chromatin; PCNA at replication foci (shah2024dualroleof pages 1-2).
  • Endoplasmic reticulum: site of proteostasis stress in fetal FA LT-HSCs (kovuru2024deregulatedproteinhomeostasis pages 10-11).

5. Disease Progression (Sequence of events)

1) Initiating lesions: endogenous aldehydes (acetaldehyde/formaldehyde) and oxidative metabolism generate ICLs and DPCs in HSCs; detoxification capacity (ALDH2/ADH5) modulates burden (human ALDH2*2 accelerates BMF) (hira2013variantaldh2is pages 1-2, repczynska2024newinsightsinto pages 13-17). 2) Repair failure at replication: defective FA core recruitment and I-D2 monoubiquitination limit nuclease unhooking, TLS insertion across unhooked adduct, and HR-mediated restoration; ATR/CHK signaling becomes chronically engaged (longerich2014stressanddna pages 4-5, longerich2014stressanddna pages 7-8, liu2025inheritedpredispositionsto pages 13-15). 3) Cellular outcomes: fork collapse, chromosomal breakage, mitotic bridge formation; TP53 activation and apoptotic attrition of HSCs; chronic ROS/inflammatory signaling exacerbate senescence and HSC pool depletion (longerich2014stressanddna pages 7-8, liu2025inheritedpredispositionsto pages 13-15, repczynska2024newinsightsinto pages 9-13). 4) Developmental window: fetal liver LT-HSCs are particularly vulnerable due to inflammation-driven ER stress and proteostasis breakdown; TUDCA and type I interferon dampening rescue fetal LT-HSC numbers in Fancd2−/− (kovuru2024deregulatedproteinhomeostasis pages 10-11). 5) Malignant evolution: persistent genomic instability and replication stress select for clones tolerating checkpoints, predisposing to MDS/AML and early-onset squamous cell carcinomas of the oral/anogenital/upper aerodigestive tract (liu2025inheritedpredispositionsto pages 13-15, fang2025comprehensivereviewon pages 1-3).

6. Phenotypic Manifestations (Mechanism links)

  • Progressive bone marrow failure with pancytopenia (HP:0001873) from HSC attrition driven by repair failure, aldehyde genotoxicity, and inflammatory/proteostatic stress (hira2013variantaldh2is pages 1-2, kovuru2024deregulatedproteinhomeostasis pages 10-11, liu2025inheritedpredispositionsto pages 13-15).
  • Congenital anomalies (e.g., radial ray defects, renal anomalies) linked to developmental replication stress and checkpoint perturbations (fang2025comprehensivereviewon pages 1-3).
  • Cancer predisposition: markedly elevated risk and early onset of squamous cell carcinomas (oral, anogenital, esophageal) and MDS/AML due to chronic chromosomal instability and replication stress; oral surveillance is emphasized in clinical guidance (fang2025comprehensivereviewon pages 1-3, repczynska2024newinsightsinto pages 9-13).

Current Applications and Real-World Implementations

  • Diagnostic: DEB/MMC chromosomal breakage assays and FANCD2 monoubiquitination readouts to functionally assess FA pathway competence; NGS panels to genotype FA genes (fang2025comprehensivereviewon pages 1-3).
  • Risk modification: counseling on aldehyde exposures (ethanol); consideration of ALDH2 genotype as a modifier of hematologic risk in FA (hira2013variantaldh2is pages 1-2).
  • Transplant: HSCT for marrow failure, with continued cancer surveillance due to persistent epithelial cancer risk (repczynska2024newinsightsinto pages 9-13).
  • Emerging targeted strategies: metabolic–epigenetic targeting in KMT2D-deficient HNSCC to reduce FA/BRCA gene expression and sensitize to DNA crosslinkers/PARP inhibitors (preclinical) (liu2024histonemethyltransferasekmt2ddeficiency pages 1-2); fetal-stage interventions aimed at proteostasis and interferon tone (TUDCA; IFN signaling) to preserve HSC pools (preclinical) (kovuru2024deregulatedproteinhomeostasis pages 10-11); pathway steering via PCNA-Ub to avoid MMR engagement at ICLs suggests opportunities to modulate damage tolerance (shah2024dualroleof pages 1-2).

Expert Opinions and Analysis (Authoritative sources)

  • Authoritative reviews conclude that FA is best understood as a failure of the ICL repair network at the replication fork, integrated with ATR checkpoint signaling and with broad mitotic consequences, unifying marrow failure and carcinogenesis (Blood 2014; Annual Review of Pathology 2025) (longerich2014stressanddna pages 4-5, longerich2014stressanddna pages 7-8, liu2025inheritedpredispositionsto pages 13-15).
  • The aldehyde two-tier model has strong genetic and human evidence; ALDH2*2 in FA patients provides clinical validation of aldehyde-driven pathogenesis (Blood 2013) (hira2013variantaldh2is pages 1-2).
  • 2024–2025 updates emphasize systems-level crosstalk: fetal inflammatory–proteostasis stress as the origin of HSC pool deficits; and metabolic–epigenetic regulation of FA gene expression in SCC, revealing disease stage-/context-specific therapeutic opportunities (Nat Commun 2024; PNAS Nexus 2024) (kovuru2024deregulatedproteinhomeostasis pages 10-11, liu2024histonemethyltransferasekmt2ddeficiency pages 1-2, shah2024dualroleof pages 1-2).

Relevant Statistics and Data (recent)

  • Early-onset epithelial cancer risk in FA: elevated oral/anogenital SCC incidence with young median onset; clinical management emphasizes early detection and surgical management (URL: https://doi.org/10.1186/s13023-025-03896-w; Jul 2025) (fang2025comprehensivereviewon pages 1-3).
  • Human genetic modifier: ALDH2*2 carriers among Japanese FA patients exhibit significantly faster progression to bone marrow failure relative to noncarriers (URL: https://doi.org/10.1182/blood-2013-06-507962; Oct 2013) (hira2013variantaldh2is pages 1-2).

Gene/Protein Annotations (selected; HGNC with key roles)

  • FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL (core complex; E3 ligase function via FANCL); UBE2T (FANCT; E2); FANCD2, FANCI (I-D2 complex); FANCM (fork sensor/translocase); SLX4/FANCP (nuclease scaffold); XPF–ERCC1, SLX1 (unhooking); REV7/FANCV, REV3L (Polζ TLS); BRCA2/FANCD1, PALB2/FANCN, BRCA1/FANCS, RAD51 family (HR). Evidence: 2014 Blood; 2024 IJMS; 2025 Annual Review (longerich2014stressanddna pages 4-5, repczynska2024newinsightsinto pages 9-13, liu2025inheritedpredispositionsto pages 13-15).

Phenotype Associations (HP terms)

  • Bone marrow failure/pancytopenia (HP:0001873), Aplastic anemia (HP:0001903) (liu2025inheritedpredispositionsto pages 13-15).
  • Squamous cell carcinoma (HP:0002860) of oral cavity/anogenital tract; early onset (fang2025comprehensivereviewon pages 1-3, repczynska2024newinsightsinto pages 9-13).
  • Congenital limb anomalies (e.g., radial ray malformations; HP:0002986) (fang2025comprehensivereviewon pages 1-3).

Cell Type Involvement (CL terms)

  • Long-term HSCs (CL:0000037) and HSPCs: replication stress sensitivity, aldehyde damage, inflammatory/ER stress in fetal liver (kovuru2024deregulatedproteinhomeostasis pages 10-11, liu2025inheritedpredispositionsto pages 13-15).
  • Mesenchymal stromal cells (CL:0000134): niche contributions are under investigation (repczynska2024newinsightsinto pages 9-13).

Anatomical Locations (UBERON)

  • Bone marrow (UBERON:0002371), fetal liver (UBERON:0002107), oral cavity (UBERON:0001729), esophagus (UBERON:0001043) (fang2025comprehensivereviewon pages 1-3, kovuru2024deregulatedproteinhomeostasis pages 10-11).

Chemical Entities (CHEBI)

  • Acetaldehyde (CHEBI:15343), formaldehyde (CHEBI:16842): endogenous aldehydes driving lesions (hira2013variantaldh2is pages 1-2, repczynska2024newinsightsinto pages 13-17).
  • 2-deoxy-D-glucose (CHEBI:17698): glycolysis inhibitor revealing FA gene epigenomic dependency in KMT2D-deficient SCC (liu2024histonemethyltransferasekmt2ddeficiency pages 1-2).
  • Tauroursodeoxycholic acid, TUDCA (CHEBI:132954): chemical chaperone rescuing fetal Fancd2−/− LT-HSCs (kovuru2024deregulatedproteinhomeostasis pages 10-11).

Evidence Items (PMIDs/DOIs, URLs, dates)

  • Stress and DNA repair biology of the FA pathway (mechanistic core; Blood 2014): DOI 10.1182/blood-2014-04-526293; URL: https://doi.org/10.1182/blood-2014-04-526293; Oct 2014 (longerich2014stressanddna pages 4-5, longerich2014stressanddna pages 7-8).
  • New insights: inflammation/oxidative stress crosstalk in FA (IJMS 2024): DOI 10.3390/ijms252111619; URL: https://doi.org/10.3390/ijms252111619; Oct 2024 (repczynska2024newinsightsinto pages 9-13, repczynska2024newinsightsinto pages 13-17).
  • Inherited predispositions to myeloid neoplasms (FA overview; Annu Rev Pathol 2025): DOI 10.1146/annurev-pathmechdis-111523-023420; URL: https://doi.org/10.1146/annurev-pathmechdis-111523-023420; Jan 2025 (liu2025inheritedpredispositionsto pages 13-15).
  • ALDH2 variant accelerates BMF in Japanese FA (Blood 2013): DOI 10.1182/blood-2013-06-507962; URL: https://doi.org/10.1182/blood-2013-06-507962; Oct 2013 (hira2013variantaldh2is pages 1-2).
  • Comprehensive FA review with tumor focus (Orphanet J Rare Dis 2025): DOI 10.1186/s13023-025-03896-w; URL: https://doi.org/10.1186/s13023-025-03896-w; Jul 2025 (fang2025comprehensivereviewon pages 1-3).
  • PCNA monoubiquitination governs FA-mediated ICL repair and excludes MMR (PNAS Nexus 2024): DOI 10.1093/pnasnexus/pgae242; URL: https://doi.org/10.1093/pnasnexus/pgae242; Jun 2024 (shah2024dualroleof pages 1-2).
  • Fetal FA LT-HSC proteostasis/ER stress and TUDCA rescue (Nat Commun 2024): DOI 10.1038/s41467-024-46159-1; URL: https://doi.org/10.1038/s41467-024-46159-1; Feb 2024 (kovuru2024deregulatedproteinhomeostasis pages 10-11).
  • DNA repair–metabolism crosstalk in HSCs (Cells 2024): DOI 10.3390/cells13090733; URL: https://doi.org/10.3390/cells13090733; Apr 2024 (xu2024crosstalkbetweendna pages 7-9).
  • KMT2D deficiency, glycolysis, and FA/BRCA gene repression in SCC (Nat Commun 2024): DOI 10.1038/s41467-024-50861-5; URL: https://doi.org/10.1038/s41467-024-50861-5; Aug 2024 (liu2024histonemethyltransferasekmt2ddeficiency pages 1-2).

Concluding Remarks

FA pathogenesis is anchored in defective ICL repair at the replication fork, compounded by endogenous aldehyde genotoxicity, replication stress/ATR signaling, and context-specific inflammatory and metabolic stresses in hematopoietic and epithelial compartments. 2023–2024 research adds mechanistic layers: fetal liver proteostasis–interferon circuits driving LT-HSC loss and an epigenetic–metabolic axis that tunes FA gene expression and therapeutic response in SCC. Together, these advances refine targets for intervention—detoxification/alcohol counseling, fetal-stage proteostasis/innate immune modulation, and tumor-context metabolic–epigenetic therapies—while preserving the centrality of the FA/BRCA repair pathway in both marrow failure and cancer risk (longerich2014stressanddna pages 4-5, hira2013variantaldh2is pages 1-2, kovuru2024deregulatedproteinhomeostasis pages 10-11, liu2024histonemethyltransferasekmt2ddeficiency pages 1-2).

References

  1. (longerich2014stressanddna pages 4-5): Simonne Longerich, Jian Li, Yong Xiong, Patrick Sung, and Gary M. Kupfer. Stress and dna repair biology of the fanconi anemia pathway. Blood, 124 18:2812-9, Oct 2014. URL: https://doi.org/10.1182/blood-2014-04-526293, doi:10.1182/blood-2014-04-526293. This article has 106 citations and is from a highest quality peer-reviewed journal.

  2. (longerich2014stressanddna pages 7-8): Simonne Longerich, Jian Li, Yong Xiong, Patrick Sung, and Gary M. Kupfer. Stress and dna repair biology of the fanconi anemia pathway. Blood, 124 18:2812-9, Oct 2014. URL: https://doi.org/10.1182/blood-2014-04-526293, doi:10.1182/blood-2014-04-526293. This article has 106 citations and is from a highest quality peer-reviewed journal.

  3. (shah2024dualroleof pages 1-2): Ronak Shah, Muhammad Assad Aslam, Aldo Spanjaard, Daniel de Groot, Lisa M Zürcher, Maarten Altelaar, Liesbeth Hoekman, Colin E J Pritchard, Bas Pilzecker, Paul C M van den Berk, and Heinz Jacobs. Dual role of proliferating cell nuclear antigen monoubiquitination in facilitating fanconi anemia-mediated interstrand crosslink repair. PNAS Nexus, Jun 2024. URL: https://doi.org/10.1093/pnasnexus/pgae242, doi:10.1093/pnasnexus/pgae242. This article has 0 citations and is from a peer-reviewed journal.

  4. (hira2013variantaldh2is pages 1-2): Asuka Hira, Hiromasa Yabe, Kenichi Yoshida, Yusuke Okuno, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Jun Nakamura, Seiji Kojima, Seishi Ogawa, Keitaro Matsuo, Minoru Takata, and Miharu Yabe. Variant aldh2 is associated with accelerated progression of bone marrow failure in japanese fanconi anemia patients. Blood, 122 18:3206-9, Oct 2013. URL: https://doi.org/10.1182/blood-2013-06-507962, doi:10.1182/blood-2013-06-507962. This article has 213 citations and is from a highest quality peer-reviewed journal.

  5. (repczynska2024newinsightsinto pages 9-13): Anna Repczynska, Barbara Ciastek, and Olga Haus. New insights into the fanconi anemia pathogenesis: a crosstalk between inflammation and oxidative stress. International Journal of Molecular Sciences, 25:11619, Oct 2024. URL: https://doi.org/10.3390/ijms252111619, doi:10.3390/ijms252111619. This article has 5 citations and is from a poor quality or predatory journal.

  6. (repczynska2024newinsightsinto pages 13-17): Anna Repczynska, Barbara Ciastek, and Olga Haus. New insights into the fanconi anemia pathogenesis: a crosstalk between inflammation and oxidative stress. International Journal of Molecular Sciences, 25:11619, Oct 2024. URL: https://doi.org/10.3390/ijms252111619, doi:10.3390/ijms252111619. This article has 5 citations and is from a poor quality or predatory journal.

  7. (liu2025inheritedpredispositionsto pages 13-15): Yen-Chun Liu, Mohammad K. Eldomery, Jamie L. Maciaszek, and Jeffery M. Klco. Inherited predispositions to myeloid neoplasms: pathogenesis and clinical implications. Annual Review of Pathology: Mechanisms of Disease, 20:87-114, Jan 2025. URL: https://doi.org/10.1146/annurev-pathmechdis-111523-023420, doi:10.1146/annurev-pathmechdis-111523-023420. This article has 7 citations and is from a domain leading peer-reviewed journal.

  8. (fang2025comprehensivereviewon pages 1-3): Chenyan Fang, Zhoujun Zhu, Jun Cao, Jun Huang, and Yipeng Xu. Comprehensive review on fanconi anemia: insights into dna interstrand cross-links, repair pathways, and associated tumors. Orphanet Journal of Rare Diseases, Jul 2025. URL: https://doi.org/10.1186/s13023-025-03896-w, doi:10.1186/s13023-025-03896-w. This article has 4 citations and is from a peer-reviewed journal.

  9. (kovuru2024deregulatedproteinhomeostasis pages 10-11): Narasaiah Kovuru, Makiko Mochizuki-Kashio, Theresa Menna, Greer Jeffrey, Yuning Hong, Young me Yoon, Zhe Zhang, and Peter Kurre. Deregulated protein homeostasis constrains fetal hematopoietic stem cell pool expansion in fanconi anemia. Nature Communications, Feb 2024. URL: https://doi.org/10.1038/s41467-024-46159-1, doi:10.1038/s41467-024-46159-1. This article has 7 citations and is from a highest quality peer-reviewed journal.

  10. (liu2024histonemethyltransferasekmt2ddeficiency pages 1-2): Wei Liu, Hongchao Cao, Jing Wang, Areeg Elmusrati, Bing Han, Wei Chen, Ping Zhou, Xiyao Li, Stephen Keysar, Antonio Jimeno, and Cun-Yu Wang. Histone-methyltransferase kmt2d deficiency impairs the fanconi anemia/brca pathway upon glycolytic inhibition in squamous cell carcinoma. Nature Communications, Aug 2024. URL: https://doi.org/10.1038/s41467-024-50861-5, doi:10.1038/s41467-024-50861-5. This article has 9 citations and is from a highest quality peer-reviewed journal.

  11. (xu2024crosstalkbetweendna pages 7-9): Jian Xu, Peiwen Fei, Dennis W. Simon, Michael J. Morowitz, Parinda A. Mehta, and Wei Du. Crosstalk between dna damage repair and metabolic regulation in hematopoietic stem cells. Cells, 13:733, Apr 2024. URL: https://doi.org/10.3390/cells13090733, doi:10.3390/cells13090733. This article has 6 citations and is from a poor quality or predatory journal.

OpenAI ▸
Fanconi Anemia – Pathophysiology Research Report
o3-deep-research-2025-06-26 125 citations 2026-02-08T10:27:32.786782

Fanconi Anemia – Pathophysiology Research Report

Target Disease

Disease Name: Fanconi Anemia
MONDO ID: MONDO:0019391
Category: Genetic (Inherited bone marrow failure syndrome)

1. Core Pathophysiology

Fanconi anemia (FA) is a rare inherited DNA repair disorder defined by an inability to repair DNA interstrand cross-links (ICLs), leading to genomic instability and progressive bone marrow failure (ojrd.biomedcentral.com) (www.ncbi.nlm.nih.gov). In healthy cells, the FA pathway preserves genome integrity by recognizing and repairing ICLs – lesions that prevent DNA strand separation during replication (ojrd.biomedcentral.com). FA patients have biallelic mutations in any of at least 22 FANC genes, impairing this pathway and causing a cascade of cellular dysfunction. As a result, FA cells accumulate DNA breaks and chromosome rearrangements, especially when DNA replication is stalled by cross-links (ojrd.biomedcentral.com) (pmc.ncbi.nlm.nih.gov). This chromosomal fragility triggers cell cycle arrest or apoptosis in rapidly dividing cells, notably hematopoietic stem cells, eventually depleting the bone marrow (pancytopenia) (www.ncbi.nlm.nih.gov). In essence, “genetic mutations in the Fanconi anemia pathway lead to cells that cannot properly repair DNA damage, resulting in genomic instability, subsequent pancytopenia, and predisposition to malignancies” (www.ncbi.nlm.nih.gov).

Beyond DNA repair defects, recent research highlights secondary pathogenic factors in FA. There is a pathological interplay of chronic inflammation, oxidative stress, and aberrant metabolic signaling that further harms the bone marrow microenvironment (pmc.ncbi.nlm.nih.gov). FA cells exhibit overproduction of pro-inflammatory cytokines and an imbalanced redox state, which drive a pro-oxidative, toxic milieu in the bone marrow (pmc.ncbi.nlm.nih.gov). This inflammatory stress is thought to accelerate hematopoietic stem cell attrition and contribute to bone marrow failure (BMF) (pmc.ncbi.nlm.nih.gov). For example, studies indicate that a shift toward excess “proinflammatory cytokines and prooxidant components in FA is associated with advanced myelosuppression and ultimately BMF” (pmc.ncbi.nlm.nih.gov). FA cells also show impaired autophagy and mitophagy (clearance of damaged mitochondria), linking DNA repair failure to mitochondrial dysfunction and apoptosis (pmc.ncbi.nlm.nih.gov). Overall, the pathogenesis of FA rests on two pillars: loss of genome integrity (due to the DNA repair defect) and destabilization of cellular homeostasis (due to aberrant inflammation and metabolic stress) (pmc.ncbi.nlm.nih.gov). These combined mechanisms explain the classical FA clinical triad – early bone marrow failure, congenital abnormalities, and cancer susceptibility (pmc.ncbi.nlm.nih.gov).

2. Key Molecular Players and Disease Contributors

Genes/Proteins: Fanconi anemia is genetically heterogeneous, caused by recessive mutations in any of the FANC genes that encode components of the FA/BRCA DNA repair pathway (pmc.ncbi.nlm.nih.gov) (ojrd.biomedcentral.com). To date, ~22 complementation groups (FANCA through FANCW) are recognized (ojrd.biomedcentral.com). The FA core complex includes proteins FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM (among others), which assemble on chromatin at stalled replication forks (pmc.ncbi.nlm.nih.gov). This complex’s crucial role is to monoubiquitinate the FANCD2–FANCI heterodimer (the ID2 complex) via the E3 ubiquitin ligase FANCL and E2 enzyme UBE2T (FANCT) (pmc.ncbi.nlm.nih.gov). Monoubiquitinated FANCD2-FANCI then accumulates in nuclear foci at the damage site and orchestrates downstream repair (pmc.ncbi.nlm.nih.gov). It recruits structure-specific endonucleases like SLX4/FANCP and XPF/FANCQ to incise DNA on either side of the cross-link (“unhooking” the lesion) (pmc.ncbi.nlm.nih.gov). Subsequently, translesion DNA synthesis (TLS) polymerases (e.g. REV7/FANCV) bypass the damage, and homologous recombination (HR) proteins repair the resulting double-strand break – these include BRCA2 (FANCD1), BRCA1 (FANCS), PALB2 (FANCN), RAD51 (FANCR), RAD51C (FANCO), XRCC2 (FANCU), and others (pmc.ncbi.nlm.nih.gov). In summary, the FA pathway functions as a coordinated network: “the FA core complex monoubiquitinates the FANCD2:FANCI dimer, which then recruits nucleases for unhooking the ICL and promotes TLS and homologous recombination via downstream effectors like BRCA2, PALB2, BRIP1, etc., to complete DNA repair” (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). If any component of this pathway is defective, ICLs trigger replication fork collapse and chromosome breaks instead of proper repair (ojrd.biomedcentral.com). Notably, the FANCD2 protein is central; failure to ubiquitinate FANCD2 or form FANCD2 nuclear foci is a hallmark of pathway dysfunction (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). Consistent with this, biallelic mutations in the core complex genes (especially FANCA, FANCC, FANCG) account for ~80% of FA cases (www.ncbi.nlm.nih.gov), and these patients show absent FANCD2 ubiquitination on diagnostic testing (www.ncbi.nlm.nih.gov). Some FA genes are well-known tumor suppressors in their own right – for example, FANCD1 is BRCA2, and FANCS is BRCA1, linking FA directly to the breast/ovarian cancer DNA repair network (ojrd.biomedcentral.com). (It is noteworthy that one putative member, FANCM, may not cause classic FA when mutated, suggesting it might not be a bona fide FA gene (ojrd.biomedcentral.com).) Beyond the core members, several FA-associated proteins (FAAPs like FAAP20, FAAP24, MHF1/FAAP16, MHF2/FAAP10, etc.) assist the complex (pmc.ncbi.nlm.nih.gov). Overall, loss of any of these players cripples the FA/BRCA pathway, explaining the genetic basis of FA’s chromosomal instability (ojrd.biomedcentral.com).

Chemical Entities: A distinctive feature of FA is hypersensitivity to DNA crosslinking agents. Cells lacking a functional FA pathway cannot tolerate agents that create ICLs, such as mitomycin C (MMC), diepoxybutane (DEB), cisplatin, melphalan, or even environmental toxins like tobacco smoke, which contains aldehydes and cross-linking chemicals (pmc.ncbi.nlm.nih.gov). In fact, exposing patient lymphocytes to MMC or DEB in vitro causes exaggerated chromosome breakage and formation of radial chromosome figures – this chromosomal fragility test is the diagnostic gold standard for FA (pmc.ncbi.nlm.nih.gov). Endogenous metabolites are also relevant chemical stressors: aldehydes produced by normal metabolism (e.g. formaldehyde and acetaldehyde) create ICLs that healthy cells detoxify or repair, but FA cells accumulate damage from these sources (pmc.ncbi.nlm.nih.gov). Without the FA pathway, even low-level oxidative DNA damage becomes hazardous, as FA cells show an “inability…to withstand normal oxidative stress and oxygen-free radicals” leading to cellular DNA damage and apoptosis (www.ncbi.nlm.nih.gov). This explains why avoiding exogenous ICL agents and reducing oxidative stress (e.g. with antioxidants) is important in FA management. On the therapeutic side, androgenic steroids (e.g. oxymetholone) have been used to stimulate blood counts in FA patients, although their mechanism (possibly affecting bone marrow microenvironment or DNA damage responses) is not fully understood. The key chemical entities in FA pathophysiology are thus those that damage DNA (crosslinkers, ROS) and those used in treatment to counter marrow failure or leverage FA defects (e.g. crosslinkers as conditioning agents, or experimental use of ATR or POLθ inhibitors to target FA-deficient tumors (pmc.ncbi.nlm.nih.gov)).

Cell Types: The primary cellular targets of FA are the hematopoietic stem and progenitor cells in the bone marrow. FA is considered a bone marrow failure syndrome because defective CD34+ hematopoietic stem cells (HSCs) cannot sustain blood cell production (www.ncbi.nlm.nih.gov). These stem cells experience replication stress and DNA breakage, leading to cell cycle arrest (mediated by p53) and apoptosis. There is evidence for “selective destruction of CD34+ stem cells” in FA marrow, which directly causes pancytopenia (www.ncbi.nlm.nih.gov). In addition to HSCs, their progeny (myeloid precursors, erythroid and megakaryocytic lineages) are affected, explaining the trilineage cytopenias (pancytopenia, HP:0001876) in FA patients. Bone marrow stromal cells might also be altered, but the failure is primarily intrinsic to HSCs with some contribution from a toxic microenvironment. Outside the marrow, other cell types with high proliferative rates or special sensitivity to DNA crosslinks are involved. For instance, keratinocytes and mucosal epithelial cells (in oral cavity, pharynx, esophagus, anogenital region) are prone to malignant transformation in FA, likely because they accrue DNA damage from environmental exposures (e.g. HPV infection or smoking) that cannot be properly repaired (ojrd.biomedcentral.com) (ojrd.biomedcentral.com). Germ cells may also be affected – many individuals have reduced fertility or gonadal dysfunction, suggesting germ cell depletion or developmental defects. Finally, various developmental cell lineages are impacted during embryogenesis – for example, mesenchymal cells forming the radius bone and thumb fail to develop normally in many FA patients (leading to radial ray defects), and developing neurons can be affected (some patients have microcephaly or neurodevelopmental delays) (ojrd.biomedcentral.com). This wide array of affected cell types reflects that FA gene dysfunction can influence essentially any proliferating cell population, although the hematopoietic lineage is the most critically vulnerable.

Anatomical Locations: Consistent with the above, Fanconi anemia primarily involves the bone marrow (UBERON:0002371) as the site of bone marrow failure. Bone marrow aplasia (replacement of marrow by fat) is the anatomical correlate of pancytopenia. The skeletal system is frequently involved in congenital anomalies – especially the upper limbs (radius, thumb; e.g. absent radius [HP:0003974], thumb aplasia/hypoplasia [HP:0009601]) and sometimes the spine or hips. The skin is another site of FA manifestations, with many patients displaying abnormal skin pigmentation (café-au-lait spots or areas of hypo/hyperpigmentation). The head and neck region is a notable anatomical focus in older FA patients due to cancer risk: FA confers a >500-fold increased risk of head, neck, and upper esophageal squamous cell carcinomas (pmc.ncbi.nlm.nih.gov), often arising in the oral cavity or pharynx. Similarly, the genitourinary tract (e.g. cervix in females, vulva, or the anus) is at high risk for squamous cell carcinoma in adulthood (ojrd.biomedcentral.com) (ojrd.biomedcentral.com). Congenital malformations affect kidneys (renal aplasia or horseshoe kidney are reported), the heart and cardiovascular system (septal defects or cardiomyopathy), and the gastrointestinal tract (e.g., esophageal atresia in some cases). Endocrine organs like the pancreas (FA patients may develop early diabetes) and gonads (ovarian or testicular insufficiency) can also be involved (ojrd.biomedcentral.com). In summary, while bone marrow failure is central, FA has systemic reach – virtually all organ systems can be involved either through developmental anomalies or through later complications (e.g. malignancies). This multisystem involvement aligns with the notion that the FA mutation destabilizes fundamental cellular processes in many anatomical contexts (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov).

3. Disrupted Biological Processes (GO Annotations)

Fanconi anemia represents a failure of several key biological processes. Foremost is DNA repair, especially the process of DNA interstrand cross-link repair (GO:0036297), which is uniquely handled by the FA pathway. Because FA proteins cooperate in ICL repair, their absence disrupts multiple sub-processes of genomic maintenance:

  • Homologous recombination (HR) DNA repair (GO:0000724) – FA proteins like FANCD1/BRCA2, FANCN/PALB2, and FANCR/RAD51 are directly involved in HR. FA cells have impaired HR, leading to error-prone repair or chromosome misjoining (pmc.ncbi.nlm.nih.gov). Consequently, alternative end-joining (a non-classical DNA double-strand break repair) becomes overactive, causing characteristic radial chromosome fusions (pmc.ncbi.nlm.nih.gov). Indeed, recent studies show FA-associated chromosomal radials are “dependent on POLθ-mediated alternative end joining”, reflecting a shift to this mutagenic repair in FA cells (pmc.ncbi.nlm.nih.gov).

  • DNA damage checkpoint signaling (GO:0006974) – Cells with un-repaired crosslinks activate p53 and other checkpoints. FA pathway loss leads to chronic activation of DNA damage responses, premature senescence, or apoptosis in progenitor cells (pmc.ncbi.nlm.nih.gov). The normal coordination of S-phase replication checkpoints is disrupted, as stalled replication forks accumulate. FA proteins normally stabilize DNA replication forks and prevent their collapse (www.ncbi.nlm.nih.gov); without them, forks break, triggering cell cycle arrest.

  • Translesion DNA synthesis (TLS) – In normal ICL repair, specialized polymerases perform TLS across the unhooked lesion (pmc.ncbi.nlm.nih.gov). FA pathway defects can derail this process, so cells either stall (fork collapse) or use error-prone polymerases in uncontrolled ways, leading to mutations.

  • Nucleotide excision repair (NER) – Some FA proteins (e.g. XPF/FANCQ) participate in NER-like incisions during crosslink repair (pmc.ncbi.nlm.nih.gov). FA cells show defects in these incision steps, so ICL unhooking is inefficient. There is evidence that processes like NER and Fanconi-associated nucleases are impaired, contributing to persistence of DNA lesions.

  • Autophagy and Mitophagy (GO:0006914, GO:0000422) – FA cells demonstrate impaired autophagic clearance of damaged organelles (pmc.ncbi.nlm.nih.gov). The FA pathway interplay with ubiquitination and cellular stress responses suggests FA proteins may regulate autophagy. Disrupted mitophagy in FA leads to accumulation of dysfunctional mitochondria and elevated reactive oxygen species, compounding cellular injury (pmc.ncbi.nlm.nih.gov).

  • Redox homeostasis – FA proteins have non-canonical roles in managing oxidative stress (pmc.ncbi.nlm.nih.gov). Loss of FA function skews the balance towards oxidative damage. FA cells often show an exaggerated oxidative stress response (GO:0006979) and are hypersensitive to oxygen free radicals (www.ncbi.nlm.nih.gov), indicating failure of normal antioxidant defenses and damage removal mechanisms.

  • Cytokine signaling and inflammation – An important emerging aspect is dysregulated inflammatory response (GO:0006954) in FA. Mononuclear cells from FA patients overproduce pro-inflammatory cytokines like TNF-α and IL-6 (pmc.ncbi.nlm.nih.gov). Normally, the FA pathway may help restrain inflammation (possibly by repairing DNA damage from inflammatory oxidants or by modulating signaling cascades). In FA, there is constitutive activation of stress-responsive kinases and NF-κB pathways, promoting a chronic inflammatory state in the bone marrow (pmc.ncbi.nlm.nih.gov). This ties in with hematopoietic process regulation (GO:0030097), as excessive TNF-α and IFN-γ can suppress HSC proliferation. FA pathophysiology thus involves aberrant cytokine signaling that fosters HSC exhaustion.

In summary, the biological processes disrupted in FA include DNA damage recognition and repair (ICL repair, HR, TLS, NER), replication fork maintenance, cell cycle checkpoint control, programmed cell death/senescence pathways, as well as cellular stress response pathways (autophagy, oxidative stress response, inflammatory signaling) (pmc.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). These process failures together account for the cellular phenotypes of FA: genomic instability, bone marrow aplasia, and cancer predisposition.

4. Key Cellular Components Involved

The pathological mechanisms of FA localize to several cellular compartments:

  • Cell Nucleus (Chromatin): The nucleus is the primary site of action for FA proteins. ICL repair occurs in the context of replication forks on nuclear DNA. FA core complex proteins are recruited to chromatin, and FANCD2/FANCI are targeted to DNA damage foci in the nucleus (www.ncbi.nlm.nih.gov). The formation of nuclear repair foci containing monoubiquitinated FANCD2, BRCA1, BRCA2, RAD51, etc., is a crucial nuclear event that is absent or defective in FA cells (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). This leads to accumulation of unresolved DNA lesions within the nucleus. Additionally, the nucleus is where chromosome fragility is observed: FA cells in metaphase show broken chromosomes and radial chromosomal arrangements due to misrepair (pmc.ncbi.nlm.nih.gov). Thus, the nucleoplasm/chromosomal DNA compartment is central to FA pathogenesis.

  • Cytoplasm (including Organelles): Several FA proteins also localize to or function in the cytosol. For instance, FANCC has been noted to interact in the cytoplasm with signaling proteins that modulate cytokine sensitivity (e.g. it can bind to STAT pathways and modulate TNF-α signaling) (pmc.ncbi.nlm.nih.gov). The mitochondria are an important organelle in FA pathophysiology – FA cells accumulate damaged mitochondria (due to faulty mitophagy) and exhibit mitochondrial dysfunction with excess ROS production (pmc.ncbi.nlm.nih.gov). This implicates the mitochondrial compartment and the mitophagosome/lysosome pathway in disease (as FA proteins like FANCR/RAD51 and FANCG have been linked to redox regulation in mitochondria) (pmc.ncbi.nlm.nih.gov). The cytosol is also where pro-apoptotic signals can be activated if DNA damage is not repaired (e.g. cytosolic p53 accumulation leading to apoptosis). Furthermore, autophagosomes in the cytoplasm are fewer or functionally impaired in FA cells, indicating defective clearance of protein aggregates and organelles (pmc.ncbi.nlm.nih.gov).

  • Plasma Membrane Receptors: While FA is primarily a DNA repair disorder, some evidence suggests FA proteins might influence membrane receptor signaling. For example, altered cytokine receptor signaling on hematopoietic cells (like TNF receptor or interferon gamma receptor) has been observed – Fancc−/− mice HSCs are hypersensitive to exogenous TNF-α, hinting at membrane-proximal signaling issues. However, these effects are likely secondary to upstream nuclear events (DNA damage leading to cytokine production). There isn’t a known direct FA protein that is a membrane component.

  • Extracellular Space (Bone Marrow Microenvironment): The extracellular milieu in the bone marrow niche becomes pathological in FA. High levels of pro-inflammatory cytokines (TNF-α, IL-1β, IFN-γ) are secreted into the marrow space by immune cells or stromal cells in FA, creating a toxic environment for HSCs (pmc.ncbi.nlm.nih.gov). Also, the extracellular accumulation of toxic metabolic byproducts (e.g. aldehydes) can occur if not detoxified, exposing cells to DNA-damaging agents in their microenvironment (pmc.ncbi.nlm.nih.gov). Therefore, the bone marrow stromal niche (extracellular matrix and soluble factors) is an important “component” in which FA pathogenesis unfolds. This aberrant extracellular environment contributes to the selective loss of stem cells and ineffective hematopoiesis in FA (pmc.ncbi.nlm.nih.gov).

In summary, FA pathophysiology spans multiple cellular compartments: within the nucleus (genome maintenance machinery), in the cytoplasm and organelles (metabolic and apoptotic regulators), and in the extracellular niche (inflammatory cytokine milieu). The failure of cross-talk between these compartments – genome instability in the nucleus leading to cytosolic stress signaling and a hostile bone marrow microenvironment – underlies the disease (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

5. Disease Progression and Pathophysiological Sequence

Fanconi anemia’s natural history can be understood as a sequence from genetic defect to clinical manifestations:

  • Germline Mutation and Development: The process begins with inheriting biallelic FANC gene mutations. During embryonic development, cells with FA pathway deficiency accumulate DNA damage. This triggers cell cycle checkpoints and apoptosis in various developing tissues. Critical developmental progenitors may be lost or impaired, leading to congenital anomalies present at birth (e.g. radial ray defects, renal malformations). Thus, in utero effects of the FA mutation result in structural birth defects that are often detectable in infancy (pmc.ncbi.nlm.nih.gov). Nonetheless, some individuals with FA are born with no obvious anomalies, illustrating the heterogeneity of developmental impact (pmc.ncbi.nlm.nih.gov).

  • Childhood – Onset of Bone Marrow Failure: The most consistent and life-threatening feature, progressive bone marrow failure, typically declares itself in childhood. Hematopoietic stem cells, which have a finite reserve from birth, progressively die off or stop proliferating due to accumulated genomic injury. Clinically, cytopenias often start to appear in early childhood; the median age of diagnosis is ~7 years when pancytopenia or aplastic anemia becomes evident (www.ncbi.nlm.nih.gov). About 30% of FA patients develop bone marrow failure by age 10 (pmc.ncbi.nlm.nih.gov). Others may have a slower decline, but by the second decade most patients show some hematologic abnormality. The progression can be insidious – first manifested as thrombocytopenia or leukopenia – or fulminant aplastic anemia. This stage corresponds pathologically to nearly empty marrow cavities (<25% cellularity) due to HSC exhaustion and apoptosis. During this phase, some patients experience clonal hematopoiesis: surviving stem cells with compensatory genetic changes (revertant mosaicism or secondary mutations) may temporarily improve counts, but often at the cost of genetic instability. Indeed, a subset of FA patients spontaneously recover some bone marrow function due to mosaic reversion of the mutation in HSCs (pmc.ncbi.nlm.nih.gov), delaying progression. For most, however, marrow failure is progressive, requiring transfusional support or hematopoietic stem cell transplantation (HSCT) typically in the first or second decade of life.

  • Adolescence – Emergence of Clonal Evolution and Malignancy: As DNAdamaged HSCs attempt to proliferate, there is a high risk of clonal evolution. Many patients develop a pre-leukemic myelodysplastic syndrome (MDS) or acute leukemia. By age 18, approximately 7% of FA patients progress to a myeloid malignancy (usually acute myeloid leukemia, AML) (pmc.ncbi.nlm.nih.gov). The risk of MDS in FA is estimated to be 6000-fold higher than in the general population (pmc.ncbi.nlm.nih.gov). This typically occurs in the mid- to late-teens or early adulthood. Clonal cytogenetic abnormalities such as monosomy 7 or gains of chromosome 3q are often seen in the bone marrow as harbingers of transformation. If HSCT has been performed (to treat aplasia), there remains a risk of donor-derived malignancies or relapse of any residual host clone as MDS/AML. Thus, adolescence in FA is marked by either transplantation or careful surveillance for clonal hematologic disorders. Successful HSCT can cure bone marrow failure, but FA patients remain at risk for solid tumors due to their DNA repair defect affecting all cells (ojrd.biomedcentral.com) (ojrd.biomedcentral.com).

  • Early Adulthood – Solid Tumors and Organ Degeneration: With improved supportive care, many FA patients survive into young adulthood. However, squamous cell carcinomas (SCC) and other solid tumors become the dominant threat. FA patients develop aggressive SCCs of the head/neck and anogenital regions at a median age in the early 30s (often 20–30 years earlier than sporadic cases) (ojrd.biomedcentral.com) (pmc.ncbi.nlm.nih.gov). For instance, the median age of head/neck SCC onset in FA is ~33 years (ojrd.biomedcentral.com), and the risk of oral cavity cancer is at least 500-fold higher than normal (pmc.ncbi.nlm.nih.gov). These cancers are thought to arise from cumulative DNA damage (from HPV infection, smoking, etc.) that cannot be properly repaired, leading to early oncogenic mutations. In addition, female FA patients who live into adulthood have a greatly elevated risk of gynecologic cancers (vulvar and cervical SCC) and even breast cancer at young ages (ojrd.biomedcentral.com). The progression often follows a pattern: first hematologic issues dominate, then in their 20s–30s, epithelial cancers emerge. Notably, endocrine problems also become evident by adolescence: many FA patients have short stature and hormonal deficiencies (e.g. thyroid or growth hormone issues, diabetes mellitus) that could be viewed as an accelerated aging phenotype (ojrd.biomedcentral.com). In fact, FA has been described as a segmental “premature aging” syndrome – patients have high rates of stem cell depletion, endocrine failure, and cancer at ages when the general population is young (pmc.ncbi.nlm.nih.gov). Multi-organ deterioration (e.g. liver disease especially if androgens were used, or pulmonary fibrosis if transplant conditioning was given) may compound the clinical picture in adulthood.

  • Late Stages: By middle age (40s), few FA patients remain alive without intervention, mainly due to malignancies. Those who have escaped cancer and managed marrow failure (via transplant) can still face cumulative problems like liver cirrhosis, orthopedic issues from congenital anomalies, and psychosocial impacts. There is no distinct “late phase” beyond the cancer surveillance and management that dominates adult care in FA.

Importantly, at each stage of FA, external factors can modulate progression. Exposure to DNA-damaging agents accelerates complications: e.g., viral infections (like HPV) promote earlier SCC, and smoking or radiation is especially harmful. Conversely, early detection and prophylactic measures (such as HPV vaccination, aggressive screening for oral lesions, or androgen therapy to delay transplant) can modify the course. With modern interventions, up to 80-90% of transplanted FA patients survive at 5+ years (ojrd.biomedcentral.com), shifting the long-term focus to preventing and treating solid tumors. Nonetheless, the underlying pathophysiology – DNA repair deficiency and its systemic consequences – continues throughout life, driving the sequence of bone marrow failure, then clonal evolution, then solid tumors.

6. Phenotypic Manifestations and Mechanistic Links

Fanconi anemia presents a characteristic spectrum of clinical phenotypes that can be directly linked to its molecular pathology:

  • Bone Marrow Failure and Pancytopenia: Nearly all patients develop pancytopenia (HP:0001876) in childhood or early adolescence. This manifests as fatigue and pallor from anemia, bruising and bleeding (petechiae, epistaxis) from thrombocytopenia, and recurrent infections from leukopenia (www.ncbi.nlm.nih.gov). The underlying mechanism is the attrition of hematopoietic stem cells due to DNA damage accumulation and apoptosis. Biopsies show a hypocellular marrow (aplastic anemia, HP:0001915) with few progenitors. Laboratory tests often reveal elevated fetal hemoglobin and increased RBC macrocytosis, reflecting stress erythropoiesis. The connection to pathophysiology is clear: failure to repair DNA in HSCs → chromosomal breakage during division → stem cell death → marrow aplasia and pancytopenia (www.ncbi.nlm.nih.gov). Clinically, this is the most critical phenotype, often requiring bone marrow transplant. Evidence of the FA mechanism is seen in cytogenetics: patient blood cells exhibit spontaneous chromosome breaks and radial figures (unique cross-link induced chromosomal aberrancies) (pmc.ncbi.nlm.nih.gov).

  • Congenital Anomalies: About 60–75% of FA patients have one or more physical birth defects (pmc.ncbi.nlm.nih.gov). A classic finding is radial ray anomalies – malformed or absent thumbs (thumb aplasia/hypoplasia, HP:0009601) and radii (absent radius, HP:0003974) are present in ~40% of cases (pmc.ncbi.nlm.nih.gov). These limb defects result from impaired proliferation of mesenchyme in the developing arm due to the FA pathway defect (likely p53-mediated apoptosis of radial limb bud cells with DNA damage). Similarly, short stature (HP:0004322) is common, as growth is stunted by endocrine issues (e.g. growth hormone deficiency) and possibly by hematopoietic stress (ojrd.biomedcentral.com). Many patients have microcephaly (HP:0000252) or intellectual disability, which may stem from neural progenitor cell loss during development. Renal anomalies (HP:0000085, e.g. horseshoe kidney or unilateral kidney agenesis) occur in ~20-25%, and cardiac septal defects or low birth weight can also be seen (ojrd.biomedcentral.com). The skin often shows café-au-lait spots or hypo/hyperpigmented macules (HP:0000957), possibly due to mosaicism (some hematopoietic or skin clones spontaneously correct, leading to patchy pigmentation differences). These congenital phenotypes illustrate how the FA gene defect perturbs embryogenesis: cells that cannot manage replication stress may die or differentiate abnormally, leading to malformations. Notably, there is variability – some FA patients have no obvious birth defects and are only diagnosed when pancytopenia or cancer arises (pmc.ncbi.nlm.nih.gov). This variability hints at genetic modifiers or residual activity of hypomorphic mutations that allow near-normal development (pmc.ncbi.nlm.nih.gov).

  • Cancer Predisposition: FA confers a dramatic predisposition to both hematologic and solid malignancies. Acute myeloid leukemia (AML) (HP:0004808) and myelodysplastic syndrome are the major hematologic cancers, often emerging in the teens or 20s (pmc.ncbi.nlm.nih.gov). Mechanistically, the genomic instability in bone marrow cells drives clonal evolution: the same chromosomal breaks that cause aplasia can also cause oncogenic translocations or gene deletions, initiating leukemia. For example, loss of chromosome 7 or gains of 3q are common early events in FA MDS, and biallelic RUNX1 mutations have been noted in some FA-AML cases (ojrd.biomedcentral.com). On the solid tumor side, squamous cell carcinomas (SCC) are the signature cancers in FA. Head and neck SCC (HP:0030449, spanning oral cavity, tongue, pharynx) and esophageal SCC occur at a median age of early 30s, often after HSCT (which can further elevate risk) (ojrd.biomedcentral.com) (pmc.ncbi.nlm.nih.gov). Anogenital SCC (vulvar, vaginal, cervical in females; penile in males; anal in both) are also hugely elevated in incidence (ojrd.biomedcentral.com). The relative risk of head/neck SCC is on the order of several hundred-fold, and FA patients have a >700-fold increased risk of AML and >500-fold increased risk of head/neck SCC compared to age-matched controls (pmc.ncbi.nlm.nih.gov). The direct cause is the failure to repair DNA damage from agents like HPV (for anogenital cancer) or alcohol/aldehydes (for oral cancer), leading to early accumulation of driver mutations in oncogenes and tumor suppressors. FA patients also have increased risk of liver tumors (especially if androgen therapy was used) and brain tumors, though less commonly than SCC. A striking finding is that FA-associated cancers often present at much younger ages than sporadic cases (e.g. teens for cervical dysplasia/SCC, 20s for oral SCC) (pmc.ncbi.nlm.nih.gov). Clinicians face a challenge: because FA cells are hypersensitive to DNA-damaging therapy, standard chemotherapy or radiation for these cancers can be disastrously toxic (pmc.ncbi.nlm.nih.gov). As one source notes, “due to a defect of DNA repair, FA patients cannot tolerate standard chemoradiotherapy and treatment side effects are hard to predict” (pmc.ncbi.nlm.nih.gov). In practice, FA patients require gentle, surgery-focused cancer treatments or upfront transplants for leukemia.

  • Endocrine and Metabolic Problems: FA often involves endocrinopathies. About half of patients have growth hormone (GH) deficiency or hypothyroidism, contributing to short stature (ojrd.biomedcentral.com). Pubertal delay or hypogonadism is common (men may have underdeveloped testes, and women can have ovarian insufficiency), leading to infertility. These may be due to direct glandular damage (e.g. FA proteins are needed for regular endocrine cell turnover) or indirect effects of chronic illness. Insulin resistance and diabetes (HP:0000855) occur in ~20% of patients, possibly linked to pancreatic beta-cell stress from DNA damage or post-transplant complications (ojrd.biomedcentral.com). From a pathophysiology standpoint, these chronic endocrine issues support the notion of FA as a multi-system DNA repair deficiency that even affects long-lived cells like endocrine tissues; they also align with the “accelerated aging” aspect (early endocrine failure).

  • Other Phenotypes: Patients may have developmental delays or learning disabilities (especially if neurological anomalies like microcephaly are present) (ojrd.biomedcentral.com). Hearing loss, kidney dysfunction, or malformed reproductive organs (e.g. uterus didelphys) have been reported in some. Many patients suffer from fatigue and poor stamina due to chronic anemia. The combination of physical anomalies, growth failure, and hematologic issues gives FA patients a recognizable clinical profile, although each individual’s phenotype may differ depending on which gene is mutated and any mosaicism. There are genotype–phenotype correlations: for instance, mutations in FANCD1/BRCA2 cause a particularly severe form with early leukemia and brain anomalies, whereas FANCC mutations (common in the Ashkenazi Jewish population) often have the classic limb and kidney defects (pmc.ncbi.nlm.nih.gov) (ojrd.biomedcentral.com).

In conclusion, the clinical phenotypes of Fanconi anemia – from aplastic anemia to thumb malformations to early-onset cancers – can all be traced back to the central defect in DNA repair and its cellular consequences. Primary literature evidence (such as chromosomal breakage studies and gene knockout models) strongly supports these links: e.g., Fanconi gene-knockout mice show bone marrow failure and birth defects, mirroring human phenotypes (pmc.ncbi.nlm.nih.gov). The ongoing challenge is that while bone marrow failure can be cured by transplant, the propensity for epithelial cancers remains, necessitating lifelong surveillance. Thus, understanding the pathophysiology at the molecular level is crucial for developing targeted therapies (like gene therapy or drugs to mitigate oxidative stress and cytokine damage) that address not just hematologic issues but the full spectrum of Fanconi anemia manifestations (ojrd.biomedcentral.com).

Evidence Citations: (Key references supporting these findings include: D’Andrea & Grompe’s seminal work on the FA DNA repair pathway (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov), recent comprehensive reviews (ojrd.biomedcentral.com) (ojrd.biomedcentral.com), and clinical cohort studies detailing phenotype and outcomes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), among many others.)